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ABSTRACT
Through their ability to self-renew and differentiate, hematopoietic
stem/progenitor cells (HSPCs) maintain the adult blood and immune systems.
The microenvironment, or niche, in which HSPCs reside, serves as a critical
regulator of HSPC functions. As previous work has identified the tetraspanin
CD82 as a mediator of HSPC-niche interactions, we aimed to determine the
mechanism by which this occurs. Our data demonstrate that CD82 expression
and scaffolding regulate HSPC interactions with niche components by organizing
the α4 integrin subunit into tightly packed nanoclusters. The HSPC niche can
also protect acute myeloid leukemia (AML) cells from therapeutics. Therefore, we
next examined how CD82 regulates AML cell interactions with the niche. Our
data show that the organization of CD82 mediates N-cadherin clustering in a
glycosylation-dependent manner for the control of AML-niche interactions. As
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AML blasts can exhibit uncontrolled signaling, we also examined how CD82
promotes Protein Kinase C α (PKCα) signal transduction in AML. Our data
demonstrate that CD82 scaffolding promotes sustained PKCα signaling for the
control of AML growth. From these studies, we suspect that targeting the
molecular organization of CD82 may provide a means by which AML cells can be
released from the bone marrow, while attenuate uncontrolled signaling in AML.
Collectively, these data shed light on the mechanisms by which CD82 and the
domains within CD82 contribute to cellular adhesion and signaling. We believe
that these data offer CD82 and palmitoylation as molecular targets for enhancing
HSPC transplantations and improving the efficacy of AML therapeutics.
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Chapter 1 – Introduction
1.1 Hematopoietic stem cells
1.1.1 History of hematopoietic stem cells
The use of the atomic bomb during World War II and the subsequent
radiation exposure experienced by civilians inspired research aimed towards
understanding methods by which bone marrow failure occurred and could be
restored (Henig and Zuckerman, 2014). Researchers began their work by using
murine models of radiation and came across the discovery of hematopoietic stem
cells (HSCs) and their therapeutic potential in transplantation, which is now a
standard of care for several diseases.
The first inkling of the therapeutic nature of HSCs was observed during
experiments monitoring the survival rate of mice with various tissues protected.
Jacobson and colleagues demonstrated that by lead-shielding the spleen, a
hematopoietic organ, they could achieve complete hematopoietic recovery in
mice that were irradiated (Jacobson et al., 1951). A series of follow-up reports
from this group further postulate upon the mechanism by which protection of the
spleen might enhance mouse survival. It was hypothesized that the cells of the
protected tissue, in this case, the spleen, produced the components responsible
for enhanced mouse survival (Jacobson, 1952). In order to further investigate this
idea, Lorenz and colleagues transplanted bone marrow from non-irradiated mice
into irradiated mice to determine if the hematopoietic components of the bone
marrow were sufficient to promote animal survival (Lorenz et al., 1952; Lorenz et
al., 1951). Indeed, the authors found that mortality following injections of bone
marrow protected animals from death and enhanced the production of
erythrocytes, reticulocytes, and leukocytes compared to animals that did not
receive a bone marrow transplantation. Further studies attempted to track the
fate of transplanted bone marrow cells throughout the animal, finding that donor
derived circulating erythrocytes as well as injected bone marrow cells are
capable of repopulating the marrow of irradiated animals (Nowell et al., 1956;
Smith et al., 1957). These studies demonstrate that bone marrow components
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can protect animals from death following irradiation, though it was unclear if the
cellular or humoral components (or both) are responsible for such actions.
A closer examination of the cellular components of the bone marrow
demonstrated that injection of bone marrow components into irradiated mice
promotes

the

formation

of

colonies

of

erythrocytes,

myelocytes

and

metamyelocytes within the spleen (Till and Mc, 1961). Additional repopulation
studies by Wu and colleagues suggested that hematopoietic and immune cells
are derived from a common stem cell (Wu et al., 1968), which is considered the
accepted principle of hematopoietic stem cell lineage today.

1.1.2 Identification of hematopoietic stem cells
Hematopoietic stem cells are defined as cells capable of self-renewal and
differentiation into blood and immune cells. HSCs can differentiate into a variety
of cell types, which are depicted in Figure 1.1. The general hierarchy of
differentiation begins with long-term HSCs (LT-HSCs), which are capable of selfrenewal or differentiation, which then become short-term HSCs (ST-HSCs) with
reduced

self-renewal

capacity.

ST-HSCs

can

undergo

self-renewal

or

differentiation into multipotent progenitor cells (MPPs), which ultimately become
lineage restricted progenitor cells, and subsequently mature effector cells
(Ivanova et al., 2002). These distinct populations of cells express unique
combinations of surface markers that allow them to be isolated.

1.1.3 Long-term hematopoietic stem cells
Long-term HSCs are defined as HSCs that when transplanted into lethally
irradiated recipients can repopulate the recipient’s hematopoietic system for life.
The first identifying marker of LT-HSCs that was explored was CD34 (Baum et
al., 1992). CD34 is a transmembrane glycoprotein, which is expressed on the cell
surface and is a ligand for L-selectin. CD34 has been demonstrated to regulate
cellular proliferation, differentiation, adhesion, and morphogenesis (Nielsen and
McNagny, 2008). Early work demonstrated that human cells within the CD34(+)
fraction were responsible for the establishment of long-term myeloid and
lymphoid cultures (Baum et al., 1992). The researchers went on to evaluate
additional markers for HSCs, demonstrating that CD34 combined with Thy-1(+)
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Figure 1.1: Diagram of hematopoiesis. Hematopoietic stem cell differentiation
first occurs when long-term HSCs differentiate into short-term HSCs, which
ultimately become multipotent progenitor cells. Multipotent progenitor cells can
then become lymphoid or myeloid progenitors. Once these cells become myeloid
or lymphoid progenitors, they are restricted in terms of the kinds of cells they can
ultimately become. Upon further differentiation, progenitor cells have the potential
to become a variety of terminally differentiated cells.

3

(CD90(+)) and lineage negative (Lin (-)) cells further purify the HSC population.
Lineage negative cells do not express surface markers that define them as
lineage committed or differentiated cells.
Additional work has demonstrated that the CD38 glycoprotein also serves
as a marker for HSCs. CD38 is an ectoenzyme, serving as an adenosine
diphosphate (ADP) ribosyl cyclase (Deaglio et al., 2008). Huang and Terstappen
demonstrated that CD34(+) and CD38(-) human fetal bone marrow cells were
enriched for the ability to differentiate into lymphoid and myeloid cells.
Furthermore, they hypothesized that the CD34(+)/CD38(-) fraction of cells could
recapitulate all phases of hematopoiesis (Huang and Terstappen, 1994). Further
analysis of CD34(+)/CD38(-) cells demonstrated that these cells represented only
0.02% of the mononuclear cells from the bone marrow and cord blood and exist
mostly in the G0/G1 cell cycle state (Hao et al., 1996). Additional work by Miller
and colleagues show that CD34(+)/Lin(-)/CD38(-) cells grown under differing
culture conditions can differentiate into natural killer cells, B-lineage cells,
dendritic cells, as well as myeloid cells (Miller et al., 1999).
Conversely, the CD45 glycoprotein serves as a distinguishing marker for
committed myeloid progenitors, B cells and naïve T cells (Altin and Sloan, 1997;
Civin and Gore, 1993; Fritsch et al., 1993). As such, it was recently shown that
the fraction of cells that express low levels of the CD45 isoform, CD45RA, further
purifies LT-HSCs (Majeti et al., 2007). Subsequent analysis of these markers
demonstrates that the Lin(-)/CD34(+)/CD38(-)/CD90(+)/CD45RA(-) has improved
long-term engraftment potential compared to the CD90(-) population (Majeti et
al., 2007). As such, the current standard set of markers used to identify LT-HSCs
in humans is Lin(-)/CD34(+)/CD38(-)/CD90(+)/CD45RA(-).

1.1.4 Hematopoietic progenitor cells
As was previously mentioned, Majeti et al. showed that CD90 expression
serves as a marker for LT-HSCs. Although the CD90(-) population has some
repopulation capacity, it is severely diminished compared to CD90(+) cells
(Majeti et al., 2007). As such, the Lin(-)/CD34(+)/CD38(-)/CD90(-)/CD45RA(-)
population of cells is considered to contain hematopoietic multipotent progenitor
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cells. The authors also find that when individual cells were plated in
methylcellulose media, the Lin(-)/CD34(+)/CD38(-)/CD90(+)/CD45RA(-) cells
repopulate the lymphoid and myeloid cells of the bone marrow more efficiently
compared
Furthermore,

to

the
the

Lin(-)/CD34(+)/CD38(-)/CD90(-)/CD45RA(-)
authors

)/CD90(+)/CD45RA(-)

LT-HSCs

demonstrate

that

become

fraction.

Lin(-)/CD34(+)/CD38(-

Lin(-)/CD34(+)/CD38(-)/CD90(-

)/CD45RA(-) expressing multipotent progenitor cells and ultimately Lin()/CD34(+)/CD38(-)/CD90(-)/CD45RA(+) expressing multipotent progenitor cells.
Downstream of multipotent progenitor cells are the lineage committed
progenitor cells, which include common lymphoid and myeloid progenitors and
further downstream, megakaryocyte/erythrocyte and granulocyte/macrophage
progenitor cells (Akashi et al., 2000). Common lymphoid progenitors will first
become lineage restricted progenitors, which include pro-dendritic cells, pro-Bcells, pro-T-cells or pro-natural killer cells. Ultimately, these restricted progenitors
will become dendritic cells, B-cells, T-cells or natural killer cells, respectively
(Galy et al., 1995). Common myeloid progenitors (CMPs) follow a different track;
these cells can first become megakaryocyte/erythrocyte progenitors or
granulocyte/macrophage
Megakaryocyte/erythrocyte

progenitors

(Seita

progenitors

can

and

then

Weissman,

become

2010).

megakaryocyte

progenitors or erythrocyte progenitors, while CMPs can differentiate into
granulocyte/macrophage progenitors. CMPs can also differentiate into prodendritic cells and ultimately dendritic cells.
The process of hematopoiesis is a complicated hierarchy that requires
several levels of regulation. In the next section, we will address some of the
signaling cascades that help to maintain proper numbers of HSCs and
differentiated cells.

1.1.5 Regulation of hematopoietic stem cells
HSCs are regulated by a variety of intrinsic and extrinsic factors that
contribute to their continued self-renewal and differentiation. It is estimated that
HSCs only replicate once every 40 weeks in vivo (Catlin et al., 2011). Upon
division, cells must decide to remain HSCs and undergo self-renewal,
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differentiate, or undergo apoptosis. The pathways that will be discussed with
regards to maintenance of HSCs are the Wnt/β-catenin pathway and Notch
signaling cascades.
The Wnt signaling pathway is generally accepted as a regulator of HSC
self-renewal and differentiation, though conflicting studies exist that challenge
this notion. In cells that are not undergoing Wnt signaling, the cytoplasmic
protein, β-catenin, is usually degraded (Reya and Clevers, 2005). However, upon
Wnt signal initiation through binding to the receptor complex of Frizzled and
Lrp5/6, β-catenin is stabilized. This stabilization allows β-catenin to ultimately
translocate to the nucleus and interact with the T-cell factor/lymphoid enhancer
factor (Tcf/Lef) transcription factors, which promotes gene transcription. It has
been described that HSCs and their surrounding microenvironmental cells can
produce Wnt proteins (Austin et al., 1997; Hackney et al., 2002; Reya et al.,
2000; Van Den Berg et al., 1998). Furthermore, studies from the laboratory of
Irving Weissman have demonstrated using several experimental approaches that
Wnt signaling promotes HSC maintenance (Rattis et al., 2004; Reya et al., 2003;
Staal and Luis, 2010; Willert et al., 2003). In contrast, follow up studies using
modified experimental setups challenged the findings from the Weissman
laboratory (Baba et al., 2005; Baba et al., 2006; Kirstetter et al., 2006; Scheller et
al., 2006). However, more recent in vitro studies have recapitulated some of the
Weissman findings, showing that Lin(-)/Sca(+)/c-Kit(-) cells engineered to
express Wnt3a exhibit a decrease in the proportion of myeloid or lymphoid
committed cells compared to total cells, suggesting that Wnt signaling indeed
plays a role in regulating HSC differentiation (Malhotra et al., 2008).
The Notch signaling pathway has also been implicated in regulating HSC
self-renewal and differentiation. Notch protein exists as a transmembrane
receptor, which is cleaved upon its engagement with a transmembrane ligand as
presented by an adjacent cell. This cleavage product, the Notch intracellular
domain, can then translocate to the nucleus to promote the transcription of target
genes, many of which contribute to HSC maintenance (Kopan, 2012).
Experiments from Varnum-Finney and colleagues determined that constitutive
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expression of the Notch1 intracellular domain in murine hematopoietic progenitor
cells shifted the cell population to hematopoietic stem cells (Varnum-Finney et
al., 2000). Furthermore, the experimenters determined that Notch signaling
promotes HSC self-renewal and differentiation into granulocytes, macrophages,
erythroid, and megakaryocyte lineages, while Notch signaling reduces
differentiation into B-cells. An additional study from the David Scadden laboratory
also expressed constitutively activated Notch1 in murine progenitor cells (Stier et
al., 2002). They found that these cells have an increased stem cell population, as
quantified by the ability for progenitor cells to repopulate lethally irradiated mice.
It is important to note that the environment in which HSCs reside can also
greatly influence their self-renewal and differentiation properties. This can be
achieved through initiation of the aforementioned signaling cascades through
paracrine signaling or adhesive signaling. These topics will be discussed later in
the “Stem cell niche” section of Chapter 1.

1.1.6 Clinical usage of hematopoietic stem cells
Due to the multipotent capacity of hematopoietic stem cells, they can be
transplanted to help treat a variety of diseases that affect the blood and immune
system. Early studies demonstrated that bone marrow transplants can protect
mice that were lethally irradiated from death (Spangrude et al., 1988).
The type of HSC transplant performed is defined by the relationship of
donor to recipient (Appelbaum, 2003). For example, syngeneic transplants
involve the transplantation of HSCs from one identical twin to another. The most
common forms of HSC transplants are autologous and allogeneic transplants.
Autologous transplants isolate cells directly from a patient to be transplanted
back into the same patient under a treatment regimen. Numerous cancer
treatment regimens require radiation therapy and chemotherapy, which can
greatly diminish the efficiency of the patient’s immune system. In order to combat
this, patients will often times undergo an autologous transplantation during their
treatment regimen. Allogeneic transplantation requires cells to be isolated from a
donor and transplanted into a different recipient. This type of transplantation is
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used primarily for the treatment of leukemias and blood diseases, as the recipient
will benefit from having their hematopoietic system replaced with a new one.

1.1.7 Hematopoietic stem cell isolation from patients
In order to improve the success of HSC transplants, it is essential that
high numbers of pure HSCs are isolated. HSCs reside in specialized
microenvironments within the bone marrow, vasculature, and spleen amongst
other locations within the body (Taichman et al., 2001). In order to reduce the
invasiveness of patient HSC isolations, it has become routine to mobilize HSCs,
or to release them from their niche to the peripheral blood prior to isolation
(Appelbaum, 2003). It was demonstrated that the mobilized cells exhibit
properties unique from the residual niche HSCs, including low expression levels
of vascular cell adhesion molecule-1 (VCAM-1), c-Kit and integrins as well as an
increased proportion of cells within the G0 cell cycle phase (Bonig et al., 2009a;
Graf et al., 2001; Scott et al., 1997; Yamaguchi et al., 1998).
One of the most commonly used agents to mobilize HSCs is granulocytecolony stimulating factor (G-CSF). The receptor for G-CSF is expressed on
hematopoietic progenitor cells, terminally differentiated cells, and surrounding
endothelial cells (Bocchietto et al., 1993). It is hypothesized that G-CSF
promotes the cleavage of stromal cell-derived factor-1 (SDF-1, also known as
CXCL12), which is the ligand for the C-X-C chemokine receptor 4 (CXCR4),
thereby reducing CXCR4-mediated HSC retention (Liu et al., 2000; Petit et al.,
2002). Furthermore, treatment of human CD34(+)/CD38(-)/(lo) cells with antiCXCR4 antibodies decreases the ability for G-CSF treatment to mobilize HSCs
(Petit et al., 2002). Additionally, in patients that do not mobilize HSCs effectively
with G-CSF alone, the CXCR4 antagonist AMD3100 (also known as Plerixafor or
Mozobil) is used in combination with G-CSF (Bonig et al., 2009a; Bonig et al.,
2009b; Burroughs et al., 2005; Devine et al., 2004; Devine et al., 2008;
Flomenberg et al., 2005; Larochelle et al., 2006).
Additional work has identified several other molecules and mechanisms by
which HSCs can be mobilized from their niches. However, the clinical relevance
of these pathways remains to be explored. For example granulocyte-macrophage
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colony-stimulating factor (GM-CSF) has also been demonstrated to promote
HSC mobilization in combination or sequence with G-CSF treatment (Lane et al.,
1999; Sohn et al., 2002). Work from Molineux and colleagues demonstrated that
mice treated with G-CSF in combination with stem cell factor (SCF), the ligand
for the c-Kit receptor, increased the frequency of blood-borne colony-forming
cells, which is an indicator of an increase in HSC release (Molineux et al., 1991).
Although this study has yet to be followed up with more sophisticated
technologies, it indicates that synergism between G-CSF and SCF may exist to
enhance HSC mobilization. Interleukins IL-2 and IL-8 have also been implicated
in mediating HSC mobilization in concert with G-CSF (Burns et al., 2000;
Watanabe et al., 1999). Furthermore, work has also demonstrated that treatment
with the chemotherapeutic agents paclitaxel and cyclophosphamide can enhance
HSC mobilization (Burtness et al., 1999; Fernandez et al., 2008; Verma et al.,
1999). Future clinical analyses of the aforementioned pathways in mediating
HSC mobilization will be required to improve mobilization efficiency.
Beyond the mobilization and isolation of HSCs, umbilical cord blood has
also been evaluated as a source for HSCs for transplantation (Appelbaum,
2003). Though the success rate is diminished compared to bone marrow
transplants (estimated at 31% versus 43%, respectively), cord blood has a lower
T cell content, reducing the risk of graft-versus-host disease (GVHD) occurrence
(Rocha et al., 2001). The major setbacks regarding umbilical cord blood
transplantations are low cell number, delayed engraftment, and reduced ability to
reconstitute the immune system (Ballen et al., 2013). As such, it will be valuable
to continue to evaluate means by which we can enhance the efficacy of umbilical
cord blood transplantations.

1.1.8 Regulation of hematopoietic stem cell transplant success
Once the donor HSCs are mobilized and collected, they are then infused
into the recipient. The sign of a successful transplantation is the repopulation of
the adult hematopoietic system. There are a number of complications that can
prevent the success of HSC transplantation. GVHD occurs when immune cells
from the transplant cause injury to the recipient (Appelbaum, 2003). This
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primarily occurs when the donor and recipient are ineffectively matched for their
human leukocyte antigen, which causes the donor cells to view the recipient’s
cells as foreign. In cases with two or more mismatched gene loci, poor survival is
expected (Anasetti et al., 1989). In cases of autologous transplantations, it is
possible that the isolated HSCs may contain tumor cells, which when re-infused
may result in disease development. There is evidence that purification of the
HSC population or treatment of the isolated cells with chemotherapeutics can
improve patient outcome, but this has yet to become standard in the clinical
setting (Appelbaum, 2003; Gribben et al., 1991).
Finally, the success of the transplantation is greatly impacted by the ability
for HSCs to effectively home to the recipient’s bone marrow. As the bone marrow
is the primary site of hematopoiesis, when HSCs reach this microenvironment,
they can undergo self-renewal and differentiation, two processes critical to
repopulating the recipients hematopoietic system (Calvi and Link, 2015). There
are numerous molecules know to regulate this process of bone marrow homing,
including integrins (α4, α5) as well as CXCR4 and it’s ligand, SDF-1 (Kollet et al.,
2001 ; Lanzkron et al., 1999; Scott et al., 2003). The role of these molecules and
signaling events in regulating HSC interactions with the bone marrow niche will
be discussed further in the “Stem cell niche” section of this introduction.

1.2 Acute myeloid leukemia
1.2.1 Acute myeloid leukemia disease properties
Acute myeloid leukemia (AML) is a blood cancer that results from a
defective hematopoietic system, which generates an increase in myeloid
progenitor cells (Lowenberg et al., 1999). The diagnosis of AML is primarily
performed through morphological identification of leukemic myeloblasts within
patient peripheral blood and bone marrow samples. Generally speaking, a blast
count of 20% or more results in a diagnosis of AML. Upon diagnosis, flow
cytometry is used to further characterize the disease based on the expression
patterns of myeloid markers, usually CD33 and CD13 (Estey and Dohner, 2006).
Genetic mapping of patient samples has demonstrated that chromosomal
abnormalities are associated with AML. For example, AML can result from
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chromosomal translocations, which often lead to the production of oncogenic
fusion proteins (Tenen, 2003). One of the most common pathways affected by
the production of fusion proteins in AML is the AML1-CBFβ heterodimeric
transcription factor. Core binding factors (CBFs) include one alpha and one β
subunit (Hart and Foroni, 2002). There are three different potential α subunits,
Runx1-3 (also known as AML1, CBFA2 or PEBP2αB), and one common β
subunit, CBFβ (Lund and van Lohuizen, 2002). Under normal conditions, the
AML1 transcription factor interacts with CBFβ, which allows transcription of
genes that regulate hematopoiesis (Lowenberg et al., 1999; Okuda et al., 1996).
However, in AML, the generation of AML1 or CBFβ fusion proteins renders the
transcription factor nonfunctional. For example, translocation of t(8;21) results in
the generation of the eight-twenty-one (ETO)-AML1 fusion protein, while inv(16)
leads to the production of the CBFβ-MYH11 chimera (Downing et al., 2000). It is
estimated that the incidence of these fusion proteins in AML is between 6-7%
(Estey and Dohner, 2006). Another commonly generated fusion protein is the
promyelocytic leukemia (PML)- retinoic acid receptor alpha (RARα) fusion
resulting from t(15:17), which has been estimated to occur in 4-7% of AML
patients (Estey and Dohner, 2006; Papaemmanuil et al., 2016). The expression
of the PML-RARα fusion protein has been shown to deregulate the differentiation
of myeloid progenitor cells (Grignani et al., 1993).
The mixed-lineage leukemia (MLL) gene can also be subject to fusions
with several partner genes to generate leukemia. Under normal conditions, MLL
controls expression of homeobox (HOX) genes, which contribute to the
maintenance of hematopoietic stem and progenitor cells (Alharbi et al., 2013).
However, in AML, MLL can become fused to the AF9 protein, which prevents
complete erythroid and myeloid maturation (Abdul-Nabi et al., 2010).
Researchers have taken advantage of this fusion protein system and integrated
the MLL-AF9 fusion protein into mouse models to study AML in mice (Corral et
al., 1996).
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1.2.2 Identifying markers of acute myeloid leukemia
Because AML is a heterogeneous disease, there is no single
immunophenotype associated with diagnosis. Rather, the blast count serves as
the best indication of disease. However, recent advances have characterized the
surface markers associated with the cancer stem cell population in leukemia.
Cancer stem cells are defined as a rare subset of cancer cells, which have stem
cell properties, making them particularly difficult to target. More specifically,
cancer stem cells are described as tumorigenic cells with the ability to self-renew
and to become any cell of the tumor population (Guo et al., 2006; Jordan et al.,
2006 ; Yu et al., 2012). AML has been described to contain a population of
cancer stem cells, which are referred to as leukemia stem cells (LSCs) (Bonnet
and Dick, 1997; Lapidot et al., 1994). Early work using patient sample xenografts
into mouse models demonstrated that LSCs are found exclusively within the
CD34(+)/CD38(-) AML blast population (Bonnet and Dick, 1997; Jordan, 2002;
Lapidot et al., 1994). Further characterization has identified numerous other
surface markers that can be used to isolate LSCs, including CD33, CD123 and
CD13 (Horton and Huntly, 2012; Taussig et al., 2005). However, from patient to
patient, there is a large degree of heterogeneity; as such, personalized targeting
of LSCs may prove to be more fruitful for AML therapeutics.

1.2.3 Aberrant signaling in acute myeloid leukemia
As is the case in most cancers, signaling in AML is significantly altered
compared to normal cellular signaling. For example, mutations in the FMS-like
tyrosine kinase 3 (FLT3) and the c-Kit receptor tyrosine kinase (RTK) have been
well documented in AML. As such, targeting RTKs is of significant therapeutic
interest. Under normal conditions, FLT3 is expressed on healthy c-Kit(+)/CD34(+)
progenitor cells, while FLT3 expression is frequently increased on AML blasts
(Drexler, 1996; Rosnet et al., 1996). Upon ligand engagement, FLT3 signal
transduction activates various downstream targets including phosphoinositide 3kinase (PI3K), Ras, signal transducer and activator of transcription 5 (STAT5),
phospholipase C-γ (PLC-γ) and Src (Gilliland and Griffin, 2002). The two most
common FLT3 mutations associated with AML are an internal tandem duplication

12

(ITD) in exons 14 and 15 or a missense point mutation in exon 20, both of which
produce a constitutively active form of FLT3 (Nakao et al., 1996; Stirewalt and
Radich, 2003). FLT3 mutations have been found in approximately 15-35% of
AML cases, demonstrating potential for FLT3 targeting as an AML therapeutic
(Nakao et al., 1996; Stirewalt and Radich, 2003). As such, several FLT3
inhibitors are undergoing phase 1 and 2 clinical trials to determine the
appropriateness of their use as single agents of in combinational therapy with
chemotherapeutics (Grunwald and Levis, 2013).
The c-Kit receptor tyrosine kinase is expressed on HSCs and contributes
to the maintenance of their stemness (Thoren et al., 2008). c-Kit (also known as
CD117) is a receptor for stem cell factor (SCF) and c-Kit positive blasts are found
in approximately 80% of AML cases (Ikeda et al., 1991). Furthermore, mutations
in c-Kit are found in approximately 17% of AML cases, but in patients with CBF
AML, the incidence is 52% (Boissel et al., 2006; Corbacioglu et al., 2006;
Goemans et al., 2005; Paschka et al., 2006). The most well characterized
mutations of c-Kit in AML are ITD of exon 11, insertion/deletion of exon 8, or a
single amino acid substitution of a valine or tyrosine for aspartate at codon 816,
referred to as D816 (Longley et al., 2001; Park et al., 2011). The activation of c-Kit
can induce various signaling cascades including PI3K, Src family kinases,
mitogen-activated protein kinase (MAPK) and phospholipase C and D
(Lennartsson and Ronnstrand, 2012). Though tyrosine kinase inhibitors (TKIs)
are already in use clinically to treat AML, current work is focusing on the
development and efficacy of c-Kit specific TKIs, such as dasatinib and
midostaurin (Dohner et al., 2015).
Intracellular kinases as well as other kinds of intracellular molecules have
also been shown to exhibit aberrant signaling in AML. For example, the Ras
family of guanosine triphosphate (GTP)-binding proteins has increased activation
in several leukemias, including AML. In particular, N- and K-RAS have been
shown to have increased activation in 20-40% of AML cases (Reuter et al.,
2000). More specifically, mutations within Ras itself, or upstream regulators, such
as c-Kit or FLT3, can render Ras constitutively activated (Bos et al., 1987; Dosil

13

et al., 1993; Farr et al., 1988; Senn et al., 1988). Ras activation requires
adequate tethering of Ras to the plasma membrane, which is mediated through
the post-translational modification of farnesylation. Though palmitoylation has
also been demonstrated to contribute to this process, it seems that farnesylation
is most critical for mediating membrane recruitment and subsequent signaling
(Heimbrook and Oliff, 1998). Therefore, the use of farnesyltransferase inhibitors
to attenuate Ras signaling has been demonstrated in cellular and animal models,
but had disappointing results when examined in human clinical trials (Reuter et
al., 2000). As such, direct inhibition of the MAPK and Akt pathways is currently
under investigation in AML patients with Ras mutations (Johnson et al., 2014).

1.2.4 Acute myeloid leukemia treatment
Conventionally, AML treatment is administered to first achieve remission
(induction therapy) and then to further ablate the disease (post-induction therapy)
(Appelbaum, 2003). In order to induce remission, patients undergo conventional
chemotherapy with the use of daunorubicin, cytarabine or a combination
(Coombs et al., 2016). Upon the achievement of remission, younger patients will
undergo high dose cytarabine, followed by a myeloablative allogenic or
autologous bone marrow transplantation. Because older patients cannot tolerate
the toxicity of high dose chemotherapy, this treatment recommendation is not
given.

Instead,

older

patients

are

recommended

to

undergo

further

chemotherapy but not at as high of a concentration or a non-myeloablative
transplant (Lowenberg et al., 1999). There are significant ongoing efforts for the
use

of

therapies

targeting

tyrosine

kinases,

farnesyltransferases,

methyltransferases as well as the proteasome for the use in older patients
(Kuendgen and Germing, 2009). Unfortunately, the overall survival rate for adults
remains low at only about 10%, primarily due to persistent or relapsed AML
(Appelbaum et al., 2001; Tallman et al., 2005). Furthermore, significant
development of post-remission and relapse therapies, particularly for older
patients, will be necessary to successfully eradicate this disease.

1.3 Stem cell niche
1.3.1 History of the stem cell niche
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The concept of the stem cell microenvironment or “niche” was coined first
by Schofield in 1978 whereby he hypothesized that the specialized surrounding
environment of stem cells contributed to their reconstitution capacity (Schofield,
1978). Furthermore, the niche contributes to the maintenance of stem cells as
well as their differentiation when appropriate. Though this dissertation will take
particular focus on the HSC niche, it is important to note that the concept of the
stem cell niche has been heavily characterized with respect to hematopoietic,
skin/hair follicle, intestine, neural and gonadal stem cells (Morrison and
Spradling, 2008). Work has also identified the role of the niche in regulating
germline stem cells in invertebrates including Drosophila melanogaster and
Caenorhabditis elegans. In particular, it was determined that the surrounding
terminal filament, cap, and inner sheath cells make up the ovarian niche in
Drosophila. Researchers determined that cap cells are essential for the
regulation of the gonadal niche structure, meanwhile, cap cells and terminal
filament cells participate in direct cellular contact with germline stem cells
(GSCs), critical for the maintenance of GSC differentiation (Xie and Spradling,
2000). Another study from around the same time characterized the GSC niche
interactions in the testis, determining that associations exist between cyst cells
and GSCs, which may contribute to GSC division and differentiation (Kiger et al.,
2000). Meanwhile, distal tip cells have been demonstrated to regulate GSC
division in Caenorhabditis elegans (Kimble and White, 1981). These fundamental
studies of how niche interactions regulate stem cell fate provided the framework
for future researchers to characterize the hematopoietic stem cell niche.

1.3.2 Hematopoietic stem cell niche
The bone marrow and vasculature represent the primary hematopoietic
stem cell niches, while the spleen is also known to be a site of extramedullary
hematopoiesis. Additionally, the fetal liver is a critical niche for HSC expansion
during development before HSCs migrate to and reside within the bone marrow
(Samokhvalov et al., 2007). The bone marrow niche is comprised of several
cellular

components

including

osteoblasts,

osteoclasts,

stromal

cells,

mesenchymal stem cells (MSCs) and adipocytes, as diagrammed in Figure 1.2.
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Figure 1.2: Components of the hematopoietic stem cell niche. The endosteal
and vascular stem cell niches are depicted in the cartoon above. The spongy
bone is magnified on the left to depict osteoblasts and osteoclasts, which are the
main cellular components of the bone marrow niche. These cells can also
deposit extracellular matrix components, to which HSCs may adhere. On the
right is a sinusoid depicting the main cellular components of the vascular niche.
HSCs may enter the vasculature by extravasating through endothelial cells.
Stromal cells, such as CAR cells and mesenchymal stem cells are on the outside
of the endothelial layer.

16

Early work shows that osteoblasts produce G-CSF, and when CD34(+) cells
were cultured with osteoblasts, there was an increase in the production of
hematopoietic cells (Taichman and Emerson, 1994). Defining studies from the
laboratory of David Scadden demonstrate that an increase in the number of
osteoblasts significantly increased the hematopoietic cell population, as defined
as Lin(-)Sca-1(+)c-Kit(+) cells, within the bone marrow (Calvi et al., 2003).
Furthermore, the authors also determined that these cells have increased
engraftment capacity compared to normal control counterparts. The authors
propose that increased γ-secretase activity contributes to enhanced Notch
signaling, thereby increasing HSC numbers. A concurrently published article
demonstrates that the presence of a particular type of osteoblast termed the
spindle-shaped N-cadherin(+)CD45(-) (SNO) cell is critical for maintenance of
HSC number (Zhang et al., 2003). The authors conclude that SNO cells enhance
bone morphogenic protein expression, which contributes to the maintenance of
niche size. It is important to note that the role of SNO osteoblasts remains highly
controversial, as reports have disputed claims of their importance in regulating
HSCs (Kiel et al., 2007).
There are several signaling pathways enacted by osteoblasts that are
implicated in regulating HSCs within the niche. For example, it has been shown
that HSCs that express the Tie2 receptor tyrosine kinase, which are determined
to be a quiescent population, are found in contact with the endosteal bone
surface (Arai et al., 2004). Furthermore, previous work has demonstrated that
signaling along the myeloproliferative leukemia (MPL)/thrombopoietin (THPO)
axis is implicated in regulating HSC quiescence (Yoshihara et al., 2007). More
specifically, the authors found that long-term MPL expressing HSCs adhered to
THPO expressing osteoblasts, indicating a potential regulatory role. The
involvement of Notch signaling from osteoblasts in regulating HSCs is somewhat
controversial. Initial reports in mice demonstrate that osteoblasts within the bone
marrow niche express the Notch ligand, Jag1 (Calvi et al., 2003). The authors
then examined the levels of the Notch intracellular domain (NCID) in murine
HSCs, finding an increase in NCID in transgenic mice with increased osteoblast
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and HSC numbers. From these data, the authors suggest that osteoblastmediated Notch signaling may play a role in regulating HSC numbers. However,
a follow-up study in 2005 concluded that Notch signaling is dispensable for the
regulation of HSC self-renewal and differentiation (Mancini et al., 2005). This
study also utilized transgenic mice, but these mice had an Mx-Cre-inducible
system whereby Jagged1 could be deleted. The authors show that HSC selfrenewal and differentiation are not affected by the absence of Jagged1 or
Notch1, providing conflicting results to the initial studies. Future work should
focus on uncovering the role of osteoblastic-mediated Notch signaling in
regulating HSCs, as it remains unclear within the field.
As the bone marrow microenvironment is highly vascularized, it is not
surprising that the endothelial cells that line the bone marrow comprise their own
vascular niche for the regulation of HSCs. These lining endothelial cells are
essential for allowing HSCs to enter and exit the bloodstream. Anatomical
studies have shown that bone marrow sinusoids are unique from regular veins;
they consist of a single layer of endothelial cells and lack any other supporting
cells (Kopp et al., 2005; Tavassoli, 1981). As was previously mentioned, HSCs
move to the fetal liver to expand prior to entering the bone marrow
microenvironment. It was found that mice lacking SDF-1 expression had
defective bone marrow colonization. Meanwhile, enforced expression of SDF-1 in
vascular endothelial cells could rescue this defect, demonstrating that signaling
from the vascular niche can regulate HSCs (Ara et al., 2003). Furthermore, early
work from the laboratory of Sean Morrison determined that LT-HSCs can interact
directly with endothelial cells within the femur in mice, providing visual and
quantitative evidence that HSCs may be regulated by interactions with these
cells (Kiel et al., 2007).
Beyond their role in regulating HSC trafficking, these endothelial cells can
also regulate HSC signaling. Recently, it was discovered that bone marrow
endothelial cells promote the maintenance of the LT-HSC compartment through
Notch-dependent signaling. The authors found that when LT-HSCs were
incubated with endothelial cells with neutralized Notch ligands, there was a
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significant decrease in proliferation and number of LT-HSCs compared to
incubation with control endothelial cells (Butler et al., 2010). A recent report has
shown that endothelial-selectin (E-selectin) is critical for regulating HSC
proliferation, whereby knocking out E-selectin in mice or treating animals with an
E-selectin agonist enhanced HSC self-renewal and slowed HSC cycling (Winkler
et al., 2012). The authors mention that the ligand by which E-selectin propagates
it’s action remains unknown, but they suggest that glycoproteins are likely
involved in regulating E-selectin signaling for the control of HSCs. Another recent
report has utilized a variety of SCF knockout mice to examine how the origin of
SCF regulates HSC signaling (Ding et al., 2012). The authors find that SCF
secreted from endothelial and perivascular cells is critical for maintaining the
repopulation capacity of HSCs, while SCF secreted from osteoblasts and
nestin(+) stromal cells is dispensable. The authors do note that other signaling
components from different niche components likely contribute to HSC
maintenance, although their study focuses on SCF signaling.
Although the osteoblastic and vascular niches represent the most well
researched regulatory niches for HSCs, HSCs may also interact with other types
of stromal cells. The bone marrow stroma includes all cells found between the
outer bone marrow blood vessels and the marrow surface which are not of the
hematopoietic lineage (Krebsbach et al., 1999). Mesenchymal stem cells (MSCs)
have been demonstrated to be in direct contact with HSCs within the niche. By
using nestin as a marker for MSCs, researchers found that these MSCs highly
express numerous genes that regulate HSCs, including genes that encode for
SDF-1, SCF, angiopoietin-1, IL-7, VCAM-1 and osteopontin. Furthermore, the
researchers determined that the presence of these nestin(+) MSCs within the
bone marrow is critical for maintaining HSC number within the bone marrow and
ultimately the presence of MSCs significantly impacts the ability for HSCs to
home to the bone marrow in transplantation assays (Mendez-Ferrer et al., 2010).
Additionally, perivascular stromal cells known as C-X-X motif ligand 12
(CXCL12)-abundant reticular cells (CAR cells) are known to regulate HSCs
through the SDF-1-CXCR4 signaling axis (Sugiyama et al., 2006). Additionally,
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an examination of the HSC repopulation capacity using HSCs from sites of
differing fatty content demonstrate that adipocytes are negative regulators of
HSCs (Naveiras et al., 2009). Further analysis into the mechanism by which this
occurs will shed light on how adipocytes regulate HSC fitness, which will be
critical towards tailoring HSC transplant therapies towards patients with obesity.
Beyond cellular components, HSCs may also interact with extracellular
matrix (ECM) components, which can control HSC signaling. For example,
integrins on HSCs may interact with ECM components deposited by osteoblasts
including fibronectin, collagen I, III and IV as well as laminin (Nilsson et al.,
1998). Hyaluronic acid (HA), which is produced by stromal and hematopoietic
cells, is also found within the bone marrow. HA is the ligand for CD44, which is
expressed on HSCs and can regulate HSC homing (Avigdor et al., 2004; Wight
et al., 1986). Furthermore, osteopontin has also been demonstrated to exist
within the endosteal region of the bone marrow niche, which can contribute to
HSC proliferation (Nilsson et al., 2005). We will discuss the molecules on HSCs
that regulate niche interactions, with a particular emphasis on integrins and
cadherins, later in this introduction.

1.3.3 Leukemia stem cell niche
The bone marrow niche provides a supportive microenvironment to
promote HSC maintenance. Unfortunately, cancerous cells can also take
advantage of this specialized microenvironment in order to evade treatment
efforts, which is a major contributor to AML patient relapse. In particular, AML
LSCs can take residence within the bone marrow niche, meanwhile remodeling
the microenvironment to meet the needs of LSCs. It has been shown that when
human AML LSCs are injected into NSG mice, they home to and engraft within
the

endosteal

region

of

the

bone

marrow

niche.

Furthermore,

this

microenvironment renders LSCs resistant to cytarabine treatment (Ishikawa et
al., 2007). As was mentioned in the hematopoietic stem cell section of this
introduction, the CXCR4 chemokine receptor is critical for maintaining HSCs
within the niche, whereby inhibition of CXCR4 signaling can mobilize HSCs into
the bloodstream. In line with this finding, it has been determined that CXCR4
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signaling can also be targeted in leukemias to disrupt LSC-niche interactions and
sensitize AML cells to therapeutics. For example, treatment with AMD3100, novel
CXCR4 blocking peptides, or CXCR4 blocking antibodies can mobilize leukemia
cells from the niche and improve their chemosensitivity (Kuhne et al., 2013; Nervi
et al., 2009; Zeng et al., 2006). Interestingly, it has also been demonstrated that
cytarabine treatment of a variety of leukemia cell lines can actually increase the
expression of CXCR4, indicating that perhaps CXCR4 should be targeted in
conjunction with chemotherapeutic regimens (Sison et al., 2013). Further studies
have determined treatment with the SDF-1 blocking peptide AMD3465 renders
AML cells susceptible to death from treatment with cytarabine as well as FLT3
inhibitors (Zeng et al., 2009). As FLT3 inhibitors have not proven to be successful
in the clinical setting, future studies should aim to re-evaluate FLT3 inhibition in
the context of CXCR4 inhibition to determine if these molecules should be
targeted in combination with one another.
Beyond the endosteal region of the niche, the vascular niche appears to
also interact with leukemia cells. Initial reports using in vivo confocal imaging of
the mouse skull demonstrate that the pre-B acute lymphoblastic leukemia cell
line Nalm6 interacts with the vasculature upon injection into NSG mice. The
authors determine that inhibition of the SDF-1/CXCR4 signaling axis diminishes
this recruitment, indicating that perhaps there is a conserved role for CXCR4
signaling in regulating leukemia interactions with both the endosteal and vascular
niche (Sipkins et al., 2005). Interestingly, the presence of leukemia cells within
the bone marrow microenvironment can dislodge healthy CD34(+) cells from their
niches, causing them to enter unconventional niche sites (Colmone et al., 2008).
Therefore, leukemia cells can significantly alter the normal landscape of the
niche, which ultimately disrupts “normal” interactions between HSCs and their
microenvironment.

1.4 Molecules regulating niche interactions
1.4.1 Introduction to integrins
One of the key molecular regulators of niche interactions is the integrin
family of adhesion receptors. Integrins are heterodimeric transmembrane
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proteins consisting of one α and one β subunit, which have been shown in
numerous systems to regulate cellular adhesion and migration (Campbell and
Humphries, 2011). In vertebrates, there are 18 α subunits and eight β subunits,
which can generate 24 known integrin heterodimers (depicted in Figure 1.3),
which have binding specificity for ECM or membrane bound ligands based on the
combination of subunits (Takada et al., 2007). It is thought that integrins exist in
two conformations; a closed (bent) inactive conformation or an open, fully
extended active conformation. Structurally, the α integrin subunit ectodomain
contains a β-propeller, a thigh, and two calf domains (Barczyk et al., 2010);
additionally, nine of the known integrin α subunits contain a α-I domain within the
β-propeller domain (Larson, 1989). Within the β-propeller region, there is a Ca2+
binding site; Ca2+ binding to this site has been demonstrated to affect integrin
ligand interactions (Campbell and Humphries, 2011 ; Humphries et al., 2003;
Oxvig and Springer, 1998). There is also a Mg2+ binding site within the metal-iondependent adhesion site (MIDAS) of the α subunit, which has been
demonstrated to contribute to integrin ligand binding and adhesion (Humphries et
al., 2003; Lee et al., 1995). There are domains within the α subunit that
contribute to the ability for integrins to tether between the open and closed
conformations. Within the α subunit, the linker domain between the β-propeller
and calf as well as the “knee” or “genu” region between the thigh and calf domain
contribute to integrin flexibility (Humphries et al., 2003; Xiong et al., 2001). The
integrin β subunit ectodomain is made up of seven domains, which are a β-Idomain, a hybrid domain, plexin-semaphorin-integrin (PSI) domain, four cysteine
rich epidermal growth factor-like repeats and a tail. The β-I-domain contains a
Mg2+ MIDAS, while also containing an inhibitory Ca2+ binding site next to the
MIDAS, termed the adjacent to MIDAS (ADMIDAS). This ADMIDAS can also
bind Mn2+, which promotes the change from the closed to open (active) integrin
conformation (Barczyk et al., 2010; Humphries et al., 2003; Lee et al., 1995).
Integrin activation can be characterized as occurring in an ‘inside-out’ or
‘outside-in’ manner. In the case of inside-out activation, signaling from the inside
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Figure 1.3: Integrin heterodimer combinations Depicted are the 24 known
human integrin subunits. The heterodimeric combinations of alpha and beta
subunits are shown. Some integrin subunits can form dimers with more than one
other subunit (ex: α4 can dimerize with β1 or β7) Schematic adapted from
(Takada et al., 2007).
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of the cell promote the conformational shift of the integrin into the open or active
conformation. This phenomena can be regulated by cytosolic proteins, such as
focal adhesion kinase (FAK), integrin linked kinase (ILK), or talin, amongst
others, interacting directly with the integrin cytoplasmic tails (Honda et al., 2009).
In the case of outside-in activation, interactions between the integrin ectodomain
and ligand can promote integrin activation (Emsley et al., 2000; Zhang et al.,
2008). There is substantial evidence from mutational studies that the
transmembrane domains of integrins form disulfide bonds with one another when
in the closed conformation (Lu and Springer, 1997; Luo et al., 2004). Meanwhile,
it appears that non-disulfide bonded integrin subunits can bind ligands, which has
led the acceptance of a model whereby integrin activation requires the physical
separation of the alpha and beta transmembrane domains. Interestingly, the
need for separation for integrin activation can be bypassed by the use of Mn2+,
which activate integrins in an ‘outside-in’ manner (Kim et al., 2003).

1.4.2 Integrin ligand interactions
The integrin ligand binding site (or pocket) has been determined to exist
between the α subunit β-propeller and β subunit I-domain (Xiong et al., 2001).
Meanwhile, the substrate binding specificity is conferred by the combination of
alpha and beta subunits, which interact with specific amino acid sequences
within integrin ligands. Integrin ligands include ECM components, cellular
receptors

(VCAM-1,

intracellular

adhesion

molecule-1

(ICAM-1))

and

microorganisms, pathogens and venoms (Arnaout et al., 2002; Gould et al.,
1990; Humphries et al., 2006; Isberg and Tran Van Nhieu, 1994; Nemerow and
Cheresh, 2002; Plow et al., 2000; Rieu et al., 1994). Although there is significant
diversity within the kinds of integrin ligands that exist, the amino acid binding
motifs remain somewhat conserved. For example, most integrins bind to ligands
with aspartic acid containing sequences, such as the RGD (α5β1, α8β1, αVβ1,
αVβ3,

αVβ5,

αVβ6,

αVβ8,

αIIbβ3),

LDV

(α4β1),

KQAGDV

(αIIbβ3),

RLD/KRLDGS (αVβ3, αMβ2), YYGDLR/FYFDLR (α2β1), and R...D (α1β1) (Plow
et al., 2000; Ruoslahti, 1996). Furthermore, a significant amount of research has
determined that the RGD amino acid motif is found within several integrin
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ligands, including fibronectin, vitronectin, fibrinogen, and collagen, which explains
why there are numerous integrins which recognize this particular sequence.
Additionally, much work has focused on identifying the ligand for the α4β1
integrin, determining that it is localized within the CS-1 region of fibronectin to the
amino acid sequence LDV (Dominguez-Jimenez et al., 1996; Komoriya et al.,
1991; Mould et al., 1991; Wayner et al., 1989).
When integrins move from their closed to open conformation, they also
move from a low to high ligand binding affinity state. With the use of integrin
membrane proximal cytoplasmic domain deletion mutants, it was determined that
the integrin subunit cytoplasmic domains are critical regulators of integrin affinity
(Crowe et al., 1994; O'Toole et al., 1994). Beyond the membrane proximal
domains, it has also been determined that the integrin C-terminal domains
contribute to their affinity regulation (Hughes and Pfaff, 1998). More specifically,
the NPxY motif within the β integrin tail is critical for regulation of integrin affinity,
as several integrin activating proteins, including talin and kindlin, bind to the
NPxY motif (O'Toole et al., 1995; Tadokoro et al., 2003). Talin is an intracellular
protein that can bind to integrin cytoplasmic tails as well as vinculin and actin
filaments, which allows it to connect integrins to the actin cytoskeleton (Ziegler et
al., 2008). It is currently accepted that talin binding to the membrane proximal
region of the β integrin subunit alters the spacing of the α and β subunits,
ultimately initiating integrin activation (Wegener and Campbell, 2008). The
contribution of integrin affinity to regulating integrin-mediated adhesion has been
explored. For example, it was shown that integrin α4β1 avidity contributes to the
adhesion of T cells to VCAM-1 and fibronectin (Feigelson et al., 2001).
Furthermore, it was shown that increased integrin affinity could also increase
Chinese hamster ovarian (CHO) cellular adhesion to the αVβ3 ligand, penton
base (Pampori et al., 1999).
It is thought that integrins become activated, bind to their ligand and then
form lateral interactions amongst each other to assume a ‘high avidity’
organization within the membrane (Cluzel et al., 2005). Ultimately, this clustering
is hypothesized to lead to the formation of highly stable focal adhesions, which
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link integrins to the actin cytoskeleton. The currently accepted sequence of
events first involves integrins to bind their ligand and then clustering into nascent
adhesions (Choi et al., 2008). Nascent adhesions can then mature into focal
complexes, which become focal adhesions and ultimately fibrillar adhesions
(Geiger et al., 2001). Previous work has demonstrated that outside-in activation
using Mn2+ can induce the formation of integrin clusters, demonstrating that
integrin activation precedes integrin rearrangement within the membrane (Cluzel
et al., 2005). Conversely, reports have demonstrated that integrin clustering
precedes leukocyte function-associated-antigen (LFA-1) integrin activation as
well as ligand binding (van Kooyk and Figdor, 2000; van Kooyk et al., 1994).
Additionally, work has demonstrated that integrin clustering is regulated by the
membrane composition. For example, it has been shown that membrane
clustering through the formation of membrane rafts can induce LFA-1 avidity
changes (Krauss and Altevogt, 1999). Furthermore, with the use of tetraspanin
CD151 knockout mice, it has been shown that CD151 contributes to α3β1
clustering in glomerular epithelial cells (Sachs et al., 2012).

1.4.3 Integrin mediated signaling
Though integrins lack catalytic activity, they can sequester intracellular
molecules to mediate signaling. Integrins are bidirectional signaling molecules
whereby intracellular signaling can promote integrin ligand binding (inside-out)
and ligand binding can also initiate intracellular signaling (outside-in) (Das et al.,
2014; Legate et al., 2009).

1.4.3.1 Outside-in signaling
Upon integrin activation, clustering, and ligand engagement, outside-in
signaling can be initiated, which helps integrins to maintain adhesions with
extracellular ligands. Recently the integrin “adhesome” was characterized with
respect to integrin binding interactions as well as signaling interactions (ZaidelBar et al., 2007). The authors identify more than 156 components within this
network with more than 500 interactions amongst components, illustrating the
complexity of the integrin adhesive signaling network. One of the most well
characterized downstream consequences of integrin outside-in signaling is the
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control of actin dynamics. For example, in T cells, LFA-1 outside-in signaling can
mediate the formation of an “actin cloud” in T cells in the cell center, which
ultimately contributes to T cell activation (Suzuki et al., 2007). Furthermore,
outside-in signaling induced by the engagement of integrin αIIbβ3 engagement in
platelets initiates the formation of actin containing filopodia (Hartwig et al., 1996;
Varga-Szabo et al., 2008). Additionally, another actin-dependent cellular process,
cell spreading, is also mediated by the activation of integrin α2β1 in platelets
(Inoue et al., 2003). Collectively, these studies demonstrate that outside-in
integrin activation can regulate actin-mediated cellular processes, which
ultimately can contribute to cellular adhesion and migration.

1.4.3.2 Inside-out signaling
Integrin inside-out signaling occurs when stimuli (internal or external)
initiate integrin activation. Several external stimuli can initiate integrin inside-out
signaling, such as T cell receptor activation (Burbach et al., 2007),

selectin

engagement (Green et al., 2004), purinergic receptor stimulation (Jung and
Moroi, 2001) as well as chemokine receptor activation (Laudanna et al., 2002). In
addition to external stimuli, integrin inside-out signaling can also be mediated
through the activation of cellular signaling pathways, including protein kinase C
(PKC), PI3K, and G proteins including Ras and Rho (Kinashi, 2005; Kolanus and
Seed, 1997; Shen et al., 2012).
One of the cellular consequences associated with integrin inside-out
signaling is the sequestration of intracellular molecules, such as talin and kindlin
(Ye et al., 2011). The recruitment and activity of these molecules can be
regulated by particular characteristics within the integrin cytoplasmic tail.
Interactions between intracellular molecules and integrins are mediated by the
NPxY motif within the cytoplasmic tail of β integrins. More specifically, proteins
that contain a phosphotyrosine-binding (PTB) domain, such as talin and the
kindlins can recognize the NPxY motif (Calderwood et al., 2003). Meanwhile, the
phosphorylation of the tyrosine residue within this motif can regulate the
particular proteins that can bind to this motif (Legate and Fassler, 2009 ; Legate
et al., 2009 ; Oxley et al., 2008). Beyond the NPxY motif, amino acid residues
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within integrin tails can also be phosphorylated by intracellular proteins. For
example, the β1 integrin can be phosphorylated at threonine 788/789 by protein
kinase C isoforms (Stawowy et al., 2005), meanwhile PKC can also promote the
phosphorylation of the serines within the β4 integrin subunit (Li et al., 2013a;
Rabinovitz et al., 2004). Furthermore, the β3 integrin subunit can be
phosphorylated at Thr799 by AKT and PDK1 (Kirk et al., 2000) and also by
extracellular signal-regulated kinase 2 (ERK2) in platelets (Lerea et al., 2007).

1.4.4 Integrins and hematopoietic stem cells and leukemia
As the niche is composed of numerous types of extracellular matrix
components, integrins have been described to be important regulators of
hematopoietic stem cell interactions with the niche. For example, early reports
demonstrate that bone marrow cells expressing the α4 integrin subunit had
increased stemness, as assessed by the ability to form colonies in a colony
forming unit (CFU) assay (Williams et al., 1991). Furthermore, the authors used
polyclonal antibodies to block the β1 integrin subunit, finding that injection of
antibody treated cells significant inhibited the ability for cells to colonize the
spleen or bone marrow. In the same year, a separate report also demonstrated
that the α4β1 integrin (also known as VLA-4) is a critical regulator of
hematopoiesis. Through the use of novel VLA-4 antibodies, the authors
demonstrate that blocking the α4β1 integrin diminishes the lymphoid potential of
long term bone marrow murine isolates, while slowing down the production of
myeloid cells (Miyake et al., 1991). Furthermore, with the use of CD34hi human
progenitor cells, it was determined that the VLA-4, VLA-5 and β2 integrins are
critical for regulating HSPC adhesion to stromal cells (Teixido et al., 1992). With
the use of isolated ECM components, they determined that VLA-4 and VLA-5 are
specifically regulating HSPC adhesion to VCAM-1 and fibronectin. Later studies
demonstrated that anti-VLA-4 antibodies inhibited the ability for murine bone
marrow cells to home to the bone marrow compared to PBS or rat IgG treated
cells (Vermeulen et al., 1998). This study also examined the ability for HSPCs to
be maintained within the niche by treating animals with VLA-4 antibodies and
examining the efflux of HSPCs into the blood. They find that anti VLA-4 antibody
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treatment significantly increases the presence of HSPCs within the blood
compared to controls. Finally, the authors isolated the mobilized cells from VLA-4
or control treated animals and injected them into a lethally irradiated recipient,
finding that the VLA-4 treated mobilized cells had increased repopulation
capacity, indicating the presence of long-term hematopoietic stem cells. Other
reports have demonstrated that blocking VLA-4 can inhibit HSPC homing (Kollet
et al., 2001), and may possibly act in concert with the α6 integrin subunit (Qian et
al., 2006). Moreover, numerous reports have demonstrated that antibodies
targeted to VLA-4 can be used to mobilize HSPCs into the blood
(Papayannopoulou and Nakamoto, 1993; Ramirez et al., 2009; Zohren et al.,
2008). Therefore, the α4β1 integrin is an attractive target with the potential to be
used to improve bone marrow homing, as well as HSPC yield during the isolation
process.
Integrins are also expressed on AML cells, which can contribute to AML
chemosensitivity and serve as a prognostic marker in certain cases. An early
study characterizing the expression of integrins on primary human AML blasts
showed that integrins VLA-4, VLA-4, LFA-1, and LFA-3 were expressed on
CD34(+) AML patient samples (De Waele et al., 1999). Additionally, it was shown
that AML adhesion to fibronectin occurs through VLA-4 and VLA-5, while laminin
binding occurs through VLA-6 (Bendall et al., 1993). Furthermore, the authors
used β1 and β2 integrin blocking antibodies and inhibited AML adhesion to bone
marrow fibroblasts, demonstrating a potential role for integrins in regulating AML
niche adhesion. Further studies demonstrate that the α4β1 integrin can regulate
HSC and AML pseudoemperipolesis, which refers to cellular migration below
stromal cells (Burger et al., 2003). Collectively, these studies show that integrins
present on AML cells can regulate AML interactions with niche components.
Clinical reports have also evaluated the suitability for VLA-4 as a predictor of
AML outcome. Contrary to several reports in adults (Matsunaga et al., 2003),
researchers demonstrate that high VLA-4 expression is associated with improved
patient outcome in child AML (Walter et al., 2010a).
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As the bone marrow may protect AML cells from therapies (Ishikawa et al.,
2007), much work has also focused on how integrins can regulate niche
interactions for chemosensitivity. Using U937 myeloid cell lines, authors
demonstrate that cells that have adhered to fibronectin have increased survival
upon daunorubicin treatment (De Toni et al., 2006). The authors go on to
demonstrate that crosstalk between the Wnt/β-catenin pathway and integrins
occurs to promote cellular survival, indicating that integrins, with other signaling
molecules, contribute to AML. Additional work focused specifically on VLA-4
mediated niche interactions shows that U937 cells adoptively transferred into
NOD scid gamma (NSG) mice can be dislodged from the bone marrow with the
administration of VLA-4 antibodies (Matsunaga et al., 2003). Furthermore, the
authors demonstrate that adhesion to fibronectin can protect patient samples
from cell death by administration of cytarabine and daunorubicin. Another report
utilizes a peptide that prevents β1 engagement with fibronectin to disrupt myeloid
adhesion. Using cell line models of leukemia, the authors show that peptide
treatment enhances cell death upon treatment with cytarabine, similarly to
treatment with VLA-4 or VLA-5 monoclonal antibodies. Further examination into
how this translates into in vivo systems show that in a mouse model of minimal
residual disease, treatment with this blocking peptide and cytarabine enhances
animal survival compared to cytarabine treatment alone. Collectively, these
studies demonstrate that integrins are critical regulators of AML niche
interactions as well as survival signaling. Therefore, integrins should continue to
be considered as potential targets for improving AML patient outcome
(Matsunaga et al., 2008).

1.4.5 Cadherins
Another critical regulator of cell-cell adhesion is the cadherin family of
membrane proteins. Cadherins are adhesion molecules that have structural
characteristics that identify them as classical, atypical, desmosomal, atypical,
and proto-cadherins (Nollet et al., 2000). Cadherins contain extracellular
cadherin (EC) domains, which are amino acid repeats found on the cadherin
extracellular region, as depicted in Figure 1.4. Cadherins propagate their
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adhesive function by binding to other cadherins on the surface of cells; this
involves both homophilic and heterophilic cadherin interactions (Niessen and
Gumbiner, 2002; Shapiro and Weis, 2009). As classical cadherins have been
determined to regulate hematopoietic stem/progenitor and acute myeloid
leukemia cell interactions, we will focus on these molecules throughout this
section.
Several classical cadherins are named for the tissue from which they were
identified. For example, N-cadherin was originally identified in chicken nerves
and has since been named neural cadherin (Hatta et al., 1988; Matsunaga et al.,
1988), while E-cadherin was characterized early on in human epithelia (Mansouri
et al., 1988; Shimoyama et al., 1989). Meanwhile, P-cadherin was characterized
in mouse placenta (Nose et al., 1987) and R-cadherin in retina (Inuzuka et al.,
1991). The ectodomain of classical cadherins, contain five extracellular (EC)
domains, which allow cadherins to participate in homophilic interactions (Koch et
al., 1999; Yap et al., 1997a). It is believed that the HAV amino acid domain within
EC1 at the amino-terminus of classical cadherins mediate their adhesive
potential in concert with hydrophobic pockets and tryptophan residues (Cavallaro
and Christofori, 2004). Interestingly, this motif is suggested to regulate
interactions between cadherins on the same cell, as well as interactions with
cadherins on adjacent cells (Bunse et al., 2013; Harrison et al., 2011). It is
important to note that both classical and atypical cadherins contain five EC
domains (Niessen et al., 2011). As such, one of the more definitive
characteristics of classical cadherins is the ability to interact with β-catenin and
p120-catenin at the cytoplasmic tail (Harris and Tepass, 2010; Nollet et al.,
2000). Classical cadherins also contain four calcium binding sites in their
ectodomain, which have been demonstrated to contribute to cadherin-mediated
adhesion (Angst et al., 2001).
Several models of the mechanism by which the ectodomain of cadherins
physically interact with each other on the same cells (cis interactions) and
adjacent cells (trans interactions) have been explored. The models range from
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A

B

Figure 1.4: N-cadherin structure and proposed cis and trans binding
models (A) cartoon depicting the full-length structure of N-cadherin. At the Nterminus is the pro-cadherin domain (pro), which is cleaved as N-cadherin moves
from the Golgi apparatus to the plasma membrane. N-cadherin consists of five
extracellular cadherin domains (E1-E5), which make up four Ca2+ binding sites.
There is a small transmembrane region, followed by a cytoplasmic Ch1 and Ch2
domain, which control p120 and β-catenin binding to N-cadherin, respectively.
(B) A model depicting N-cadherin interactions within the same cell (cis) and a
potential model for how the EC1 and EC2 domains mediate N-cadherin
interactions between cells (trans). Model adapted from (Langer et al., 2012).
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cadherins existing in highly ordered straight conformations to cadherins
assuming a bent conformation to promote EC1 domain interactions with
neighboring cadherins (Koch et al., 1999; Niessen et al., 2011). The jury is still
out regarding which models correctly predict cadherin cis and trans molecular
interactions. Beyond self-interactions, cadherins can also associate with
intracellular signaling molecules, such as β-catenin. This interaction helps to link
cadherins to α-catenin, vinculin and ultimately to the actin cytoskeleton, which is
critical for sustained cellular adhesion. (Cavallaro and Christofori, 2004 ; Yap et
al., 1997a).
The most well explored cadherin in regulating HSCs is N-cadherin,
although the role of N-cadherin in regulating HSPC-niche interactions remains
extremely controversial (Li and Zon, 2010). Reports have found N-cadherin
expressed on osteoblasts to be critical for regulating niche interactions (Arai et
al., 2004; Calvi et al., 2003; Zhang et al., 2003), meanwhile others have found no
such evidence for this phenomena (Kiel et al., 2009; Kiel et al., 2007). It remains
to be determined whether N-cadherin is expressed on hematopoietic stem cells
and if N-cadherin is a critical regulator of HSCs and their niche interactions.
Cadherins have a much better accepted role in regulating acute myeloid
leukemia. In particular, N-cadherin expression has been identified as being
enriched on human AML stem cells (as identified as CD34(+)/CD38(-)/CD123(+)
cells) (Zhi et al., 2010). The authors characterize the proportion of N-cadherin
positive AML stem cells following chemotherapy treatment, finding that this
population increases under treatment conditions. These data indicate that Ncadherin could mark a chemotherapy resistant population. A follow-up study
utilizing the CD34(+)/CD38(-) population of cells to represent human AML stem
cells demonstrated that N-cadherin(+) LSCs have an improved ability to induce
leukemia in xenograft models (Qiu et al., 2014). These studies demonstrate that
N-cadherin should be considered as a potential therapeutic target for AML.
However, the mechanisms underlying N-cadherin mediated chemoresistance
remains to be elucidated.
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1.4.6 Molecular clustering
The

clustering

of

adhesion

and

signaling

molecules

has

been

demonstrated to be a critical regulator of molecular functions and in particular,
cellular signaling. Early reports have identified a role for growth factor receptor
dimerization/clustering in mediating downstream signaling. For example, the
dimerization of the fibroblast growth factor receptor is tightly controlled by
extracellular receptor regions to prevent spontaneous dimerization, which
ultimately controls unwanted downstream signaling (Kiselyov et al., 2006).
Additionally, the epidermal growth factor receptor requires dimerization to
promote trans-autophosphorylation and subsequent activation of downstream
signaling cascades (Schlessinger, 2000). Additional work has demonstrated that
cytoplasmic proteins, such as Ras, can form short-lived nanoclusters or longlived microclusters, which have differential signaling capacities (Cebecauer et al.,
2010). As such, understanding how molecular clustering is controlled is critical
for developing therapies that can be used to attenuate aberrant signaling.
Beyond the control of cellular signaling, the formation of clusters of
adhesion receptors, such as integrins, can promote and strengthen cellular
adhesion. In order for integrins to cluster, they must first bind ligand and assume
the activated conformation and associate with talin at their cytoplasmic tails
(Cluzel et al., 2005). The means by which this ultimately results in the formation
of oligomers of α and β integrin subunits is not clearly defined. However, it has
been hypothesized that the local lipid environment may contribute to integrin
oligomerization and thus, the formation of integrin clusters (Kaiser et al., 2011).
Additional evidence supports a model whereby the force generated by the cell
also contributes to integrin clustering (Wehrle-Haller, 2012). Several reports have
determined that the spatial arrangement of integrins is a critical component of
early adhesion, adhesion strengthening, and integrin mechanotransduction (Koo
et al., 2002; Roca-Cusachs et al., 2009; Selhuber-Unkel et al., 2008).
In addition to integrins, the lateral organization of cadherins can also
contribute to cadherin-mediated adhesion. N-cadherin can exist as monomers
and dimers on the same cell. Cadherin dimers have been determined to have an
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increased probability of ligand binding compared to monomers (Zhang et al.,
2009). Furthermore, through interactions between adjacent cells, N-cadherin can
oligomerize into larger scale platforms, which have been demonstrated to
contribute to the generation of strong cadherin-mediated adhesions (Yap et al.,
1997b). The underlying mechanisms that regulate cadherin clustering are poorly
defined. As such, understanding the means by which N-cadherin clustering is
regulated can provide us with means aberrant N-cadherin-mediated adhesion
may be attenuated.

1.5 Tetraspanins
Section adapted from (Termini and Gillette, 2017)
Tetraspanins Function as Regulators of Cellular Signaling. Frontiers in Cell and
Developmental Biology. 2017 Apr 06 doi: 10.3389/fcell.2017.00034

1.5.1 Introduction to tetraspanins
Tetraspanins are membrane-spanning proteins with a conserved structure
that function primarily as membrane protein organizers. Phylogenetic analysis
identified 33 tetraspanins in humans, 37 in Drosophila melanogaster (Charrin et
al., 2014), and 20 in Caenorhabditis elegans (Huang et al., 2005), while only 17
were identified in Arabidopsis thaliana (Boavida et al., 2013). Tetraspanins have
also been identified in the ameoba, Dictyostelium discoideum, which exists as
both a unicellular and multicellular organism (Albers et al., 2016). While some
tetraspanins are expressed ubiquitously in humans, others are cell or tissue
specific (de Winde et al., 2015; Maecker et al., 1997), providing a means to
regulate the signal transduction associated with a breadth of cellular processes.
Members of the tetraspanin family of proteins have four transmembrane
domains, which contribute to the creation of a small (EC1) and large (EC2)
extracellular loop (Figure 1.5). The large extracellular loop contains a conserved
Cys-Cys-Gly amino acid motif (CCG-motif), as well as two other conserved
cysteine residues. EC2 of CD81 was resolved using crystallography (Kitadokoro
et al., 2001), where the authors demonstrated that the four conserved cysteine
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Figure 1.5: Schematic of tetraspanin molecular structure (Based on
(Zimmerman et al., 2016). Cartoon depicting the structural characteristics of
tetraspanins. Tetraspanins have four transmembrane domains (TM1-TM4), which
create one small (EC1) and one large (EC2) extracellular loop as well as a short
inner loop. The N- and C-termini of tetraspanins are localized to the intracellular
side of the membrane. The Cys-Cys-Gly amino acid motif is depicted in addition
to the two characteristic disulfide bonds that are formed in EC2.
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resides within EC2 promote the formation of disulfide bridges, as had been
suggested by previous reports (Levy et al., 1991; Maecker et al., 1997;
Tomlinson et al., 1993). Moreover, molecular modeling studies using the CD81
EC2 structure as a template predicted the topography of several other
tetraspanins including CD37, CD53, CD82 and CD151 (Seigneuret, 2006;
Seigneuret et al., 2001). These studies demonstrated that the EC2 domain of
tetraspanins consist of one conserved and one variable domain, with the
conserved domain consisting of a three-helix bundle while the variable domain is
unique to particular tetraspanins. A recent report resolved a crystal structure of
full-length CD81, finding that the four transmembrane domains create a
cholesterol-binding pocket (Zimmerman et al., 2016). Furthermore, the authors
performed molecular dynamics simulations that suggest CD81 can adopt an
open or closed conformation depending on whether or not cholesterol is bound.
In addition to the defining features of tetraspanins, many members of the
tetraspanin family also contain post-translational modifications. For example,
tetraspanins may be palmitoylated at membrane proximal cysteine residues,
which was demonstrated to regulate protein-protein interactions (Berditchevski et
al., 2002; Charrin et al., 2002; Yang et al., 2002; Yang et al., 2004). Meanwhile,
tetraspanins can also be N-linked glycosylated at asparagine residues, which is
less clearly understood (Marjon et al., 2015; Ono et al., 1999 ; Stuck et al., 2012).
Tetraspanins may also be ubiquitinated at cytoplasmic sites, which contributes to
their down-regulation (Lineberry et al., 2008; Wang et al., 2012b). An example
structure of tetraspanin CD82 is depicted in Figure 1.6, with the post-translational
modifications highlighted. How these tetraspanin post-translational modifications
impact signal transduction will be addressed in more detail later in this review.
Through their function as molecular scaffolds, tetraspanins contribute to
organismal development, reproduction, and immunity (Garcia-Frigola et al., 2001;
Han et al., 2012; Jarikji et al., 2009; Kaji et al., 2002; Kaji et al., 2000; Le Naour
et al., 2000; Levy and Shoham, 2005; Miyado et al., 2000; van Spriel, 2011).
Consistent with their expression being primarily found in multicellular organisms,
it is not surprising that many processes to which tetraspanins contribute center
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Figure 1.6: CD82 structure and motifs. Cartoon depicting CD82 topology within
the plasma membrane and important motifs. CD82 contains five membrane
proximal cysteine residues (shown in green) at residues 5, 74, 83, 251 and 253,
which can be palmitoylated. There are three asparagine residues in EC2 (shown
in orange) that are predicted to be N-linked glycosylated at residues 129, 157,
198. There are four cytoplasmic lysine residues 7, 10, 263, and 266 (shown in
grey), which are predicted to be ubiquitinated. The C-terminal tyrosine based sort
motif (YXXø) is depicted in blue at amino acids 261-264; for CD82 this motif is
Tyr-Ser-Lys-Val.
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around cell-cell- interactions. Additionally, numerous tetraspanins are also
associated with the development and progression of disease, in particular, with
respect to cancer and cancer cell-niche interactions (Hemler, 2013; Zoller, 2009).
Although tetraspanins do not have known adhesive ligands or catalytic activity,
they contribute to cellular physiology by organizing molecules within the plasma
membrane into microdomains.
The proposed function of tetraspanins is to organize the plasma
membrane by facilitating the formation of what are termed tetraspanin enriched
microdomains (TEMs). TEMs consist of homophilic and heterophilic interactions
amongst tetraspanins, interactions between tetraspanins and other membrane
proteins, as well as interactions between tetraspanins and proteins at the
membrane/cytoplasm interface (Charrin et al., 2014; Charrin et al., 2009b ;
Hemler, 2005; Stipp, 2010). Moreover, these protein associations can occur
through direct binding between tetraspanins and other proteins or through
tetraspanin interactions with a common binding partner.
Interactions between tetraspanin and signaling molecules have been
detected for various types of proteins, including adhesion and signaling
receptors, and cytosolic signaling molecules, which are depicted in Figure 1.7.
The downstream cellular consequences of these interactions vary, ranging from
regulation of cellular adhesion, migration, contractility and morphology. As recent
comprehensive reviews focused on tetraspanin regulation of immune signaling
are available (Halova and Draber, 2016 ; Levy and Shoham, 2005), we will
discuss other major classes of signaling molecules regulated by tetraspanins, as
well as the cellular consequences of such regulations.

1.5.2 Tetraspanins as regulators of cellular adhesion
Through their service as molecular scaffolds, tetraspanins can interact
with integrins to promote cellular adhesion. Several reports have demonstrated
direct or indirect interactions between tetraspanins and integrins using
biochemical approaches. For example, tetraspanins CD81, CD82, CD63 and
CD53 were shown to associate with integrin α4β1 with the use of extensive
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Figure 1.7: Tetraspanin enriched microdomains with signaling molecules.
Illustration of the plasma membrane depicting tetraspanin interactions with
membrane and cytosolic signaling molecules. The downstream signaling
consequences attributed to tetraspanin regulation are indicated beneath. Key
signaling molecules modulated by tetraspanins include: (A) Adhesion-Mediated
Signaling (Integrins/FAK), (B) Receptor-Mediated Signaling (GPCRs, EGFR, cKit, c-Met, ADAMs, TGF), and (C) Intracellular signaling (PKC, PI4K, RhoGTPases, and β-catenin).
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biochemical

approaches

(Mannion

et

al.,

1996).

Additional

work

has

demonstrated that tetraspanins CD9and CD151 can interact with laminin-binding
integrins, such as α3β1 and α6β1 (Gustafson-Wagner and Stipp, 2013; Stipp,
2010; Zoller, 2009). Beyond the interaction between tetraspanins and integrins,
tetraspanins have also been shown to regulate integrin-dependent adhesion. For
example, the expression of CD82 was shown to control αVβ3-mediated adhesion
(Ruseva et al., 2009) as well as α6 (He et al., 2005) and β1-dependent (Jee et
al., 2007) adhesion, while tetraspanin CD37 can control β2-mediated adhesion
(Wee et al., 2015).
Tetraspanins can regulate several aspects of integrins, including integrin
expression, internalization, organization, and integrin-dependent signaling, all of
which can contribute to cellular adhesion. For example, loss of CD82 expression
led to increased αIIβ3 expression in mice (Uchtmann et al., 2015), while
decreased expression of CD9 can reduce β1 integrin expression in ovarian
cancer cells (Furuya et al., 2005). One mechanism by which integrin expression
can be controlled is through alterations in integrin internalization and recycling.
The internalization of α3β1 has been shown to be reduced in cells with
decreased CD151 expression (Winterwood et al., 2006), suggesting that
tetraspanins control integrin trafficking. More specifically, the YXXφ motif at the
C-terminus of tetraspanins was demonstrated to mediate integrin trafficking (Liu
et al., 2007). Tetraspanins can also regulate the organization of integrins, which
is critical to generate stable adhesions. For example, tetraspanin CD37 can
regulate the organization of α4β1 (van Spriel et al., 2012). Moreover, CD81 was
shown to promote cellular adhesion to VCAM-1 by increasing the avidity of α4β1
under shear flow (Feigelson et al., 2003).

1.5.3 Tetraspanins function as regulators of cellular signaling
1.5.3.1 Tetraspanins and adhesion-mediated signaling
One of the most prominent classes of adhesion receptors which
tetraspanins are known to regulate is the integrin family of proteins. Integrins are
heterodimeric proteins consisting of one α and one β subunit, and this
combination of subunits dictates their ligand specificity (Humphries et al., 2006).
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Numerous studies identified direct and indirect interactions between integrins and
tetraspanins (Berditchevski, 2001; Berditchevski et al., 1996; Mannion et al.,
1996; Rubinstein et al., 1994; Slupsky et al., 1989; Stipp and Hemler, 2000;
Yanez-Mo et al., 1998; Yanez-Mo et al., 2001). Though integrins lack intrinsic
catalytic activity, they propagate signals through a variety of cytoplasmic
signaling molecules, many of which are components of focal adhesions
(Schwartz, 2001). Through a combination of imaging and biochemical studies,
researchers showed that tetraspanins colocalize with the focal adhesion proteins
vinculin and talin as well as myrstoylated alanine-rich C-kinase substrate,
(MARCKS), which is involved in PKC-mediated signaling (Berditchevski and
Odintsova, 1999). Moreover, signaling downstream of integrins is also mediated
by the focal adhesion kinase, which is further regulated by tetraspanins as
indicated below.

1.5.3.1.1 Focal adhesion kinase
Focal adhesion kinase (FAK) is a cytosolic protein which can interact
directly with the integrin cytoplasmic tail, thereby allowing integrins to link to the
actin cytoskeleton and promote downstream signaling (Schlaepfer et al., 1999).
Immunoprecipitation studies demonstrated that tetraspanins CD9, CD63, CD81,
CD82, and CD151 interact with the phosphorylated form of FAK (Berditchevski
and Odintsova, 1999). Additionally, cells plated on anti-tetraspanin monoclonal
antibodies demonstrated reduced FAK phosphorylation, further suggesting that
tetraspanin scaffolding can contribute to FAK activation.
As suggested, a number of tetraspanins have been implicated in FAK
regulation. It was shown that the siRNA knockdown of CD151 resulted in
diminished phosphorylation of FAK, p130Cas, paxillin and Src (Yamada et al.,
2008). In fact, treatment with a CD151 monoclonal antibody, which reduced
CD151 interactions with α3β1, also led to a reduction in FAK phosphorylation. In
an attempt to rescue this phenotype, control or CD151 knockdown cells were
treated with a β1 integrin activating antibody and these data demonstrated that
FAK phosphorylation could not be rescued under enforced integrin activation. As
such, this study provides evidence that tetraspanins may regulate integrin-
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mediated signaling through a mechanism independent of initial integrin
activation. The authors quantified FAK autophosphorylation (Tyr397), which is a
FAK modification stimulated by integrin clustering (Schlaepfer et al., 1999). As
tetraspanins have been previously demonstrated to regulate integrin clustering
(Termini et al., 2014; van Spriel et al., 2012), perhaps the loss of CD151
diminishes

integrin

clustering,

thereby

reducing

FAK

phosphorylation.

Additionally, the presence of CD151 increased FAK and Src phosphorylation in
response to plating on extracellular matrix components, which modulated
GTPase activation and downstream cell migration (Hong et al., 2012). The
authors demonstrated that there is a greater increase in FAK and Src activation
in response to plating on laminin than fibronectin, which is consistent with
previous findings that CD151 is closely associated with laminin binding integrins
(Berditchevski et al., 2002; Stipp, 2010).
Another tetraspanin identified to regulate FAK activity is CD9. In the case
of lymphatic dermal endothelial cells, CD9 knockdown diminished FAK
phosphorylation in response to VEGF-1 administration, demonstrating that
tetraspanin regulation of FAK signaling can occur through multiple activating
stimuli (Iwasaki et al., 2013). The authors further demonstrated that this CD9mediated reduction in post-adhesion signaling impaired lymphangiogenesis.
Consistent with previous studies of CD151 (Yamada et al., 2008), RochaPerugini et al. demonstrated that silencing of CD151 or CD9 reduced the
expression of phospho-FAK and phospho-ERK in response to T-cell engagement
(Rocha-Perugini et al., 2014). A decrease in the accumulation of activated β1
integrins and phospho-FAK was also detected at the immune synapse in CD9
and CD151 knockdown cells, suggesting that CD9 and CD151 promote the
recruitment to and retention of integrins at the immune synapse, which results in
diminished integrin downstream signaling. Therefore, the influence that
tetraspanins have on integrin localization provides a critical means to regulate
integrin-mediated signaling.
Though not technically considered a tetraspanin, the L6 tetraspan protein,
TM4SF5, has sequence characteristics and structural properties similar to
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tetraspanins (Wright et al., 2000). It was shown that the intracellular loop of
tetraspan TM4SF5 is critical for promoting an interaction between TM4SF5 and
FAK (Jung et al., 2012). The authors performed in vitro pull-down assays using
the N- or C-terminal cytoplasmic regions of TM4SF5 or the TM4SF5 intracellular
loop to assess FAK binding. It was found that only the intracellular loop
interacted with FAK, although the precise sites of association remain unknown.
Future studies focused on identifying the particular amino acid residues within
tetraspans that promote this association may offer potential targets to attenuate
FAK signaling, which can be deregulated in numerous types of cancer
(Sulzmaier et al., 2014).

1.5.3.2 Tetraspanins and receptor-mediated signaling
1.5.3.2.1 G-protein coupled receptors
G-protein coupled receptors (GPCRs) are seven membrane-spanning
proteins that transmit signals with the help of intracellular G proteins (Kobilka,
2007). Upon ligand binding, GPCRs can be coupled to Gα, Gβ, and Gγ subunits
to activate numerous cellular responses including calcium and potassium
channel regulation, as well as phospholipase C (PLC) and phosphoinositide 3kinase (PI3K) signaling (Tuteja, 2009). With the use of model systems such as
Drosophila, it was determined that tetraspanins can regulate GPCR-mediated
signaling. For example, the Drosophila-specific tetraspanin, Sunglasses or Sun,
is required for the light-induced down-regulation of rhodopsin, a light-sensitive
GPCR (Xu et al., 2004). Interestingly, Sun was concentrated in the retina and
removal of Sun resulted in retinal degeneration. Moreover, the authors
determined that in flies with reduced Sun expression, extended exposure to light
resulted in the diminished ability to down regulate rhodopsin. In line with these
findings, Sun is most closely related to human tetraspanin, CD63, which is
enriched within the lysosome (Metzelaar et al., 1991). Therefore, it is likely that
Sun assists with GPCR signal attenuation by directing its endosomal trafficking in
a similar manner to CD63. Additionally, an interaction between Sun and the Gq
subunit of rhodopsin was identified, which was further proposed to help Sun
promote the endocytosis of rhodopsin (Han et al., 2007).

44

The regulation of GPCRs by human tetraspanins has also been explored.
It was shown that the GPCR, GPR56, associates with tetraspanins CD9 and
CD81 (Little et al., 2004; Xu and Hynes, 2007), two tetraspanins which have also
been demonstrated to interact with one another (Stipp et al., 2001). Through the
use of mass spectrometry, it was also determined that the G protein subunits,
Gα11 Gαq and Gβ associate with CD81 and further immunoprecipitation studies
demonstrated that this association is not detected with tetraspanins CD63 or
CD151 (Little et al., 2004). The authors postulate that perhaps the regulatory role
of tetraspanins with respect to GPCRs may be to enhance ligand binding and
downstream signaling, though this has yet to be directly tested. Important future
studies will involve the analysis of downstream signaling through tetraspaninmediated changes in GPCRs, including the potential regulation of GPCR-ligand
affinity.

1.5.3.2.2 Epidermal growth factor receptor
In addition to GPCRs (Han et al., 2007; Metzelaar et al., 1991; Xu et al.,
2004) and integrins (He et al., 2005; Termini et al., 2014; Winterwood et al.,
2006), tetraspanins have also been demonstrated to regulate the trafficking and
signaling downstream of the epidermal growth factor receptor (EGFR). EGFR is
a transmembrane receptor that can be activated by numerous ligands including
epidermal growth factor (EGF) and transforming growth factor-α (TGF-α). Ligand
binding induces EGFR dimerization, which enhances EGFR catalytic activity
(Jura et al., 2009; Valley et al., 2015). Moreover, EGFR endocytosis can serve as
both a positive and negative regulatory signaling mechanism (Tomas et al.,
2014). The contribution of tetraspanins in mediating EGFR trafficking has been
extensively studied (Berditchevski and Odintsova, 2007; Odintsova et al., 2000;
Odintsova et al., 2003).
Through a series of immunoprecipitation studies, it was shown that
tetraspanin CD82 associates with EGFR and the overexpression of CD82
controls the phosphorylation kinetics of EGFR, Grb2, and Shc (Odintsova et al.,
2000). It was determined that this regulation mediates the morphological
response of HB2 cells to EGF stimulation. Interestingly, in cells expressing
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CD82, there was a more rapid down-regulation of EGFR upon EGF stimulation
compared to cells that do not express CD82, indicating that CD82 contributes to
EGFR down-regulation through modified internalization kinetics. This led the
authors to suggest that the presence of CD82 modulates the signaling potency of
the receptor even before it is activated. Furthermore, the authors speculate that
the combination of reduced CD82 and increased EGFR expression may lead to
uncontrolled signaling. Therefore, CD82, and likely other tetraspanins, may
provide a means to attenuate signaling through modulations in EGFR trafficking.
A follow-up study found that CD82 negatively regulates ligand-induced
dimerization of EGFR, but does not affect the dimerization of ErbB2 or ErbB3
(Odintsova et al., 2003). Although the authors did not examine the downstream
effects

of

altered

dimerization,

they

suggest

that

the

differential

compartmentalization of EGFR by CD82 might alter cellular signaling.
Further studies examined the role of the vesicular associated membrane
protein (VAMP), TI-VAMP, and CD82 in regulating the surface dynamics of
EGFR. In this study, knockdown of CD82 led to increased EGFR endocytosis
upon EGF stimulation through increased AP-2 recruitment (Danglot et al., 2010).
Furthermore, CD82 knockdown also altered the EGFR diffusion patterns on the
plasma membrane and reduced ERK phosphorylation upon EGF stimulation,
providing evidence that tetraspanins can regulate the spatial dynamics of
proteins for controlling downstream signaling. This report provides a unique
mechanism by which CD82, through cooperation with TI-VAMP and AP-2, can
regulate EGFR signaling and surface dynamics. Moreover, the authors propose
that these regulatory mechanisms may be in part controlled by CD82-mediated
alterations in actin dynamics or the membrane lipid composition.
EGFR regulation by CD82 was also shown to mediate ganglioside
production. More specifically, the overexpression of CD82 in combination with
inhibition of ganglioside production resulted in increased EGFR phosphorylation
in response to EGF stimulation (Li et al., 2013b). The authors speculate that
significant interplay occurs between glycosphingolipid enriched microdomains
and TEMs, which cooperatively regulate cellular signaling. The overexpression of
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CD82 might promote EGFR clustering, which may stimulate dimerization and
thereby enhance downstream EGFR signaling. Alternatively, the reduction in
ganglioside production might improve EGFR phosphorylation by reorganizing the
receptors into clusters within TEMs, since gangliosides have been demonstrated
to contribute to TEM organization (Odintsova et al., 2006).
Beyond the prominent role of CD82 in regulating EGFR, additional studies
also identified CD9 as a mediator of EGFR signaling. With the use of an
autocrine system of MDCK cells co-expressing CD9 and TGF-α, TGF-α
stimulation promoted EGFR activation (Shi et al., 2000). The authors also utilized
a paracrine system whereby CHO cells expressing TGF-α alone or TGF-α and
CD9 together were plated with 32D cells expressing EGFR. This experiment
demonstrated that co-expression of TGF-α and CD9 increases EGFR activation,
although the precise mechanism by which CD9 modulates EGFR signaling
remains unclear. Regardless, this study provides unique insight into how CD9
may regulate cellular signaling initiated through contact between adjacent cells.
Interestingly, another report investigated the effect of CD9 expression on EGFR
signaling, finding that increased expression of CD9 resulted in decreased
phosphorylation of EGFR, Shc, and total Grb2 expression (Murayama et al.,
2008). Though these studies demonstrate opposing effects of CD9 on EGFR,
they also indicate that TNF-α plays a role in mediating EGFR activation through
CD9. These studies open the possibility that other tetraspanins such as CD82
may also work in concert with TNF-α, similar to CD9 and TNF-α in mediating
EGFR activation. Therefore, future analyses would benefit from examining the
interplay of TNF-α with other tetraspanins in regulating EGFR signaling.

1.5.3.2.3 c-Kit
The stem cell factor receptor or c-Kit (CD117) is a receptor tyrosine kinase
that binds to its ligand, stem cell factor (SCF), which is also known as steel factor
(SLF) or kit ligand (Lennartsson and Ronnstrand, 2012). c-Kit signaling can
activate several signaling cascades, including PI3K, Src family kinases, and
MAPK to name a few. Moreover, c-Kit mediated signaling can control numerous
cellular processes including migration, survival and the differentiation of
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hematopoietic progenitor cells. With the use of immunoprecipitation studies, it
was determined that c-Kit associates with tetraspanins CD9, CD63 and CD81
and this interaction was enhanced upon treatment with SCF (Anzai et al., 2002).
Although the authors found increased phosphorylation of c-Kit within the
immunoprecipitated fraction, they determined that this does not enhance kinase
activity in response to SCF treatment. Rather, the kinetics of SCF binding to c-Kit
were altered when c-Kit associated with CD63. The authors suggest that this
might be because free c-Kit is internalized upon SCF binding, implying that
perhaps the CD63/c-Kit complex is more stable on the cellular surface. While this
study alludes to a role for tetraspanins in regulating c-Kit phosphorylation, further
analysis is necessary to determine the downstream consequences of tetraspanin
mediated c-Kit activation. Additionally, the possibility that tetraspanins, such as
CD63, might stabilize c-Kit and modulate signaling through alterations in protein
trafficking could have significant impact on specific leukemias where c-Kit
expression and activation are known to be dysregulated (Boissel et al., 2006;
Corbacioglu et al., 2006; Goemans et al., 2005; Ikeda et al., 1991; Paschka et
al., 2006).

1.5.3.2.4 c-Met
c-Met is a receptor tyrosine kinase that can activate numerous pathways
to promote cellular survival, motility, and proliferation (Birchmeier et al., 2003).
Hepatocyte growth factor (HGF) binding to c-Met causes c-Met dimerization,
which helps to initiate various cellular signaling cascades including AKT,
ERK/MAPK, and JNK (Organ and Tsao, 2011). Furthermore, the overexpression
of CD82 diminished the phosphorylation of c-Met in response to integrin ligand
engagement, resulting in reduced Src phosphorylation (Sridhar and Miranti,
2006). In the case of invasive tumor situations, the authors’ data suggest that the
loss of CD82 leads to enhanced activation of c-Met through integrin activation.
Although the regulatory mechanism remains unknown, this study provides a clear
indication that tetraspanins can modulate c-Met mediated signaling downstream
of integrin engagement.
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It was also shown through immunoprecipitation studies that CD82 and cMet interact (Takahashi et al., 2007). Moreover, the authors demonstrated that
upon the ectopic expression of CD82, activation of c-Met with HGF led to
increased formation of lamellipodia and filipodia through modulations in GTPase
activities. Additionally, the ectopic expression of CD82 also prevented c-Met
association with Grb2 and PI3K, implicating that CD82 has an inhibitory role with
respect to these binding events. As such, perhaps the Grb2 and PI3K binding
sites within c-Met become inaccessible in the presence of the c-Met/CD82
interaction.
The regulatory role of CD82 with respect to c-Met-mediated signaling has
also been extended to controlling ERK1/2 and AKT signaling in hepatocellular
carcinoma cells (Li et al., 2013b). An alternative report focused on CD151 with
respect to Met signaling, showing that knockdown of CD151 led to diminished
HGF-induced proliferation (Franco et al., 2010). The researchers determined that
CD151 knockdown decreased tyrosine phosphorylation of the β4 integrin subunit,
which decreased MAPK signaling through ERK in response to HGF. Therefore,
this study suggests that the c-Met-CD151-β4 complex is critical for MAPK
signaling. While the molecular link between tetraspanins and ERK or AKT
downstream of c-Met remains an open question, this work implicates integrins as
a possible connection.

1.5.3.2.5 Transforming growth factor signaling
Transforming growth factor α (TGF-α) is synthesized as a transmembrane
protein, which can become cleaved by metalloproteinases to release soluble
TGF-α (Pandiella and Massague, 1991). This cleavage is stimulated by
endotoxins (Breshears et al., 2012; Liu et al., 2013b) and reactive oxygen
species (Boots et al., 2009) and is mediated primarily by ADAM17 (Peschon et
al., 1998), but also by ADAM10 (Hinkle et al., 2003) and MeprinA (Bergin et al.,
2008; Minder et al., 2012; Singh and Coffey, 2014). Moreover, TGF-α can
interact with and activate EGFR on neighboring cells (Moral et al., 2001;
Schlessinger and Ullrich, 1992; Thorne and Plowman, 1994). An association
between CD9 and transmembrane TGF-α was identified and found to be
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dependent on the TGF-α ectodomain (Shi et al., 2000). The experimenters
illustrated that the cleavage of TGF-α was inhibited by CD9, implicating a role for
the association between CD9 and TGF-α as a means of protecting TGF-α from
proteolytic cleavage.

The authors suggested that the inhibition of TGF-α

cleavage feeds into enhanced TGF-α induced EGFR activation, which can
increase cellular proliferation. This study provides evidence that tetraspanins,
such as CD9, can promote cellular signaling by stabilizing transmembrane
proteins, thereby providing a potent activation stimulus to mediate juxtacrine
signaling. Protein kinase C (PKC) and MAPK signaling can also regulate TGF-α
cleavage (Baselga et al., 1996; Fan and Derynck, 1999). As tetraspanins can
regulate PKC and MAPK signaling (Termini et al., 2016; Zhang et al., 2001), a
closer examination into the interplay between these molecules in mediating TGFα signaling may provide a more comprehensive view of the complex regulatory
networks at play within TEMs.
A follow up study demonstrated that CD9 expression enhances TGF-α
expression at the cell surface using MDCK cells (Imhof et al., 2008). Here, CD9
was shown to promote the trafficking of TGF-α from the Golgi to the cell surface
by stabilizing the glycosylated and prodomain-removed forms of TGF-α.
Furthermore, the authors demonstrated that the expression of TGF-α and CD9
alters actin organization and focal adhesion formation, supporting the notion that
the combination of CD9 and TGF-α expression produces dramatically different
signaling responses than the expression of TGF-α alone. Therefore, the
tetraspanin expression profile should be considered when characterizing TGF-α
signaling, particularly in many cancers where TGF-α expression is thought to
support cancer progression (Kenny and Bissell, 2007).
Additionally, the contribution of tetraspanins to the regulation of the TGF
isoform TGF-β1 has been assessed. Researchers used CD151 knockdown
MDA-MB-231 cells and determined that in the presence of TGF-β1, CD151
knockdown cells had a significantly decreased proliferative rate compared to
control cells (Sadej et al., 2010). More specifically, in the CD151 knockdown
cells, TGF-β1 stimulation led to reduced p38 phosphorylation, resulting in
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decreased metastasis. Mechanistically, the authors propose that CD151
modulations of the plasma membrane may alter the distribution of TGF-β1
receptors and downstream signaling. Future studies may focus on determining
how CD151 modulates the molecular organization of the TGF receptor, as this
may provide a mechanism to regulate downstream signaling.

1.5.3.2.6 A disintegrin and metalloproteases
The A Disintegrin and Metalloprotease (ADAM) family of transmembrane
and secreted proteins contribute to the regulation of cellular adhesion, migration,
proliferation and signaling (Seals and Courtneidge, 2003). As the name states,
ADAMs contain a disintegrin and a metalloprotease domain. While the
metalloprotease domain can cleave extracellular matrix components and mediate
ectodomain shedding of cytokines, growth factors, the disintegrin domain can
interact with integrins. Recent comprehensive reviews provide insight on the role
that tetraspanins play in regulating membrane proteases, with a particular
emphasis on their role in regulating ADAM10 and ADAM17 (Matthews et al.,
2016 ; Yanez-Mo et al., 2011). Initial reports demonstrated that ADAM10 is
associated with CD9, CD81 and CD82, indicating that ADAM10 likely exists
within TEMs. Interestingly, treatment with anti-tetraspanin antibodies stimulated
the release of TNF-α and EGF in an ADAM10-mediated manner. Furthermore,
through mass spectrometry studies and extensive immunoprecipitation studies,
Tspan12 was found to associate with ADAM10, which contributed to the ability of
ADAM10 to process amyloid precursor protein for shedding (Xu et al., 2009b).
Using several mutated TSPAN12 constructs, this association was determined to
be regulated by EC1, the C-terminal tail and TSPAN12 palmitoylation. More
recent co-immunoprecipitation studies revealed that the subgroup of TspanC8
tetraspanins (Tspan5, 10, 14, 15, 17 and 33) interact with ADAM10 (Dornier et
al., 2012). Additionally, ADAM17 was also found to associate with tetraspanin
CD9 in leukocytes and endothelial cells, which diminishes ADAM17-mediated
TNF-α and ICAM-1 shedding. Interestingly, CD9 can regulate the catalytic activity
of ADAM17 with regards to shedding of LR11 in monocytes, promonocytes and
B-lymphoblastoid cell lines (Tsukamoto et al., 2014). As ADAMs are implicated in
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regulating various cancer cell types (Mochizuki and Okada, 2007), the role of
tetraspanins in regulating ADAMs in malignant cells will provide significant insight
and perhaps a means to attenuate aberrant ADAM activity.
ADAMs are produced as immature, inactive, preforms in the endoplasmic
reticulum (ER). During trafficking from the ER to the plasma membrane, the
enzyme’s prodomain is removed and ADAMs are then rendered catalytically
active (Seals and Courtneidge, 2003). Interestingly, it was determined that
TspanC8 contributes to ADAM10 maturation and ultimately the stabilization of
ADAM10 at the cell surface (Prox et al., 2012). Furthermore, Tspan33
knockdown in erythrocytes resulted in diminished ADAM10 surface expression.
Meanwhile, ADAM10 surface expression remained unchanged in platelets,
demonstrating that tetraspanin regulation of ADAM10 is likely cell-type specific
(Haining et al., 2012). Additionally, the role of Tspan33 in regulating ADAM10 for
the control of macrophage activation was recently explored (Ruiz-Garcia et al.,
2016). Researchers utilized Tspan33 overexpressing Raw 264.7 cells and
demonstrated that increased Tspan33 expression results in increased ADAM10
processing, consistent with the earlier aforementioned studies.

1.5.3.3 Tetraspanins and intracellular signaling
Although tetraspanins are known to primarily affect the properties of other
membrane proteins, they have also been shown to regulate cytoplasmic
signaling molecules. Signaling proteins are often recruited to the cytoplasmic
interface of the plasma membrane where they initiate signaling and TEMs can
serve as a potential membrane recruitment site. Therefore, in the following
section, we will review how tetraspanins control the localization, kinetics, and
signaling properties of cytosolic proteins.

1.5.3.3.1 Protein kinase C
The Protein Kinase C (PKC) family of enzymes are regulators of
numerous cellular processes, many of which can be deregulated under
cancerous conditions (Griner and Kazanietz, 2007). There are 10 identified PKC
isozymes, which can be classified into three different types. Classical PKC
isozymes, which include PKCα, PKCβI, PKCβII and PKCγ, are calcium
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dependent enzymes. Meanwhile, the calcium independent novel PKC isozymes
are PKCδ, ε, η and θ and the atypical PKC isozymes are PKCζ and PKCι. The
structure of PKC isozymes can be broken into several components. Firstly, all
PKC isozymes consist of one catalytic and one regulatory region (Mackay and
Twelves, 2007). Secondly, PKCs are built from four conserved domains, C1-C4
(Figure 1.8) (Coussens et al., 1986; Parker et al., 1986). Conventional PKC
isozymes consist of C1-C4, while novel PKC isozymes contain a modified C2
domain and atypical isozymes lack a C2 domain completely, and instead contain
a modified C1 domain (Newton, 2010). These structural differences have
significant consequences on the means by which these enzymes are activated
and signal. For example, the C2 domain of conventional PKC isozymes has a
Ca2+ binding site, while the C1 domain has a binding site for diacylglycerol
(DAG)/phorbol esters. Meanwhile, the modified C2 domain within novel PKC
isozymes lacks Ca2+ binding ability (Newton, 1995). Due to their involvement in
leukemia and HSC regulation, we will focus on classical PKCs.
Classical PKCs (cPKCs) contain a flexible hinge region between the C2
and C3 domains, allowing autoinhibition during times of inactivation (Newton,
2010). In order to ensure appropriate signal regulation, cPKCs contain a
pseudosubstrate region at the N-terminus, which interacts with the substrate
binding pocket within the kinase domain to promote this autoinhibition (Rosse et
al., 2010). Upon activation, the pseudosubstrate can be cleaved by proteolysis
(Orr et al., 1992). As PKCs can be activated by various stimuli, it is important to
note that Ca2+ binding to the C1 domain promotes PKC interactions with DAG or
phorbol esters, while Ca2+ binding to the C2 domain promotes the interaction of
PKC with anionic phospholipids at the membrane (Dempsey et al., 2000). During
times of activation, cPKCs can also interact with scaffold proteins at the
membrane to induce their activation. For example, the receptors for the activated
C kinase (RACKs) proteins, can interact with PKCs to relieve their autoinhibition
(Ron and Mochly-Rosen, 1995). Beyond RACK proteins, PKCs can also interact
other types of scaffolding proteins, such as tetraspanins (Zhang et al., 2001),
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Figure 1.8: PKCα structural domains and protein conformations. (A) PKCα
is a 672 amino acid protein with structural features depicted above. PKCα
consists of a regulatory domain, made up of the PS pseudosubstrate), V1, C1A,
C1B, V2, and C2 domains, while the kinase domain consists of the C3, V4, C4
and C5 domains. The V3 domain is the hinge region, which allows PKC to
autoinhibit itself. The C1 domains are responsible for DAG/PMA binding, while
the C2 domain promotes Ca2+ binding. Meanwhile, the C3 domain confers ATP
binding and the C4 domain contains the activation loop, which helps PKCα
autoinhibit itself. (B) In an inactive state, the hinge region provides PKCα with
flexibility, which allows an interaction between C4 and the pseudosubstrate. (C)
Upon PKCα activation, the kinase domain becomes free. PKCα becomes
phosphorylated on Ser319 within the hinge region, as well as Ser638 and Ser657
within the C4 region.
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caveolin (Oka et al., 1997), annexins (Hoque et al., 2014) and A-kinase
anchoring proteins (Greenwald et al., 2014).
Once activated and recruited to the plasma membrane, PKC can now
elicit a downstream response. Although PKCs have been discovered for
decades, there is still very little known about their downstream targets (Steinberg,
2008). PKC enzymes have been shown to phosphorylate myrstoylated alaninerich c-kinase receptor substrate (MARCKS) (Herget et al., 1995), which is an
actin-filament

binding

protein

(Hartwig

et

al.,

1992).

PKCs

can

also

phosphorylate the myosin light chain II (Liu et al., 2013a), PKD2 (Navarro and
Cantrell, 2014; Waldron et al., 2001), and Ras GEFs (Jun et al., 2013). It will be
valuable for future work to continue to examine PKC substrates, as many remain
undiscovered. Beyond the direct substrates, PKC can induce several well-known
signaling pathways. For example, PKCs can serve as an anti- or pro-apoptotic
signaling regulator depending on the cell type (Lucas and Sanchez-Margalet,
1995) and a role for PKC in mediating apoptosis through caspases has been
established (Gutcher et al., 2003; Nowak, 2002). PKCs can also promote cellular
growth and proliferation signaling through MAPK signaling, in particular through
ERK1/2 activation (Clerk and Sugden, 2001). Meanwhile, PKCs also play a role
in mediating differentiation, which has been extensively studied in myeloid
lineages (Clemens et al., 1992).
PKC can also mediate differentiation signaling in hematopoietic progenitor
cells. For example, when granulocyte-macrophage colony-forming cells were
transfected with a constitutively activated form of PKCα, there was an increase in
the production of macrophages when cells were treated with macrophage colony
stimulating factor, G-CSF, or IL-3, indicating that PKC activation can regulate
progenitor differentiation (Pierce et al., 1998). Another group used real time
polymerase chain reaction (rtPCR) to quantify PKC isozyme transcript levels in
CD34(+) cells and progenitor cells, finding fluctuations in isozyme expression
upon differentiation (Oshevski et al., 1999). Beyond differentiation, PKC has also
been shown to regulate HSC homing. A previous study demonstrates that
treatment of CD34(+) human HSPCs with chelerythide chloride, which inhibits
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PKCs, reduces HSPC homing to the bone marrow and spleen (Kollet et al.,
2001). An additional report shows that treatment with the PKC inhibitor,
GF109203X, reduces cellular migration and appears to do so through the
activation of FAK (Wang et al., 2000).
There is evidence that PKCs can also be deregulated in several cancers
(Griner and Kazanietz, 2007), in particular in leukemias (Redig and Platanias,
2008). For example, PKCs can be deregulated in chronic lymphocytic leukemia
(CLL), giving CLL cells a survival advantage (Alkan et al., 2005; Barragan et al.,
2002). Additionally, the expression of PKCα (Guzman et al., 2007) and PKCβ
(Ruvolo et al., 2011) is increased in AML cells compared to healthy CD34(+)
counterparts. Meanwhile, it was found that patients with expression of active
BCL-2 coupled with active PKCα exhibited decreased overall survival,
demonstrating the clinical potential of PKC in leukemias (Kurinna et al., 2006).
However, the precise mechanisms by which PKC regulates leukemia cell and
patient survival remain unclear. Future work focused on providing mechanistic
insight into the action of PKC in regulating these processes will have significant
clinical value.
The

interaction

between

tetraspanins

and

PKC

was

originally

demonstrated in K562 cells using an elaborate series of immunoprecipitation
experiments (Zhang et al., 2001). The experimenters used phorbol 12-myristate
13-acetate (PMA), which mimics diacylglycerol (DAG) to activate PKC (Castagna
et al., 1982). Under PMA stimulated conditions tetraspanins CD9, CD53, CD81,
and CD82 individually interact with PKCα and not with PI3K. Additionally, they
determined that CD81 and CD151 associate with PKCβII. Moreover, in a PKCα
pull-down, β1, α3, and α6 integrins were detected in complex with PKC.
Therefore, it was suggested that tetraspanins serve to link PKC to integrins. In
order to assess the tetraspanin domains that control PKC associations, chimeric
mapping was performed by replacing portions of CD9 with portions of the nonPKC associating tetraspanin, A15/Talla1. These findings demonstrated that PKC
association with tetraspanins occurs outside of the short inner loop, the large
outer loop, and transmembrane 3 or 4.
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A recent report also demonstrated that tetraspanin CD151 regulates skin
squamous cell carcinoma through STAT3 and PKCα signaling (Li et al., 2013a).
Utilizing wild type or CD151 ablated A431 epidermoid carcinoma cells, it was
shown that the loss of CD151 reduces STAT3 activation in response to 12-OTetradecanoylphorbol-13-acetate (TPA) stimulation, which is another known
activator of PKCα. The authors found that PKCα only associates with α6β4 upon
TPA stimulation when CD151 is present. Together, these data suggest that
perhaps the role for CD151 is to recruit PKCα into close proximity with the α6β4
integrin, which ultimately aids in the phosphorylation of α6β4. As such, these
data build upon previous implications that tetraspanins link PKC to integrins
(Zhang et al., 2001), but also provide evidence that this scaffolding is important
for epidermal proliferation and STAT3 activation.
Another interesting report investigated how CD9, CD81 and CD151
expression affects PKCα association with TEMs (Gustafson-Wagner and Stipp,
2013). It was demonstrated that CD9/CD81 knockdown diminishes the ability for
the α3 integrin to associate with PKCα, which delays cell spreading on laminin
and directed migration. In contrast, CD151 knockdown enhanced the association
of PKCα with the α3 integrin, while promoting cell migration on collagen-I. The
authors propose that CD9/81 may serve as linkers of PKC to the α3 integrin
subunit, or there might be an indirectly associating molecule at play.
Furthermore, the authors propose that perhaps upon CD151 depletion, there is
increased association between PKC and α3 due to the loss of CD151, which
makes CD9/81 available to fully associate with α3, thereby promoting PKCintegrin association. This study provides substantial evidence that the roles of
tetraspanins CD9, CD81 and CD151 are unique in their regulation of PKCαintegrin interactions.
Further examination into the regulatory role of tetraspanins with respect to
PKC-mediated signaling has uncovered many unique cellular responses. For
example, treatment of A431 cells with Calphostin C to inhibit PKCα reduced
filipodia extensions as well as E-cadherin puncta formation, demonstrating the
involvement of actin in tetraspanin-regulated PKC signaling (Shigeta et al.,
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2003). The authors suggest that CD151 directly or indirectly associates with
PKCα, which they propose may activate Cdc42 to promote filipodia formation.
A more recent report from our laboratory demonstrated that CD82
regulates PKCα signaling in acute myeloid leukemia (AML) (Termini et al., 2016).
Using quantitative FRET imaging and KG1a AML cell lines that overexpress wild
type CD82 or a palmitoylation deficient form of CD82 (Delandre et al., 2009), we
found that upon PMA stimulation, PKCα was recruited to the plasma membrane
where it associates with CD82. However, upon extended PMA stimulation, this
PKCα/CD82 association is reduced in cells overexpressing the palmitoylation
deficient form of CD82, demonstrating that the palmitoylation of CD82 regulates
the stability of the PKCα interaction. We went on to use super-resolution imaging
to examine how the scaffolding properties of CD82 regulate the macromolecular
clustering of PKCα and found that upon disruption of the CD82 scaffold, there is
a significant reduction in the size of PKCα clusters. Moreover, using CD82 knockdown cells, we found that while PKCα is still recruited to the membrane upon
PMA stimulation, large-scale PKCα clusters are not detected. This change in
PKCα clustering was then linked to alterations in downstream ERK1/2 signaling
that influenced the aggressive phenotype of AML (Termini et al., 2016).
Interestingly, the kinetics of PKCα oligomerization were recently quantified and
modeled using HEK cells where they found that the intramolecular clustering of
PKCα contributes to downstream phosphorylation (Bonny et al., 2016).
Collectively, these studies illustrate that the modulation of signaling molecule
clusters may serve as an important regulatory mechanism for stabilizing and/or
attenuating signal transduction pathways. Moreover, our work implicates
tetraspanins as critical mediators of cluster size and stability. Future super
resolution imaging studies focused on identifying how the clustering of
tetraspanins can modulate downstream signaling through PKC and other
molecules such as Rac or Cdc42 would be valuable to help clarify how
tetraspanins and PKCα mediate cytoskeleton-dependent cellular responses such
as adhesion and migration.
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An interesting link was also discovered between PKC and EGFRmediated signaling that is enhanced by CD82. c-Cbl is an ubiquitin ligase
recruited to EGFR where it assists with receptor down-regulation (Joazeiro et al.,
1999). The authors found that PKC mediates c-Cbl phosphorylation upon EGF
stimulation in CD82 expressing H2B cells (Odintsova et al., 2013). The
phosphorylation of c-Cbl serves as a negative regulator of enzyme function
(Ryan et al., 2006), which may be responsible for inhibiting EGFR
downregulation. Therefore, without CD82 present, EGFR can be quickly
downregulated as PKC is not present to regulate c-Cbl. Collectively, these
studies provide substantial evidence that implicates tetraspanins as signaling
scaffolds that promote the close proximity of PKC with integrins, EGFR and
cytoplasmic proteins like c-Cbl.

1.5.3.3.2 Phosphatidylinositol 4-kinase
Phosphatidylinositol

4-kinase

(PI4K)

catalyzes

the

conversion

of

phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PI4P), which is an
important intermediate for lipid-mediated signaling (Clayton et al., 2013). A series
of biochemical experiments demonstrated that PI4K exists within α3 integrin and
CD63 containing TEMs (Berditchevski et al., 1997). The authors suggest that
perhaps TEMs are responsible for linking the α3β1 integrin to PI4K. A follow up
study from the same group explored this further, demonstrating that
immunoprecipitation of α3 or CD151 yields similar levels of PI4K activity based
upon PI4P production (Yauch et al., 1997). Additionally, using cells with
diminished α3 expression, CD151 was pulled down, demonstrating that there is
still PI4K associated with the complex. Conversely, immunodepletion of CD151
resulted in significantly diminished lipid kinase activity associated with α3, while
CD63 and/or CD81 deletion did not have as significant of an effect. Collectively,
these data implicate CD151 as a critical linker between PI4K and α3β1, which
the authors suggest may support cell migration.
A subsequent follow up study demonstrated that PI4K associates with
tetraspanins A15/TALLA1, CD63, CD151, CD9 and CD81, however it does not
appear to associate with NAG-2, CD53, CD37 or CD82 (Yauch and Hemler,
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2000). Moreover, PI3K and PI4P5K activity were not detected in CD63, CD81
and CD151 complexes, indicating that perhaps the association is specific to
PI4K. Studies with CD9/CD82 chimeras were unsuccessful at determining the
site of association with PI4K. Therefore, a closer examination into the structural
domains within tetraspanins that contribute to their association with PI4K could
provide insight into the mechanism by which tetraspanins may regulate the
catalytic activity of PI4K and downstream responses.

1.5.3.3.3 GTPases
Rho GTPases mediate signal transduction by switching between a GTPbound (active) and GDP-bound (inactive) state (Bishop and Hall, 2000). There
are numerous effector proteins downstream of GTPases including PI3K, PI-4P5K, MEKK1, and DAG kinase. The Rho family GTPases Rac1, RhoA, and
Cdc42 as well as the Ras family of GTPases translocate to the plasma
membrane upon activation (Collins, 2003), where their regulation by tetraspanins
continues to be defined.
For example, CD151 was demonstrated to regulate Cdc42 for the control
of cellular adhesion. Using A431 cells, CD151 antibody treatment or CD151
overexpression was found to increase Cdc42 activation, which the authors
suggest controls actin reorganization, promoting filopodia-based adhesions
(Shigeta et al., 2003). Another study assessed how the coexpression of CD9 and
TGF-α regulates GTPase signaling, finding increased and decreased levels of
activated Rac1 and RhoA respectively, with Cdc42 levels remaining unchanged
upon coexpression of CD9 and TGF-α (Imhof et al., 2008). This shift in signaling
was determined to be due to enhanced EGFR signaling, which ultimately
contributed to enhanced stress fiber formation. Additionally, the overexpression
of CD82 was shown to decrease the proportion of GTP-bound Rac1, while RhoA
and Cdc42 levels remained unchanged (Liu et al., 2012).
Previous work also demonstrated that CD151 promotes the association
between CD151-β1 complexes and Ras, Rac1 or Cdc42. Immunofluorescence
imaging showed that CD151 regulates the translocation of Rac1 and Ras to the
membrane and promoted colocalization with β1 integrins (Hong et al., 2012).
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Interestingly, through the use of a CD151 chimera with disrupted α3β1 integrin
association, the authors showed that this mutant is unable to recruit Rac1 to the
membrane. Therefore, integrins also have the capacity to link GTPases to
tetraspanins in a manner similar to what was previously proposed for PKC and
tetraspanins (Li et al., 2013a; Zhang et al., 2001). An association between Rac1
and the C-terminal, cytoplasmic region of CD81 has also been suggested based
on the use of an eight amino acid C-terminal tail peptide (Tejera et al., 2013).
Future experiments that mutate or delete the CD81 C-terminal tail will be
important to demonstrate that such a mutation eliminates Rac1 association,
further validating the interaction. Furthermore, upon EGF stimulation, it was
shown that knockdown of CD81 increases Rac activation. A more recent study
identified a correlation between CD9 expression and GTP bound Rac1
expression in acute lymphoblastic leukemia patient samples (Arnaud et al.,
2015). Moreover, this group also determined that the C-terminal tail of CD9 is
important for regulating Rac1 activation. Interestingly, the C-terminal region of
CD9 has two known palmitoylation sites (Charrin et al., 2002), and Rac can also
be palmitoylated (Tsai and Philips, 2012). Therefore, it is possible that these
post-translational modifications may help to anchor tetraspanins and GTPases
into similar membrane compartments.
Tetraspanin regulation of RhoA signaling, which can promote changes in
cytoskeletal organization, has also been characterized (Sit and Manser, 2011).
Using human aortic smooth muscle cells, CD9 knockdown decreased the
expression of GTP-bound RhoA, leading to defects in cellular morphology,
spreading and contraction (Herr et al., 2014). The authors suggest that integrins
are involved in CD9-mediated alterations in RhoA activation by possibly
stabilizing integrin-ECM interactions, augmenting RhoA activation. Interestingly,
a recent report demonstrates that the loss of CD151 in breast cancer cells
resulted in increased RhoA activation as quantified using FRET biosensors
(Novitskaya et al., 2014). These data are contrary to Hong et al. (Hong et al.,
2012), who showed no change in Rho activation upon CD151 depletion.
However, the change in FRET efficiency detected was less than 5%, which
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would likely be below the detection of the small GTPase protein pull-down
assays used by Hong et al. Moreover, a separate report demonstrated that the
knockdown of CD151 in human dermal microvascular endothelial cells resulted in
an increase in RhoA-GTP and decreased Rac1-GTP (Zhang et al., 2011). Future
studies focused on the mechanism by which tetraspanins can modulate GTPase
activation will be important for determining how certain tetraspanins may be
targeted to control specific GTPase activities in specialized cell types.

1.5.3.3.4 β-Catenin
β-catenin is a component of the Wnt signaling pathway that binds to the
cytosolic portion of cadherins to initiate cellular signaling (Valenta et al., 2012).
Through this complex formation, β-catenin promotes the internalization and
recycling of E-cadherin, thereby destabilizing the complex and ultimately
reducing cell-cell adhesion. Researchers determined that ectopic CD82
expression in h1299 cells relocalizes β-catenin to E-cadherin at the cell
membrane, which stabilizes complex formation (Abe et al., 2008). Furthermore,
they showed that ectopic CD82 expression increased cancer cell aggregation. To
assess the downstream consequences of altered β-catenin localization, the
authors stimulated cells with EGF or HGF, demonstrating that ectopic expression
of CD82 diminished β-catenin phosphorylation. While β-catenin phosphorylation
is known to destabilize the E-cadherin complex, the mechanism for tetraspanin
involvement remains to be clearly defined. Based on our previous work with Ncadherin (Marjon et al., 2015), we speculate that the CD82 scaffold might
contribute to cadherin clustering, which may stabilize β-catenin membrane
interactions, thereby protecting β-catenin from phosphorylation and downregulation.
More recently, CD63 was shown to stabilize β-catenin signaling. In this
study, shRNA knockdown of CD63 decreased β-catenin protein expression
levels, which was suggested to occur through diminished levels of inactive
GSK3β, leading to increased levels of phosphorylated β-catenin (Seubert et al.,
2015). Furthermore, decreased levels of the β-catenin targets, MMP-2 and PAI-1,
were detected, demonstrating CD63-mediated changes in downstream β-catenin
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signaling. The authors went on to find that the reduced expression of CD63
diminishes the metastatic potential of lung cancer cells, while the overexpression
promoted tumor aggressiveness. However, modulations in signaling induced by
CD63 overexpression were not explored. A previous study provided evidence
that disrupting the interaction between the α3β1 integrin and CD151 enhanced βcatenin phosphorylation (Chattopadhyay et al., 2003). Therefore, it is plausible
that the combination of integrins and tetraspanins serves to stabilize β-catenin
within TEMs.

1.5.3.4 Tetraspanin post-translational modifications and
signaling
1.5.3.4.1 Palmitoylation
S-palmitoylation is the addition of a 16-carbon fatty acid chain, palmitate,
to cysteine residues of either cytoplasmic or membrane proteins (Blaskovic et al.,
2013). Palmitoylation of cytoplasmic proteins promotes membrane anchoring,
while palmitoylation of membrane proteins facilitates trafficking and membrane
organization. Palmitoylation has been confirmed for tetraspanins CD9, CD151
(Yang et al., 2002), CD81 (Delandre et al., 2009), and CD82 (Mazurov et al.,
2007), however other tetraspanins also contain conserved cysteine residues that
are predicted to be palmitoylated. The defined role for palmitoylation is to
modulate TEM formation (Yang et al., 2004). Therefore, we took a closer
examination of how tetraspanin palmitoylation contributes to the signaling that
occurs downstream of TEM associated proteins.
For example, the expression of the palmitoylation deficient form of CD151
weakened its association with integrins (Berditchevski et al., 2002), resulting in
diminished phosphorylation of AKT in response laminin-5 engagement. These
data indicate that palmitoylation-mediated disruption of TEMs can reduce
downstream signaling responses. Additionally, a palmitoylation deficient form of
Tetraspanin12 was shown to have diminished association with ADAM10,
resulting in decreased ADAM10 activity as assessed by amyloid precursor
protein (APP) shedding (Xu et al., 2009b). Recent work from our lab has shown
that overexpression of a palmitoylation-deficient form of CD82 diminishes PKC
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membrane stabilization, reducing ERK1/2 activation and downstream leukemia
colony formation (Termini et al., 2016). Collectively, these studies demonstrate
that tetraspanin palmitoylation contributes significantly to the regulation of
downstream cellular signaling. Intracellular signaling molecules such as Ras
(Eisenberg et al., 2013), Rac (Tsai and Philips, 2012), and PKC (Ford et al.,
1998) can themselves be palmitoylated to assist with their membrane anchorage.
As tetraspanin palmitoylation is thought to regulate lateral protein associations
within TEMs, perhaps tetraspanin palmitoylation functions in concert with the
palmitoylation of cytoplasmic proteins to produce stable membrane interactions
critical for sustained signaling.

1.5.3.4.2 Glycosylation
Although the large extracellular loop of many tetraspanins has been
demonstrated to have one or more potential N-linked glycosylation sites, little is
known about the functional consequences of this post-translational modification.
The N-glycosylation pattern of CD82 was recently identified using proteomics
and glycomics, determining that there are three putative N-glycosylation sites
(Wang et al., 2012a). Previously, these sites were suggested to regulate
apoptosis, however the researchers did not examine the signaling that led to
these apoptotic changes (Ono et al., 1999). Interestingly, the photoreceptorspecific tetraspanin retinal degeneration slow (RDS) can also be glycosylated
(Conley et al., 2012; Kedzierski et al., 1999). More recently, the function of RDS
glycosylation was re-examined by expressing a glycosylation deficient version of
RDS in mice, which identified differential functional outcomes in cones versus rod
photoreceptor cells (Stuck et al., 2015). Moreover, the authors determined that
glycosylation regulates the formation of RDS complexes with another tetraspanin
ROM-1, demonstrating that glycosylation can modulate tetraspanin complex
formation. A recent report from our laboratory examined the role of CD82
glycosylation with respect to acute myeloid leukemia homing (Marjon et al.,
2015). In this study, we demonstrated that mutation of the three glycosylation
sites within CD82 to inhibit glycosylation resulted in increased AML cell homing
to the bone marrow, which we linked to increased molecular packing of N-
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cadherin via super resolution imaging. Although we have yet to examine
signaling deficits in cells with disrupted CD82 glycosylation, it is possible that
these changes in the molecular organization of N-cadherin may modulate the
activation or stability of p120 catenin or β-catenin signaling downstream of Ncadherin.

1.5.3.4.3 Ubiquitination
Protein ubiquitination is important for regulating cellular signaling by
selectively targeting proteins for degradation. Both CD81 and CD151 were
shown to interact with gene related to anergy in lymphocytes (GRAIL), which
promotes

tetraspanin

ubiquitination,

ultimately

downregulating

surface

tetraspanin expression (Lineberry et al., 2008). Interestingly, it was determined
that these tetraspanins can only be ubiquitinated at their N-terminus. Through
mutational studies, it was shown that mutation of K8 and K11 diminished the
ubiquitination of CD81, while mutation of K8, K11 and K17 ablated the
ubiquitination of CD151. More recently it was demonstrated that TSPAN6
interacts with the adaptor mitochondrial antiviral signaling (MAVs) in 293T cells to
inhibit RIG-I-like receptor (RLR) mediated signaling (Wang et al., 2012b). The
authors went on to show that induction of RLR signaling promoted the
ubiquitination of TSPAN6 at K11, K16, and K43, which are sites found within the
TM1

of

TSPAN6.

Additionally,

the

authors

determined

that

TSPAN6

ubiquitination serves to inhibit the formation of the signalosome, effectively downregulating RLR signaling. As ubiquitination can target proteins for degradation,
we suspect that tetraspanin ubiquitination will be a regulatory mechanism to
allow for specific and efficient attenuation of tetraspanin-mediated signaling.

1.5.4 Concluding remarks
Tetraspanins

and

their

formation

into

TEMs

enable

the

compartmentalization of membrane receptors within the plasma membrane. In
this review, we focus on how tetraspanins also serve to connect these
membrane-associated molecules with intracellular signaling complexes. It is now
clear that tetraspanins regulate diverse cell signaling pathways that impact a
breadth of biological processes. However, though numerous signaling molecules
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have been demonstrated to associate with tetraspanins, the mechanisms by
which tetraspanins precisely modulate signal transduction remains relatively
undefined. Future studies focused on how domains and motifs within
tetraspanins promote or perhaps attenuate cellular signaling will help us
understand the specific mechanisms used by this family of proteins to control
signaling. Many laboratories are now using sophisticated imaging techniques to
provide novel insight into the spatiotemporal interactions mediated by
tetraspanins and TEMs. These studies will help to define how the scaffolding
properties of tetraspanins contribute to the formation, stabilization and dynamics
of signal transduction complexes at the plasma membrane. Moreover, these
studies may provide the needed insight to establish tetraspanins and TEMs as
potential therapeutic targets for the modulation of aberrant signal transduction
that mediates processes such as inflammation, wound healing, and various types
of cancer.

1.6 Tetraspanins and leukemia
One of the earliest clues of the involvement of tetraspanins in regulating
leukemia comes from a study first examining the expression profile of
tetraspanins in healthy HSCs (Burchert et al., 1999). The authors utilized flow
cytometry to determine that CD82 is expressed in peripheral blood leukocytes
from healthy donors, with differential expression patterns found depending on the
class of leukocyte examined. The authors also examined blood from leukemic
patients, findings increased CD82 surface expression in blood samples from
patients with chronic myeloid leukemia, chronic lymphoid leukemia and AML.
These data demonstrate that CD82 expression may serve as a marker of the
aggressiveness of blood cancers, a notion that researchers have more recently
examined in mechanistic detail.
Previous studies demonstrate that the CD34(+)/CD38(-) AML cell fraction
highly express CD82, which contributes to cell migration to mesenchymal stem
cells. The authors also show that treatment with CD82 shRNA can significantly
reduce AML colony growth in the CD34(+)/CD38(-) fraction, indicating that CD82
is critical for AML propagation in these cells (Nishioka et al., 2013). Two follow up
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reports from the same laboratory demonstrate that CD82 expression can also
regulate STAT5 signaling in AML cells, which promotes cellular survival
(Nishioka et al., 2015a; Nishioka et al., 2014). Furthermore, the Yokoyama
laboratory has also shown that the utilization of a CD82 monoclonal antibody can
enhance AML cell death under chemotherapeutic conditions (Nishioka et al.,
2015c). In line with these findings, there are also tetraspanin antibodies under
clinical evaluation for the treatment of chronic lymphocytic leukemia (Beckwith et
al., 2015).
It has been shown that tetraspanin CD9 (Leung et al., 2011) as well as
CD82 (Larochelle et al., 2012) can regulate the adhesion and homing of CD34(+)
HSPCs. As tetraspanins can promote healthy interactions between HSCs and
their microenvironment, several other groups have also examined how leukemic
cells can utilize tetraspanins to integrate into the niche and propagate disease
pathologies. For example, a recent report from the Reya laboratory demonstrated
using Tspan3 knockout mice that Tspan3 is essential for the migration of AML
cells into the bone marrow niche and ultimately AML disease progression (Kwon
et al., 2015). Collectively, these studies have provided significant insight
regarding the role of tetraspanins in mediating disease progression and survival.
Future work that examines the mechanism underlying tetraspanin mediated
leukemia progression will likely lead to more specific treatment options for
patients with aberrant tetraspanin expression.

1.7 Summary and discussion
Although the work described throughout the introduction has provided
significant insight regarding the mechanisms by which HSCs and AML are
regulated, there are still several unanswered questions within the field. For
example, the involvement of integrins in mediating HSC adhesion and homing
has been established, the precise molecular means by which integrins assist with
this task remain unclear. Based on previous evidence demonstrating the
importance of the α4 integrin subunit in regulating HSC adhesion and homing, as
well as reports that tetraspanins can regulate the molecular avidity of integrins,
we hypothesize that CD82 regulates the molecular organization of the α4 integrin

67

subunit to promote HSPC adhesion. Furthermore, previous studies indicate that
the palmitoylation of tetraspanins can regulate protein-protein interactions.
Therefore, we also hypothesize that CD82 palmitoylation controls the
organization of the α4 integrin subunit. In Chapter 2, we utilize cell lines to model
HSPCs and determine how CD82 expression and palmitoylation control HSPC
adhesion to ECM components. Our findings demonstrate that the overexpression
of CD82 results in increased adhesion to fibronectin, and that this increased in
mediated through the α4β1 integrin. Furthermore, overexpression of a
palmitoylation mutant form of CD82 does not result in an increase in HSPC
adhesion to fibronectin. Additionally, using quantitative imaging techniques, we
determine that CD82 palmitoylation is a critical regulator of the molecular density
of the α4 integrin subunit.
As cadherins are critical regulators of AML-niche interactions, we also
examined the role of CD82 in mediating AML homing and adhesion. In Chapter
3, we use cell line models of AML as well as AML blast patient samples to
examine how CD82 expression and post-translational modifications regulate
AML bone marrow homing. Our data demonstrate that knockdown of CD82
expression leads to a reduction in bone marrow homing compared to control
cells. Furthermore, in patient samples with increased CD82 expression, we find
that there is an increase in bone marrow homing, demonstrating a role for CD82
expression in mediating this process. Further examination shows that this
adhesion occurs in an N-cadherin dependent manner, whereby CD82
palmitoylation regulates the number of N-cadherin clusters, meanwhile, CD82 Nlinked glycosylation controls the packing of N-cadherin clusters. These data
provide a role for the molecular organization of N-cadherin in mediating AML
niche-interactions, which can be regulated by CD82.
We have also studied the role of tetraspanin CD82 in regulating signaling
in AML with a particular focus on PKCα signaling. In Chapter 4, we use AML cell
lines to demonstrate that the scaffolding of CD82 is critical for sustained PKCα
signaling.

Using

quantitative

imaging

techniques,

we

find

that

CD82

palmitoylation regulates PKCα membrane interactions as well as interactions with
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CD82. Additionally, we find significant defects in PKCα clustering upon
palmitoylation mutation, demonstrating that disruption of the scaffold diminishes
PKCα organization at the membrane. Furthermore, increased CD82 expression
leads to sustained ERK1/2 signaling, which ultimately feeds into propagating a
more aggressive AML phenotype in clonogenic assays.
Collectively, these chapters establish tetraspanin CD82 as a critical
regulator of HSPC adhesion, AML homing/adhesion and AML signaling.
Furthermore, through its role in controlling integrins, cadherins and signaling
proteins, CD82 may be a valuable target for therapeutics addressing a variety of
different cancers. Additionally, our work provides significant insight into the role
of tetraspanin palmitoylation, which may prove to be a suitable therapeutic target
on CD82 and potentially several other palmitoylated tetraspanins.

69

Chapter 2: The membrane scaffold CD82 regulates cell adhesion
by altering α4 integrin stability and molecular density.
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2.1 Abstract
Hematopoietic stem and progenitor cell (HSPC) interactions with the bone
marrow microenvironment are important for maintaining HSPC self-renewal and
differentiation. In recent work, we identified the tetraspanin protein, CD82, as a
regulator of HPSC adhesion and homing to the bone marrow, although the
mechanism by which CD82 mediated adhesion remained unclear. In the current
study, we determine that CD82 expression alters cell-matrix adhesion as well as
integrin surface expression. By combining the super-resolution microscopy
imaging

technique,

direct

stochastic

optical

reconstruction

microscopy

(dSTORM), with protein clustering algorithms, we identify a critical role for CD82
in regulating the membrane organization of α4 integrin subunits. Our data
demonstrate that CD82 overexpression increases the molecular density of α4
within membrane clusters, thereby increasing cellular adhesion. Furthermore, we
find that the tight packing of α4 into membrane clusters is dependent upon CD82
palmitoylation and the presence of α4 integrin ligands. In combination, these
results provide unique quantifiable evidence of CD82’s contribution to the spatial
arrangement of integrins within the plasma membrane and suggest the regulation
of integrin density by tetraspanins as a critical component of cell adhesion.

2.2 Introduction
Cells receive signals or cues from their surrounding environment and
respond in ways to optimize survival, maintain quiescence, promote proliferation
and differentiation. Stem cells, in particular, rely on physical interactions with their
surrounding microenvironment or “niche” for the regulation and maintenance of
proper stem cell function. In the case of hematopoietic stem/progenitor cells
(HSPCs), which reside primarily in the bone marrow, direct contact with the
surrounding microenvironment is essential for regulating HSPC proliferation,
multipotentiation, and self-renewal (Renstrom et al., 2010; ter Huurne et al.,
2010; Zhang and Li, 2008). The bone marrow niche is a complex
microenvironment consisting of a number of different cellular and extracellular
matrix (ECM) components including fibronectin, collagen I, III and IV, as well as
laminin (Klein, 1995). In addition to the bone marrow, HSPCs can traffic into and
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out of the peripheral blood, which is utilized clinically for stem cell isolations and
transplantation. Furthermore, under stress conditions and/or injury, HSPCs can
migrate to other tissues such as the spleen, the liver, and even the heart to aid in
tissue repair and remodeling (Losordo et al., 2011; Oostendorp et al., 2000;
Taniguchi et al., 1996). However, the molecular mechanisms orchestrating the
interactions between HSPCs and various niche components are not well
understood.
The tetraspanins are a family of multi-spanning membrane scaffold
proteins that regulate intercellular interactions. CD82 (also known as Kai1) is a
member of the tetraspanin family of proteins, which are evolutionarily conserved
proteins present in most eukaryotes that function in many aspects of cell
physiology as mediators of cell adhesion, membrane trafficking and cell signaling
(Charrin et al., 2009a). One of the most distinct features of tetraspanins is their
ability to associate in cis with other tetraspanins, integrins, members of the
immunoglobulin superfamily of cell adhesion molecules and signaling receptors,
thereby forming tetraspanin-enriched microdomains (TEMs) (Bassani and
Cingolani, 2012; Charrin et al., 2009a; Hemler, 2008a). Formation of TEMs
enables tetraspanins to serve as molecular facilitators or organizers for a number
of transmembrane proteins. Tetraspanins also recruit and maintain intracellular
signaling molecules in close proximity with membrane proteins, thus regulating
downstream biochemical pathways (Choi et al., 2009; Hemler, 2005; Li et al.,
2010; Wang et al., 2007a).
In its role as a protein scaffold, CD82 can form TEMs hypothesized to be
critical for the organization and function of several membrane proteins including
integrins (Han et al., 2012; He et al., 2005). Integrins are heterodimeric cell
adhesion receptors consisting of one α and one β subunit and are expressed by
all multicellular organisms. Components of the ECM as well as specific cell
surface receptors serve as integrin ligands (Barczyk et al., 2010; Harburger and
Calderwood, 2009; Johnson et al., 2009). Integrins are capable of transmitting
signals across the plasma membrane, which can promote cell migration, survival,
differentiation and motility. Specifically, the α4 integrin, which is highly enriched in
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HSPCs, regulates HSPC migration, homing, proliferation, and differentiation
(Arroyo et al., 1999; Coulombel et al., 1997; Papayannopoulou and Nakamoto,
1993). Furthermore, previous studies in mice show that defects occur in HSPC
homing and short-term engraftment upon conditional α4 knockout (Scott et al.,
2003),

and

anti-α4β1antibodies

mobilize

HSPCs

into

the

bloodstream

(Papayannopoulou and Nakamoto, 1993). How CD82 can regulate integrinmediated cellular and molecular functions including migration, adhesion, and
signaling remains unclear. Furthermore, fundamental questions concerning the
formation and regulation of TEMs and their potential modulation of integrin
organization also still exist.
Previous work from our lab identified CD82 as a regulator of HSPC
homing and osteoblast adhesion (Larochelle et al., 2012). Using monoclonal
antibodies specific to CD82, we demonstrated an inhibition of HSPC homing to
the bone marrow and were able to reduce HSPC adhesion to osteoblasts. In the
current study, we set out to identify the mechanism by which CD82 regulates
HSPC niche interactions. We find that CD82 expression alters integrin
expression by contributing to integrin stabilization on the plasma membrane
through modulation of integrin internalization and recycling. Furthermore, we
apply direct stochastic optical reconstruction microscopy (dSTORM) analysis to
evaluate how CD82 and modifications in the palmitoylation sites of CD82
regulate the nanoscale clustering of integrins. Our data suggest that CD82
modulates the molecular packing of α4 molecules within clusters, thereby
regulating the local molecular density of α4. As such, CD82 functionally regulates
niche adhesion by modifying the organization of integrins into tightly packed
clusters, which serves to strengthen cell adhesion to the ECM.

2.3 Results
2.3.1 CD82 expression regulates cell-matrix adhesion
To begin analyzing the molecular mechanism by which CD82 regulates
HSPC interactions with niche components, we generated a CD82 overexpressing
cell line (CD82OE) using the human acute myelogenous leukemia progenitor-like
cells, KG1a. We created a fusion protein where CD82 was tagged with the
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mCherry fluorescent protein at the amino-terminus. Stably transfected cells were
selected and sorted. Figure 2.1B illustrates the plasma membrane and
endosomal localization of mCherry-CD82, which is consistent with the
localization of endogenously expressed CD82 (Larochelle et al., 2012). A stably
expressing mCherry control cell line (control) was also generated (Fig.2.1A).
Flow cytometry analysis indicates a two-fold increase in CD82 surface
expression between overexpressing and control cells (Fig.2.1D). Since our
previous data suggested that CD82-specific antibodies alter in vitro adhesion and
in vivo homing, we evaluated the CD82OE cells for changes in ECM adhesion.
Using a fluorescence-based adhesion assay to quantify changes in cell-matrix
adhesion to various substrates, we identified an increase in cell adhesion with
the CD82OE cells (Fig.2.1E). More specifically, we found that CD82OE cells
display an increase in cell adhesion to laminin and an even greater increase in
adhesion to fibronectin when compared to control cells. Similarly, we found that
the reduction of CD82 expression could also affect cell-matrix adhesion. CD82
knockdown cells (CD82KD) were generated in the KG1a cell line using siRNA
and shRNA. The CD82KD cells were found to express less than 10% of wild type
CD82 expression, as determined by Western blot and flow cytometry analysis
(Fig.2.1F,G). When the CD82KD cells were assessed for cell adhesion, we
detected a significant decrease in cell-matrix adhesion to fibronectin (Fig.2.1H)
that was rescued when the CD82KD cells were transiently transfected with
mCherry-CD82 (Suppl. Fig.S.2.1A-D). In combination these data suggest a role
for CD82 expression in the regulation of cell-matrix adhesion.
The function of CD82 as a molecular organizer can be regulated by the
ability of CD82 to cluster and form TEMs. Based primarily on biochemical
studies, palmitoylation of the intracellular cysteines of tetraspanins has been
suggested to play an important role in the maintenance of tetraspanin-tetraspanin
interactions and to facilitate the oligomerization and dynamic reorganization of
proteins into TEMs (Berditchevski et al., 2002; Charrin et al., 2002; Kovalenko et
al., 2004; Stipp, 2010; Yang et al., 2002). To assess whether the five, membrane
proximal cysteine residues known to be palmitoylated in CD82 are critical for

74

75

76

Figure 2.1: CD82 expression mediates HSPC adhesion to fibronectin.
Epifluorescent images depicting stable KG1a cell lines generated with (A)
mCherry, (B) mCherry-CD82, and (C) mCherry-Palm-CD82 constructs. (D) The
surface expression of CD82 was analyzed for each cell line using flow cytometry.
(E) Cellular adhesion of each cell line was measured using a fluorescencebased adhesion assay. Cells were plated on FBS as a control or the indicated
ECM proteins. To knock-down CD82, KG1a cells were transfected with control
siRNA, CD82 siRNA, and CD82 shRNA. The reduction of CD82 surface and total
expression was measured by flow cytometry (F) and Western blot analysis (G).
The adhesive abilities of these KD cells were then measured with the
fluorescence adhesion assay (H). Error bars indicate SD; n ≥ 3 (* p < 0.05, ** p <
0.01, **** p < 0.0001).
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HSPC adhesion, we generated the mCherry-Palm-CD82 KG1a cells (PalmCD82OE). The Palm-CD82 construct was generated by mutating the five
cysteine residues at 5, 74, 83, 251 and 253 to serine, thereby preventing their
palmitoylation (Mazurov et al., 2007). Characterization of the Palm-CD82OE cells
indicates that the localization and expression of mCherry-Palm-CD82 is
consistent with that of mCherry-CD82 based on epifluorescence imaging
(Fig.2.1C) and flow cytometry analysis (Fig.2.1D). To assess whether the
palmitoylation sites alter the ability of CD82 to regulate cell-matrix adhesion, we
performed matrix adhesion assays with the Palm-CD82OE cells and found a
significant decrease in adhesion when compared to the CD82OE cells. These
data indicate that the palmitoylation of CD82 is essential for its ability to regulate
cell-matrix adhesion.

2.3.2 CD82 expression modifies the profile of surface integrin
expression
Cell adhesion to ECM proteins such as laminin and fibronectin occurs
through specific integrin heterodimers. Tetraspanins form complexes with
integrins, which can regulate ligand binding and integrin signaling properties
(Johnson et al., 2009; Kotha et al., 2008; Nishiuchi et al., 2005; Sridhar and
Miranti, 2006). Furthermore, recent studies suggest that tetraspanins can also
regulate integrin trafficking and complex assembly (He et al., 2005; Liu et al.,
2007; Xu et al., 2009a). Therefore, we set out to determine whether CD82
expression levels affect the surface expression of specific integrins that are
critical for HSPC adhesion. Flow cytometry analysis suggests that while the
levels of CD82 expression have minimal effect on α3, α5, β1, or β7 surface levels
(Fig.2.2D, Suppl. Fig.S.2.2), CD82 overexpression results in an increase in α2
and α4 expression (Fig.2.2A,B). This observed increase in α2 and α4 is
consistent with the detected increase in adhesion to laminin and fibronectin,
respectively (Fig.2.1E). In contrast, we detect a significant reduction in α6
expression in the CD82OE and the Palm-CD82OE cells. This decrease in α6
likely results in the availability of β1 to bind to α4, which could explain the lack of
β1 expression increase in the CD82OE cells (Fig.2.2C). Our cytometry data also
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Figure 2.2: CD82 expression modulates integrin expression. Protein surface
expression was assessed by flow cytometry for the (A) α2, (B) α4, (C) α6, and
(D) β1 integrin subunits. (E) Confocal microscopy was used to assess
colocalization of α4 and CD82 in each cell line. Pearson’s correlation was
determined using ImageJ analysis (R = 0.99 for each image). (F) Control and
CD82OE cells were treated with the α4β1-specific monovalent blocking peptide,
LDV, and adhesion to fibronectin was quantified using the fluorescence adhesion
assay (* p < 0.05). Western blot analysis of total α4 protein expression in (G)
control, CD82OE and Palm-CD82OE cells or upon CD82 knock-down in KG1a
cells transfected with (H) control siRNA, CD82 siRNA and CD82 shRNA vectors.
Western blot analysis of total β1 protein expression in (I) control, CD82OE and
Palm-CD82OE cells or upon CD82 knock-down in KG1a cells transfected with (J)
control siRNA, CD82 siRNA and CD82 shRNA vectors.
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indicate that CD82KD results in a decrease of α2 and α4 surface expression
(Fig.2.2A,B). In combination, these data suggest that modifications in CD82
expression levels can serve to regulate the surface expression of specific
integrins.

2.3.3 CD82-mediated adhesion to fibronectin is modulated by the
α4β1 integrin
On the surface of HSPCs, the predominant integrins involved in fibronectin
binding are αVβ3, α5β1, α4β7, and α4β1 (Coulombel et al., 1997; Mazo et al.,
2011). Of these fibronectin-binding integrins, α4β1 is well-established as a critical
regulator of HSPC/niche cell contact, mobilization and homing. As CD82 was
described previously to interact with α4β1 (Mannion et al., 1996), we first
analyzed the localization of CD82 with respect to the α4 integrin. Confocal
images in Figure 2.2E suggest a similar membrane localization of CD82 with α4
further indicating a potential interaction. To determine more specifically whether
the CD82-mediated increase in fibronectin adhesion occurs through the
regulation of α4β1, we added a specific blocking peptide to the adhesion assay.
Using a saturating concentration (1 µM) of the α4β1-specific monovalent ligand,
LDV, which binds to α4β1 and subsequently blocks its function (Jackson et al.,
1997), we observe an inhibition of the CD82-mediated increase in adhesion to
fibronectin (Fig.2.2F). These data suggest that the CD82-mediated adhesion to
fibronectin involves the α4β1 integrin. In addition to fibronectin, we also
evaluated adhesion to the α4β1-specific ligand, vascular cell adhesion molecule1 (VCAM-1) (Suppl. Fig.S.2.3). Consistent with our fibronectin data, CD82
expression also regulates adhesion to VCAM-1 further supporting the
involvement of the α4β1 integrin.
Next, we evaluated whether CD82 alters the global expression levels of
either α4 or β1, which could affect cell adhesion to fibronectin. Western blot
analysis indicates that CD82 overexpression increases the expression of mature
and immature forms of α4 (Fig.2.2G). Based on densitometry analysis, the
increase in mature α4 expression is approximately 20%, which correlates with
the

increase

in

α4

surface

expression
82

observed

by

flow

cytometry.

Overexpression of the Palm-CD82 mutant also results in an increase in α4
expression (Fig.2.2G), whereas knock-down of CD82 using si- or sh-RNAs leads
to decreased expression of α4 (Fig.2.2H) with no perturbations of β1 expression
(Fig.2.2J). Similarly, we were unable to detect differences in β1 expression in the
CD82OE or Palm-CD82OE cells by Western blot analysis (Fig.2.2I). In addition,
we were unable to detect a direct interaction between CD82 and α4 via
immunoprecipitation analysis, consistent with previous reports (Serru et al., 1999
and Suppl. Fig.S.2.4A). Finally, evaluation of α4 mRNA levels by real-time PCR
indicates that the α4 expression decrease in CD82KD cells does not result from
changes in mRNA expression (Supp. Fig.S.2.4B). These data suggest that CD82
alters the integrin expression profile of the cells and specifically affects α4
expression, which may alter cell-fibronectin adhesion.

2.3.4 CD82 expression alters the endocytosis and recycling of the

α4 integrin
Recently a number of tetraspanins, including CD82, were shown to
regulate integrin turnover during Drosophila oocyte development (Han et al.,
2012). As such, one mechanism by which CD82 could alter the surface
expression of α4 is through changes in internalization. To monitor the
internalization rate of the α4 integrin, we performed a fluorescence-quenching
internalization assay using flow cytometry. Following surface labeling of α4 at
4°C with a specific Alexa-488 conjugated-antibody, we quenched the surface
fluorescence of α4 with an anti-Alexa-488 antibody and quantified the remaining
fluorescence as internalized α4 integrin. Figure 2.3A,B illustrates the percent of
total surface α4 internalized over time and demonstrates that the CD82OE cells
have reduced internalization when compared to control cells. The internalization
of α4 in the Palm-CD82OE cells is similar to the internalization of the CD82OE
cells suggesting that the palmitoylation of CD82 has no affect on the
internalization of α4. Therefore, one mechanism by which CD82 can modify the
surface expression of integrins is by altering their endocytosis.
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Figure 2.3: CD82 expression regulates α4 stability on the cell surface. (A, B)
Control, CD82OE and Palm-CD82OE cells were assessed for α4 internalization
using a fluorescence based internalization assay. Cells were labeled using an
Alexa Fluor 488 integrin α4 antibody, allowed to internalize for 10, 20, and 30
minutes, and the surface fluorescence was quenched using an anti-Alexa Fluor
488 antibody (Invitrogen). The remaining fluorescence indicates internalized
protein, which was compared to 100% α4 surface labeling. (C) α4 recycling after
30 minutes was quantified from three independent experiments using a modified
version of the internalization assay. Cells were allowed to internalize protein for
30 minutes. Cells were then quenched and allowed to recycle protein back to the
cell surface for 30 minutes. Surface fluorescence was quenched again and the
difference between the first and second quench represents the amount of protein
recycled back to the plasma membrane. Error bars indicate SD; n = 3 (* p < 0.05,
*** p < 0.001, **** p < 0.0001).
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Once internalized, integrins can either be degraded through trafficking to
the lysosome or they can be recycled to the surface via the recycling endosome.
To evaluate whether the reduced α4 internalization observed in the CD82OE
cells (Fig.2.3A) could be due to changes in integrin recycling, we quantified α4
recovery to the surface. Following the internalization and quench described for
the endocytosis assay, we placed the cells back at 37°C for 30 minutes to
evaluate the rate of α4 recycling. Figure 2.3C illustrates that in both the CD82OE
and Palm-CD82OE cells, we detect an increase in α4 recycling to the plasma
membrane. These data suggest that the decreased rate of α4 internalization
observed with CD82 overexpression is likely mediated by an increase in α4
recycling. Together these data support a role for CD82 in regulating integrin
expression through modulation of endocytosis and the recycling endosome
pathway.

2.3.5 CD82 expression does not affect the α4β1 affinity state
Our data suggest a role for CD82 in the regulation of α4 integrin
expression and its trafficking. However, in addition to differences in the
expression of integrins, changes in cell adhesion can also be modulated by
changes in integrin affinity. As such, we wanted to determine whether CD82
expression could change the α4β1 affinity state. To quantify potential differences
in α4β1 affinity, we measured the binding affinity of LDV-FITC to cells using a
flow cytometer (Chigaev et al., 2007). Binding isotherms or Langmuir plots were
generated by incubating increasing concentrations of LDV-FITC with cells, and
the measured fluorescence was fit to a suitable non-linear regression function to
calculate the Kd values. These data suggest that CD82 overexpression does not
statistically alter the affinity state of the α4β1 integrin (Suppl. Fig.S.2.5A). Next,
we used real-time flow cytometry to analyze the dissociation kinetics or “off rate”
of LDV-FITC upon addition of a saturating, competitive concentration of
unlabeled LDV (1 µM) (Suppl. Fig.S2.5B). The dissociation rate constant, Koff,
was determined from the nonlinear fit and indicates that CD82 overexpression
does not affect the off rate of LDV. Taken together, CD82 overexpression does
not appear to alter the affinity state of the α4β1 integrin.
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2.3.6 Palmitoylation of CD82 regulates its surface clustering
The overall strength of cellular adhesiveness is regulated by a
combination of the affinity of individual integrins and their local density or surface
geometry. As tetraspanins are known to organize proteins into clusters or “webs”,
which could potentially alter the organization and density of surface integrins, we
set out to evaluate the membrane distribution of CD82 and its effects on α4.
Using the super-resolution imaging technique, dSTORM (Heilemann et al.,
2008), we reconstructed images of the single molecule distribution of CD82 on
the surface of each of the cell lines (Fig.2.4A-C). From the magnified images, we
were able to observe clusters of CD82 on the surface of the control cells
(Fig.2.4A), the CD82OE cells (Fig.2.4B) and the Palm-CD82OE cells (Fig.2.4C).
To quantify the sizes of the identified CD82 clusters, we used the pair autocorrelation function (Fig.2.4D-F). Previously described for dSTORM, the pair
auto-correlation analysis establishes the probability of finding a molecule at a
given distance from another molecule and does not depend on the number of
times an average molecule is counted (Sengupta et al., 2011; Veatch et al.,
2012). Applying this analytical method, we quantified the average, radial, protein
cluster sizes of CD82 within the cell membrane. CD82 clusters measured on the
control cells were significantly smaller (92 nm) than the average clusters in the
CD82OE cells (140 nm) (Fig.2.4G). Interestingly, even though the CD82 surface
expression is the same between the CD82OE cells and the Palm-CD82OE cells
(Fig.2.1D), the measured cluster size of CD82 on the surface of the PalmCD82OE cells is significantly smaller (97 nm). These data illustrate that the
palmitoylation sites within CD82 are critical for the molecular organization of
CD82 into clusters. While the role of palmitoylation in regulating tetraspanin
clustering has been implicated from biochemical experiments (Berditchevski et
al., 2002; Charrin et al., 2002; Stipp, 2010; Yang et al., 2002; Yang et al., 2004),
our data provide quantifiable imaging evidence that illustrates the importance of
these sites for CD82 organization.
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Figure 2.4: CD82 palmitoylation contributes to CD82 oligomerization.
Reconstructed dSTORM images of representative (A) control, (B) CD82OE, and
(C) Palm-CD82OE cells plated on fibronectin and labeled with an Alexa Fluor
647 anti–human CD82 antibody. CD82 cluster size was assessed using the pair
autocorrelation function (Veatch et al., 2012) for control (D), CD82OE (E), and
Palm-CD82OE (F); this function determines the probability, g(r), of localizing a
molecule a given radius, r, away from another localized molecule. Radially
averaged autocorrelation functions were calculated from three 3 × 3 µm regions
of each cell as described in Materials and Methods, Super resolution imaging.
The mean autocorrelation function from these three regions is shown in blue. (G)
Average CD82 cluster size, σDom, extracted from the fitting equation for each
cell and plotted for each population of cells. Error bars, SEM; n = 19 cells for
control, 20 cells for CD82OE, and 17 cells for Palm-CD82OE (**p < 0.01, *p <
0.05).
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2.3.7 The α4 integrin is organized into small-scale clusters
Once we established the distribution of CD82 on each of our cell lines, we
determined whether the expression and/or organization of CD82 had any effect
on the clustering of the α4 integrin. Again, we used dSTORM imaging to assess
potential changes in the α4 surface distribution between the control, CD82OE
and the Palm-CD82OE cells. From the dSTORM images (Fig.2.5A-C), we detect
small-scale clusters of α4 in each cell line. Using the pair auto-correlation
function described above, we fit the α4 localization data (Fig.2.5D-F) and
extracted cluster sizes that were significantly smaller than those calculated for
CD82 (Fig.2.5G). The average cluster size for each of the cell lines is
approximately 35 nm. These data suggest that the α4 integrin is organized into
small-scale membrane clusters on the order of 35 nm, which is not affected by
CD82 expression.

2.3.8 Palmitoylation of CD82 regulates molecular density of α4
clusters
The contribution of integrin clusters to cellular adhesion is heavily
dependent upon their larger scale molecular organization and protein density,
which can alter the strength of the adhesive complex. While the pair autocorrelation function is effective at quantifying the average uniform size of α4
clusters, the function output is representative of a singular α4 cluster. In order to
assess the potential for CD82 to regulate the large-scale organization of α4, we
analyzed the dSTORM images with the density-based spatial clustering of
applications with noise (DBSCAN) data clustering algorithm (Ester et al., 1996a).
DBSCAN quantifies cluster size in terms of cluster area, providing valuable
information about the two-dimensionality of protein clusters (Kim et al., 2013).
This density-based clustering algorithm identifies clusters by evaluating the
number of localizations that are within a density-reachable area and outputs the
cluster sizes (in µm2) found within a region of a cell. As such, the identified
clusters are no longer dependent upon a radial cluster size. Evaluating sections
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Figure 2.5: The α4 subunit is organized into small-scale clusters.
Reconstructed dSTORM images of representative (A) control, (B) CD82OE, and
(C) Palm-CD82OE cells plated on fibronectin and labeled fluorescently for the α4
integrin subunit using a monoclonal α4 integrin primary antibody and goat antimouse Alexa Fluor 647 secondary antibody. The α4 cluster size was assessed
using the pair autocorrelation function (Veatch et al., 2012) for control (D),
CD82OE (E), and Palm-CD82OE cells; this function determines the probability,
g(r), of localizing a molecule a given radius, r, away from another localized
molecule. Radially averaged autocorrelation functions were calculated from three
3 × 3 µm regions of each cell as described in Materials and Methods,
Superresolution imaging . The mean autocorrelation function from these three
regions is shown in blue. (G) Average α4 cluster size, σDom, extracted from the
fitting equation for each cell and plotted for each population of cells. Error bars,
SEM; n = 13 cells for control, 20 cells for CD82OE, and 20 cells for PalmCD82OE.
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of the reconstructed dSTORM images from cells with approximately the same
number of α4 localizations, (Fig.2.6A-C) we quantified the number of larger-scale
α4 clusters or “DB clusters”. Using DBSCAN, we observed an increased number
of total DB clusters of α4 in the CD82OE and Palm-CD82OE cells (Fig.2.6G),
which we attribute to the aforementioned increase in α4 surface expression in
these cell lines (Fig.2.2A).
Integrins must organize into adhesive clusters that can resist the strong
forces present at sites of adhesion, while maintaining ligand engagement
(Balaban et al., 2001; Roca-Cusachs et al., 2009; Selhuber-Unkel et al., 2008).
Therefore, we used the DBSCAN to quantify the organization of α4 localizations
into clusters as a mechanism of increased HSPC adhesion. More specifically, we
set out to determine the percent of α4 localizations determined to be clustered,
as well as the number of α4 localizations found within clusters. In both the
CD82OE and the Palm-CD82OE cells, we calculated an increase in the percent
of localizations that are considered clustered (Fig.2.6H) by the DBSCAN.
Furthermore, we found an increase in the average number of α4 localizations
found within DB clusters for CD82OE as well as Palm-CD82OE cells (Fig.2.6I).
These increases are likely due to our previous finding that the CD82OE and
Palm-CD82OE cells exhibit an increase in α4 surface expression as compared to
the control cells (Fig.2.2A). Moreover, since both the CD82OE and PalmCD82OE cells show an increase in the percent of α4 clustered as well as number
of α4 localizations within a cluster, these results are unlikely to account for the
change in adhesion between the CD82OE and Palm-CD82OE cells.
Adhesion complex stability can be strengthened by the tight packing of
multiple integrins into clusters (Geiger et al., 2001; Kiessling et al., 2006;
Mammen et al., 1998; Selhuber-Unkel et al., 2008). Upon further evaluation of
the DBSCAN clusters, we observed a striking difference in the size of α4 clusters
as well as the spatial organization of α4 molecules within these clusters. When
we magnify the reconstructed images to analyze the size and shape of the DB
clusters (Fig.2.7A-C), we find that the CD82OE cells have smaller, more tightly
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Figure 2.6: CD82 expression regulates α4 molecular organization.
Reconstructed dSTORM images of representative (A) control, (B) CD82OE, and
(C) Palm-CD82OE cells plated on fibronectin and labeled fluorescently for α4.
(D–F) The DBSCAN algorithm was used to examine cluster organization within a
subregion of the cells. The DBSCAN parameters used were ε = 1 pixel and n =
30 localizations. Colored localizations denote localizations organized into a
cluster, and gray localizations indicate molecules not organized, as they did not
meet the DBSCAN parameters. (G) Quantification of the total clusters
determined by DBSCAN. (H) Quantification of the percentage of α4 localizations
determined to be organized into clusters. (I) Average number of α4 localizations
per cluster as determined by DBSCAN. Error bars, SD; n = 4 cells (*p < 0.05, **p
< 0.01).
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packed clusters of α4 when compared to control or Palm-CD82OE cells.
(Additional larger fields of view are illustrated in Suppl.Fig.S.2.6A-C.) In order to
assess differences in the distribution of clusters found using DBSCAN, we
generated cumulative distribution plots of DB cluster sizes (Fig.2.7D)(Suppl.
Fig.S.2.7A-B). The cumulative distribution plot illustrates the overall cluster sizes
from all of the cells, which enables us to assess the percentage of clusters within
a given size. Using the Kolmogorov-Smirnov test to assess if two data sets differ
significantly, we find that the distribution of clusters found in the CD82OE cells
differs from the distribution found in the control cells, as well as the PalmCD82OE cells. These data suggest that the size of the α4 DB clusters present on
the CD82OE cells are smaller than those measured on the control and PalmCD82OE cells.
We next examined the size distribution of clusters found by DBSCAN by
binning the data by α4 cluster area (µm2). This allows us to extract the relative
percentages of various sized DB clusters detected and quantify differences in the
types of DB cluster sizes identified as well as their relative abundance. We found
that in the CD82OE cells, there is an increase in the percent of DB clusters that
fall within the smaller 0-0.0025 µm2 bin (Fig.2.7F). In contrast, an increase in the
larger DB clusters (> 0.005 µm2) are detected upon Palm-CD82OE. In Figure
2.7E, we provide a visual reference for the length dimensions that would result in
each of the square cluster areas. Taken together, these data indicate that there
is a difference in the relative abundance of small and large α4 clusters between
the overexpressing cell lines. Furthermore, these data suggest a functional
difference between the ability of the CD82OE and Palm-CD82OE cells to
contribute to α4 cluster size. More specifically, the palmitoylation mutant form of
CD82 is less effective at tightly packing the α4 molecules into a cluster, and as
such, the α4 clusters in the Palm-CD82OE cells contain an increased proportion
of clusters > 0.005 µm2.
In addition to identifying CD82-mediated changes in α4 cluster size, we
also detected a difference in the spatial organization of α4 localizations within the
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Figure 2.7: CD82 palmitoylation regulates the α4 density within clusters.
Enlarged DBSCAN regions of (A) control, (B) CD82OE, and (C) Palm-CD82OE
cells showing representative α4 clusters. (D) Cumulative distribution plot of the
clusters compiled from n = 4 cells of each cell line plated on fibronectin; >250
clusters. Statistics determined using the Kolmogorov–Smirnov test. (E)
Representative cluster geometry as depicted by black squares. Corresponding
dimensions that give rise to cluster areas (0.0025, 0.005, and 0.01 µm2) drawn to
scale of images in A–C. (F) Percentage of total clusters that fall within the cluster
area bins determined for cells plated on fibronectin. (G) Average number of α4
molecular localizations/0.01 µm2 determined for cells plated on N-cadherin,
fibronectin, and VCAM-1 using DBSCAN. Error bars, SD; n = 4 cells (*p < 0.05,
**p < 0.01). the cells are plated on an 4 ligand (Fig.7G)(Suppl.Fig.8A-C,G). When
the cells are plated on N-cadherin, we no longer detect a change in integrin
density (Fig.7G)(Suppl.Fig.8D-F,H). In combination, these data suggest a critical
role of tetraspanins in promoting the organization of integrins into adhesion
complexes, which allows for proper cell-ECM interactions. More specifically, our
data suggest that CD82 mediates the tight packing of 4 into clusters upon ligand
engagement, which increases the molecular density of 4 and enhances cellmatrix adhesion. Furthermore, our data indicate that CD82 palmitoylation is
required for the effective formation of tightly packed integrin clusters.
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clusters. To quantify these differences, we calculated the number of α4
localizations per unit cluster area of the cell (0.01 µm2) (Fig.2.7G). From these
data, we found an increase in the average number of α4 localizations per 0.01
µm2 in the CD82OE cells indicating an increase in the number of α4 molecules
packed into a smaller area of the membrane. When we compare these results to
the α4 packing in the Palm-CD82OE cells, we find that Palm-CD82OE does not
promote the compact lateral packing of α4 molecules within clusters. Next, we
assessed whether the presence of α4 ligand has an effect on the CD82-mediated
changes in α4 density. To quantify this potential difference, we completed the
dSTORM imaging and analysis on cells that were plated on VCAM-1 (α4 ligand)
or N-cadherin (non-ligand). Interestingly, our data indicate that the increase in α4
density measured in the CD82OE cells occurs only when occurs only when the
cells are plated on an α4 ligand (Figure 2.7G and Supplemental Figure S.2.8, A–
C and G). When the cells are plated on N-cadherin, we no longer detect a
change in integrin density (Figure 2.7G and Supplemental Figure S.2.8, D–F and
H). In combination, these data suggest a critical role of tetraspanins in promoting
the organization of integrins into adhesion complexes, which allows for proper
cell–ECM interactions. More specifically, our data suggest that CD82 mediates
the tight packing of α4 into clusters upon ligand engagement, which increases
the molecular density of α4 and enhances cell–matrix adhesion. Furthermore, our
data indicate that CD82 palmitoylation is required for the effective formation of
tightly packed integrin clusters.

2.4 Discussion
Tetraspanin-tetraspanin and tetraspanin-integrin interactions modify cellcell and cell-matrix adhesion; although, the molecular mechanisms that mediate
these processes remain unclear. Our study provides strong evidence that the
tetraspanin, CD82, can regulate the membrane organization of integrins resulting
in the formation of tightly packed integrin “nanoclusters”, which increases matrix
adhesion. Moreover, if we inhibit lateral CD82 clustering by overexpressing a
mutant form of CD82, which cannot be palmitoylated, we diminish the
organization and molecular packing of α4 integrins and ultimately block cell-
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matrix adhesion. These results have led us to propose a model whereby CD82
TEMs serve to regulate the molecular density of integrins by recruiting integrins
into and/or stabilizing them within plasma membrane clusters in a ligand
dependent manner (Fig.2.8).
Trafficking of HSPCs into and out of the bone marrow is essential
throughout life to maintain homeostasis of the hematopoietic system and
participate in innate immune responses. It is also critical in the clinical setting
where HSPCs can be isolated from normal donors and transplanted back into
patients to replenish a compromised hematopoietic system. Previous work from
our group identified the enrichment of CD82 at HSPC contact sites with
osteoblasts, which led us to evaluate its potential role in HSPC/bone marrow
interactions (Gillette and Lippincott-Schwartz, 2009). In a follow up study, we
found that treatment of human CD34(+) cells with CD82 monoclonal antibodies
inhibited CD34(+) cell adhesion and homing to the bone marrow, although the
mechanism for this CD82-mediated effect on adhesion and homing remained
unknown (Larochelle et al., 2012). In this study, we evaluate how CD82
expression regulates cell adhesion, with a particular focus on modifications in
integrin interactions. First, we demonstrate a role for CD82 in cell adhesion,
finding that CD82OE increases cell adhesion to fibronectin, whereas CD82KD
results in decreased adhesion. Interestingly, it is important to note that this
CD82-mediated increase in fibronectin adhesion requires the palmitoylation of
CD82, since an increase in cell adhesion was not observed with the PalmCD82OE mutant.
Previously, the expression of CD82 was shown to modify adhesion
through the αVβ3 (Ruseva et al., 2009) as well as the α6 (He et al., 2005) and β1
integrins (Jee et al., 2007). As such, we went on to evaluate CD82-mediated
differences in integrin surface expression and identified changes in α4
expression. Signaling through the α4β1 integrin is known to regulate HSPC
adhesion and homing to the bone marrow (Hartz et al., 2011). For example,
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Figure 2.8: Proposed model for CD82 regulation of molecular clustering
and protein density. On the basis of super-resolution microscopy data, we
propose a model in which CD82 expression and clustering modulate α4 protein
density. (A) CD82OE facilitates the membrane clustering of CD82, which leads to
larger CD82 clusters and more tightly packed α4 clusters. The detected increase
in α4 density upon CD82OE depends on α4 ligand engagement. In contrast,
Palm-CD82OE is unable to promote effective TEMs, which results in smaller
CD82 clusters and reduced molecular density of α4. (B) The spatial arrangement
of molecules within TEMs is essential for organizing adequate adhesion and
signaling platforms, which are weakened by palmitoylation site mutation. The
association of CD82 with other tetraspanins, a process strengthened by
tetraspanin palmitoylation, could indirectly affect the molecular density of α4
clusters by disrupting the organization within the TEM required to establish
effective packing of α4 molecules. The increased α4 molecular density results in
α4 molecules within close proximity of one another, which contributes to the
overall strength and activity of the adhesion complex.
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treatment of mice with α4-blocking antibodies results in HSPC mobilization into
the blood (Craddock et al., 1997; Papayannopoulou et al., 1995). In addition,
HSPC homing to the bone marrow is perturbed by α4-blocking antibodies
indicating that α4 plays a role in regulating HSPC/bone marrow niche interactions
(Papayannopoulou et al., 1995). Our results demonstrate that the CD82mediated increase in fibronectin adhesion occurs primarily through the α4β1
integrin. Furthermore, we identified an increase in the surface expression of α4
upon CD82OE or Palm-CD82OE and a decrease in surface expression with
CD82KD. Recent studies have shown that tetraspanins can modulate integrin
surface distribution and function through the regulation of integrin internalization
(Liu et al., 2007; Winterwood et al., 2006) and trafficking through the endosomal
pathway (Caswell et al., 2009). Previous studies have shown that the rate of
α4β1

internalization

was

significantly

reduced

in

CD151-silenced

cells

(Winterwood et al., 2006). In addition, the YXXφ motif in CD151 was identified as
a structural element that determines the trafficking of its associated integrins (Liu
et al., 2007). In both the CD82OE and Palm-CD82OE cells, we detect a
decreased rate of α4 internalization as well as an increased rate of α4 recycling
when compared to control cells. These data suggest that CD82OE can increase
the surface expression of integrins, independent of palmitoylation status, by
enhancing their plasma membrane recycling rate. In combination, these data
implicate a mechanism for our measured expression increase of surface α4;
however, it is clear that α4 expression alone cannot account for the observed
change in cell adhesion, since both CD82OE and Palm-CD82OE cells express
approximately the same amount of surface α4 yet illustrate dramatically different
adhesion abilities.
TEMS have been proposed to enhance cell adhesion by clustering
functionally related molecules or tightly packing specific receptors into the
plasma membrane (Yanez-Mo et al., 2009). Palmitoylation can play a key role in
the stable association of tetraspanins with each other (TEMs) and adhesionrelated proteins. In fact, several reports have shown that mutation of the
intracellular membrane proximal cysteines reduces interactions between
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tetraspanins (Berditchevski et al., 2002; Charrin et al., 2002; Delandre et al.,
2009; Stipp, 2010; Yang et al., 2002; Yang et al., 2004; Zhou et al., 2004). In this
study, we utilize the dSTORM super-resolution imaging technique to visualize
and quantitatively demonstrate palmitoylation-mediated alterations in tetraspanin
organization. Our data indicate that mutation of the CD82 palmitoylation sites
reduces the size of CD82 clusters within the plasma membrane and leads to
changes in the membrane organization of the α4 integrin. While previous work
has established that CD82 does not directly interact with α4β1 (Serru et al.,
1999), it is clear that α4β1 and CD82 exist within the same membrane complex
(Mannion et al., 1996). Therefore, the interaction of CD82 with other
tetraspanins, which is stabilized by palmitoylation, likely contributes to the indirect
linking of α4β1 into TEMs.
Previous work has shown that tetraspanin association facilitates the
recruitment of cell adhesion molecules such as VCAM and ICAM into adhesive
“nanoclusters” (Barreiro et al., 2008). Similarly, CD81 was proposed to generate
rapid adhesion strength to VCAM-1 through the augmentation α4β1 avidity
(Feigelson et al., 2003). More recently, CD37 was also shown to regulate the
mobility and clustering of α4β1 in B cells (van Spriel et al., 2012). Our clustering
data indicate that CD82OE results in α4 clusters, which are smaller in area (µm2)
when compared to clusters found in control or Palm-CD82OE cells. However,
despite the difference in average α4 cluster area, the number of α4 molecular
localizations within each cluster remains the same. The molecular density of a
protein cluster can be modified by altering the number of localizations found
within a cluster area. Therefore, fitting the same number of localizations into a
smaller area results in the increased molecular density of α4 in the CD82OE
cells. The number and strength of bonds between integrins and ECM
components can contribute to the overall strength of the adhesion complex
(Maheshwari et al., 2000). Our data suggest that it is the tight packing of α4
molecules, as promoted by CD82 upon α4 ligand engagement, which enhances
the overall adhesive contribution of α4 clusters. The increase in laminin adhesion
by CD82OE cells may also suggest that CD82 alters the clustering and
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potentially the density of laminin binding integrins α3 and α6. Previous studies
assessing the importance of integrin spacing for adhesive contribution postulate
that proper positioning is necessary to maintain integrin linkages with one
another, as well as adequate integrin binding to ECM components (Arnold et al.,
2004; Selhuber-Unkel et al., 2008). Moreover, Arnold et. al show that improper
integrin binding site separation results in limited cell attachment due to restricted
integrin clustering. In our study we find that CD82OE can facilitate the
organization of α4 integrins into densely packed structures implicating the
importance of α4 molecular density for cell adhesion. Furthermore, we speculate
that the compromised α4 receptor clustering observed in the Palm-CD82OE cells
reduces adhesion by limiting the recruitment or stability of structural and/or
signaling elements.
Among the tetraspanins, CD82 is largely studied in cancer where its
expression is inversely correlated with metastasis formation (Miranti, 2009; Tsai
and Weissman, 2011; Zoller, 2009). The ability of CD82 to regulate metastasis is
likely related to its ability to modulate integrin function, which we demonstrate in
this study involves molecular density regulation. Taken together, CD82 can
modify not only the assembly of membrane protein structures, but also the
molecular concentration of integrins within these structures. As such, we propose
that the molecular crowding of α4, which is regulated by CD82 and its
palmitoylation state, modulates the overall adhesive strength of cells to the ECM.
Finally, our detailed insight into how CD82 contributes to the coordinated
molecular regulation and organization of α4 implicates CD82 as an attractive
potential therapeutic target to improve HSPC mobilization and engraftment
capabilities.

2.5 Materials and methods
2.5.1 Cell culture
KG1a human hematopoietic myeloid progenitor cells (ATCC CCL-246.1,
Manassas, VA) were cultured in RPMI 1640 Medium (Mediatech, Manassas,
VA.), supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad,
CA), 2 mM L-glutamine (Invitrogen, Carlsbad, CA), 100 Units/mL penicillin and
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100 µg/mL streptomycin (PenStrep; Invitrogen, Carlsbad, CA). Human
microvascular endothelial cells (hMVECs) were purchased and cultured as
indicated by Cell Applications. Cells were incubated at 37°C, 5% humidity, and
5% CO2.

2.5.2 Overexpression and knockdown vector constructs
To generate the mCherry-CD82 plasmid, CD82 was subcloned from the YFPCD82 construct (Addgene) into the mCherry-C1 Vector (Invitrogen) using the
XhoI and SacII restriction sites. The YFP-Palm-CD82 (CD82 palmitoylation
mutant) construct was a generous gift from D. Derse (NIH) (Mazurov et al.,
2007). To crease the mCherry version of the construct, the PALM--CD82 insert
was

PCR

amplified

with

the

following

CTCGAGCGATGGGCTCAGCC-3’

and

primers

(Forward:

Reverse:

5’5’-

CCGCGGAAGCTTTCAGTACTTGGG-3’) and inserted into the mCherry-C1 with
the XhoI and SacII restriction enzymes. The CD82 shRNA plasmid (Santa Cruz
Biotechnology, Santa Cruz, CA) consisted of a pool of three to five plasmids
encoding 19-25 nucleotides (plus hairpin). CD82-targeted siRNAs consisting of
pools of three 20-25 nucleotide siRNA sequences and the scrambled control
siRNA were also purchased from Santa Cruz Biotechnology.

2.5.3 Nucleofection
KG1a cells were transfected according to the manufacturer’s instructions using
the Lonza Nucleofection Kit (Lonza, Walkersville, MD). Stable cell lines
expressing mCherry, mCherry-CD82, and mCherry-Palm--CD82 constructs were
selected for with 500 µg/mL Geneticin® (G418; Invitrogen, Carlsbad, CA). Stably
expressing cells were isolated via fluorescence-activated cell sorting (FACS;
UNM Facilities).

2.5.4 Flow cytometry
Cells were labeled in PAB buffer (PBS + 1% BSA + 0.02% sodium azide) for 30
minutes on ice with either Alexa Fluor 647 CD82 (clone ASL-24; BioLegend),
Alexa Flour 488 integrin α4 (clone 7.2R; R&D), FITC integrin α6 (clone GoH3;
BioLegend), Alexa Flour 488 integrin α3 (clone ASC-1; BioLegend), APC integrin
α5 (clone NKI-SAM-1; BioLegend), PE integrin α2 (clone HAS3; R&D), FITC
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integrin β7 (clone FIB27; BioLegend), or Alexa Flour 647 integrin β1 (clone
TS2/16; BioLegend). Separate tubes of cells were labeled with either Alexa Flour
488 mouse IgG1, κ, isotype control (clone 11711; R&D), FITC rat IgG2a, κ,
isotype control (clone RTK2758; BioLegend), Alexa Flour 647 mouse IgG1, κ,
isotype control (clone MOPC-21; BioLegend), PE mouse IgG2a, κ, isotype
control (clone MOPC-173; BioLegend), APC mouse IgG2b, κ, isotype control
(clone MPC-11; BioLegend). Cells were washed 3 times with PAB buffer and
analyzed using Accuri C6 flow cytometer. Histograms were created using FlowJo
software; fluorescence values were normalized to the mode.

2.5.5 Western blot and immunoprecipitation
Cells were lysed in RIPA buffer. Protein concentration was determined using the
bicinchoninic acid (BCA) assay (Pierce). 25 µg of protein was subjected to 8% or
10% SDS-PAGE. The proteins were then transferred to a nitrocellulose
membrane. Membranes were blocked with 5% dry milk in PBS with 0.22%
Tween-20 for 1 hour at room temperature. Membranes were then incubated with
either β-Actin (clone AC-74; Sigma Aldrich), Calnexin (clone C5C9, Cell
Signaling), integrin α4 (clone EPR1355Y; Novus), integrin β1 (Cell Signaling),
CD82 (clone ab66400; AbCam) or integrin α6 (clone ab97760; AbCam) diluted in
5% milk/PBST overnight at 4°C. The membranes were washed three times for 10
minutes in PBS/0.22% Tween-20. Membranes were then incubated with
peroxidase-conjugated AffiniPure goat anti-rabbit IgG or peroxidase-conjugated
AffiniPure goat anti-mouse IgG secondary antibody diluted in 5% dry milk in
PBS/0.22% Tween-20 for 1 hour at room temperature. The membrane was
washed three times for 10 minutes in PBS/0.22% Tween-20. HRP conjugate
enzymes were stimulated with SuperSignal® West Pico Chemiluminescent
Substrate (Pierce). Blots were imaged using the ChemiDoc XRS Imager (BioRad) and analyzed using ImageJ densitometry software. For immunoprecipitation
experiments, BRIJ O10 cell lysates were incubated with CD82 antibody overnight
at 4°C. Protein A/G Beads (Santa Cruz Biotechnology) were washed and added
to the lysates for 30 min at room temperature. The supernatants were removed

107

and the beads were washed 3x before the beads and supernatants were
analyzed for CD82 and α4 by Western blot as described above.

2.5.6 Adhesion assay
96-well microplates were coated with either fibronectin (10 µg/mL in phosphatebuffered saline (PBS); Millipore, Billerica, MA), collagen I (10 µg/mL in PBS;
Sigma-Aldrich, St. Louis, MO), laminin (10 µg/mL in PBS; BD Biosciences,
Franklin Lakes, NJ), or 10% FBS as a control. For the VCAM-1 adhesion assay,
10 µg/ml of recombinant VCAM-1 (R&D) was used to coat wells. Cells were
labeled for 20 min with 2 µM calcein AM fluorescent dye (Invitrogen, Carlsbad,
CA) in Hank’s buffered salt solution (HBSS). After washing twice with HBSS, the
cells were plated at 100,000 cells/well and incubated at 37°C for 2 hrs. The
microplate was washed to remove non-adherent cells and the remaining
adherent cells were measured using a fluorescence plate reader with excitation
wavelength of 488 nm emission detected at 512 nm. Fluorescence data were
then normalized to the mean fluorescence obtained for control cells. To measure
α4β1 specific adhesion, cells were treated with either dimethyl sulfoxide (DMSO)
or blocked with the monovalent peptide LDV (1 µM), which was a generous gift
from Drs. Larry Sklar and Tione Buranda (UNM).

2.5.7 Immunofluorescence
Cells were fixed in 4% PFA then blocked and permeabilized with PBS + 1.0 %
BSA + 0.1% tween 20. Alexa Fluor 647-conjugated anti-human CD82 (Clone
ASL-24, Biolegend) and Alexa Fluor 488-conjugated anti-human integrin α4
(clone 7.2 R; R&D) were added to the sample. Immunofluorescence of VCAM-1
was completed with the mouse anti-human VCAM-1 primary antibody (Abd
Serotec) and the Alexa Fluor-488 goat anti mouse secondary antibody (Life
Technologies). Cells were labeled for 30 minutes. Cells were washed 3 times
with PBS + 1% BSA and then imaged in an 8 well chamber slide. Cells were
imaged by laser scanning confocal microscopy with a Zeiss Axiovert 100M
inverted microscope (LSM 510) system using excitation wavelengths of 488 or
633 nm and a 63X 1.2 N.A. oil immersion objective. Image analysis was
performed using the Zeiss LSM 510 software of Image J (NIH, Bethesda, MD).
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2.5.8 Internalization assay
Cells were labeled for 1 hour on ice using an Alexa Fluor 488 integrin α4
antibody (clone 7.2R, R&D). Cells were washed three times using cold medium
and resuspended in RPMI medium. An aliquot of cells was used to determine
median fluorescence using the Accuri C6 flow cytometer; this is considered
100% surface labeling. The remaining cells were put into the incubator (37° C,
5% CO2) for 10, 20 and 30 minutes. At the respective time point, 150,000 cells
were moved to individual tubes. Cells were treated with 1 µg of anti-Alexa Fluor
488 antibody, (Clone A-11094, Invitrogen) which quenches surface fluorescence;
cells were quenched on ice for 1 hour, with > 90% quenching efficiency. After
quenching, cells were then fixed for 20 minutes with 4% PFA. Median
fluorescence in the FL-1 channel was read using Accuri C6 flow cytometer.
Percent internalized was calculated by dividing the median fluorescent intensity
quenched value (normalized to background quench) by the median total α4
surface label intensity.

2.5.9 Recycling assay
Cells were labeled for 30 minutes on ice using an Alexa Fluor 488 integrin α4
antibody (clone 7.2R, R&D). Cells were washed three times using cold medium
and resuspended in RPMI medium. Before allowing internalization, two aliquots
of cells were removed. The first is to determine 100% α4 surface labeling. The
second aliquot was quenched, and fixed; this aliquot represents the quenched
background fluorescence. The remaining cells were put back into the incubator
(37° C, 5% CO2) and allowed to internalize for 30 minutes. Cells were then
treated with 1 µg of anti-Alexa Fluor 488 antibody, (Clone A-11094, Invitrogen) to
quench surface fluorescence; cells were quenched on ice for 1 hour. Cells were
then moved back to the incubator (37° C, 5% CO2) and allowed to recycle for 30
minutes. After 30 minutes, the samples were moved back on ice and quenched
again for 1 hour. Cells were then fixed with 4% PFA, and median fluorescence
was determined using Accuri C6 flow cytometer. The difference between the
internalized value and the recycled value gives the amount of α4 recycled back to
the membrane. To calculate recycled α4, the fluorescent intensity values were
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normalized. Since fluorescent recycling changes are relatively small, quenched
background was subtracted from the internalized and recycled median
fluorescent values. The percent of α4 recycled was calculated by taking the
difference between the normalized internalized and normalized recycled
fluorescent median values, and dividing this number by the normalized
internalized value. This gives the percent of α4 that was labeled, allowed to
internalize for 30 minutes, and quenched upon recycling back to the plasma
membrane.

2.5.10 Super resolution imaging
25 µg/ml of human plasma fibronectin (Millipore) diluted in PBS was used to coat
the wells of an 8 well chamber slide for 20 minutes. 15 µg/ml of recombinant Ncadherin (R&D) diluted in PBS and wells were coated for 30 minutes. 10 µg/ml of
recombinant VCAM-1 (R&D) was also used to coat wells for 1 hour. Cells were
then plated on the coated wells and incubated overnight at 37°C. The following
day cells were fixed with 4% PFA for 20 minutes, washed once with 1%
BSA/PBS and then blocked with 1% BSA/PBS for 1 hour. For CD82 staining,
cells were labeled with Alexa Fluor 647 anti-human CD82 antibody (1:125) (clone
ASL-24; BioLegend) diluted in 1% BSA/PBS. The wells were then washed three
times with 1% BSA/PBS and fixed again with 4% PFA. For α4 staining, cells were
first labeled with monoclonal α4 integrin primary antibody (1:200) (clone Bu49;
ThermoScientific) diluted in 1% BSA/PBS for one hour. The well was then
washed three times with 1% BSA/PBS and subsequently labeled with goat-antimouse Alexa Fluor 647 secondary antibody (1:200) (Invitrogen) diluted in 1%
BSA PBS for one hour. The wells were then washed three times with 1%
BSA/PBS and fixed again with 4% PFA.
Labeled cells were imaged in a reducing buffer including 50 mM βmercaptoethylamine as a reducing agent. Reference beads were used as a
reference point to stabilize the sample during imaging; drift corrections were
performed using MCL NanoDrive stage controller. The sample was imaged for
10,000 frames using the microscope set up previously described (Huang et al.,
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2011; van den Dries et al., 2013). After obtaining molecule localization estimates
and uncertainties, super resolution images were reconstructed using MATLAB
analyses (Huang et al., 2011).
The pair autocorrelation function (Veatch et al., 2012) was used to analyze CD82
and α4 cluster size. Radially averaged autocorrelation functions were calculated
from three 3 x 3 micron sized areas in each cell. Autocorrelation functions from
the same cell were averaged and fit to the functional form gmeas(r)=B*exp{r2/4σPSF2}/(4πσPSF2ρ) + g(r>0)*gpsf. In order to decouple cluster sizes from
broadening due to finite localization precision, domains are evaluated as 2D
Gaussian shapes, giving g(r>0)= A*exp{-r2/4σDom2}/(4πσDom2) and therefore the
fitting function

gmeas(r)=B*exp{-r2/4σPSF2}/(4πσPSF2ρ)+ A*B*exp{-r2/4(σDom2+

σPSF2)}/(4π(σDom2+ σPSF2)ρ)+1. Here A is the number of molecules per domain, B
is the number of repeat observations per molecule, σPSF is the fluorophore
localization precision, σDom is the cluster size, and ρ is the observed localization
density. The value for ρ was calculated directly from the selected regions, while
A,B, σPSF, and σDom were simultaneously estimated by performing a non-linear
least-squares fit of the average autocorrelation to gmeas(r). The magnitude of g(r)
is a function of both the density and number of repeat observations of each
molecule and can therefore differ with expression level, labeling efficiency and
imaging conditions, whereas the cluster size is extracted from the shape of the
curve and is independent of these effects. The average cluster size for a
population of cells was assessed statistically using Student’s unpaired t-test.
The DBSCAN cluster algorithm was used to assess larger scale α4 clustering. A
56 x 56 pixel box (5.975 x 5.975 µm box) was examined for clustering. Epsilon
value of 1 pixel (106.7 nm) and n value of 30 localizations were used to examine
α4 cluster area. In order to validate our parameters, we also tested the modified
parameters epsilon = 0.5, n = 30 and epsilon = .5, n = 20 and saw the same
trends of the cumulative distribution plots as assessed using the KolmorgovSmirnof test (Suppl. Fig. S.2.7A-B)
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2.5.11 Statistics
All experiments were performed at least three times independently. Results are
expressed as mean ± SD or SEM. Student’s t test was used for mean
comparisons. The Kolmogorov-Smirnov test was used for comparison of
cumulative distributions. Statistical analyses were performed using Prism 5
(Graphpad software). Significant differences are indicated using asterisks (* p <
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
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3.1 Abstract
Communication between acute myeloid leukemia (AML) and the bone marrow
microenvironment is known to control disease progression. Therefore, regulation
of AML cell trafficking and adhesion to the bone marrow is of significant interest.
In this study, we demonstrate that differential expression of the membrane
scaffold CD82 modulates the bone marrow homing of AML cells. By combining
mutational analysis and super-resolution imaging, we identify membrane protein
clustering by CD82 as a regulator of AML cell adhesion and bone marrow
homing. Cluster analysis of super-resolution data indicates that N-linked
glycosylation and palmitoylation of CD82 are both critical modifications that
control the microdomain organization of CD82 as well as the nanoscale
clustering of associated adhesion protein, N-cadherin. We demonstrate that the
inhibition of CD82 glycosylation increases the molecular packing of N-cadherin
and promotes the bone marrow homing of AML cells. In contrast, we find that the
inhibition of CD82 palmitoylation disrupts the formation and organization of Ncadherin clusters and significantly diminishes bone marrow trafficking of AML.
Taken together, these data establish a mechanism where the membrane
organization of CD82, through specific posttranslational modifications, regulates
N-cadherin clustering and membrane density, which impacts the in vivo
trafficking of AML cells. As such, these observations provide an alternative model
for targeting AML where modulation of protein organization within the membrane
may be an effective treatment therapy to disrupt the bone marrow homing
potential of AML cells.

3.2 Introduction
AML, the most common acute leukemia affecting adults, is characterized
by an increase of immature myeloid blasts in the bone marrow that results from a
loss of normal differentiation and proliferation of hematopoietic stem/progenitor
cells (HSPCs) (Machida et al., 1999). Multiple subtypes of AML exist with a range
of aggressiveness and treatment sensitivity (Guzman and Allan, 2014). One sign
of disease aggressiveness is the ability of AML cells to home to the bone marrow
and displace HSPCs (Konopleva et al., 2002). Homing requires multiple steps
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including the ability to respond to a chemotactic gradient, extravasation, and
adhesion to specialized niches within the bone marrow. In fact, adhesionmediated interactions between AML cells and the bone marrow play an important
role in disease progression and chemoresistance (Bradstock and Gottlieb, 1995;
Gibson, 2002; Jin et al., 2006; Zhang et al., 2013). Therefore, identifying the
molecules and mechanisms that mediate AML-bone marrow adhesion and
homing are fundamental to the development of future therapeutic treatments.
Recently, an AML protein profile was identified for a subpopulation of
leukemic blasts, the leukemia stem cells (LSCs). This mass spectrometry study
found an enrichment of specific adhesion-related proteins including CD44,
integrin α6, CD47 and CD82 on LSCs (Bonardi et al., 2013). An alternative AML
screen also identified the upregulation of CD82 in LSCs where it was suggested
to modulate AML adhesion to the bone marrow (Nishioka et al., 2013). Following
its initial cloning (Gil et al., 1992; Imai et al., 1992; Lebel-Binay et al., 1994), the
tetraspanin CD82 (or Kai1) was described as a metastasis suppressor in solid
tumors (Dong et al., 1995). Tetraspanins are evolutionarily conserved membrane
proteins present in most eukaryotes that function as mediators of cell adhesion,
trafficking, and cell signaling (Boucheix and Rubinstein, 2001). Through their
ability to associate in cis with other tetraspanins, cell adhesion molecules, and
signaling receptors, tetraspanins form tetraspanin-enriched microdomains
(TEMs) (Bassani and Cingolani, 2012; Hemler, 2008b). Formation of TEMs
enables tetraspanins to serve as molecular organizers for membrane proteins
(Hemler, 2008b). Our recent work identified a role for CD82 in the homing of
human HSPCs, which we linked to the membrane organization of CD82 and
associated adhesion and signaling molecules (Larochelle et al., 2012). Currently,
basic questions concerning the formation and regulation of TEMs and their
modulation of adhesion receptors, which specifically impact bone marrow
homing, still remain.
N-cadherin is a classical cadherin that interacts homophilically with
cadherins on neighboring cells to form adherence junctions, which mechanically
link cells and relay signaling information from the extracellular environment
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(Kemler, 1993; Takeichi, 1995). While the function of N-cadherin remains
controversial for HSPCs (Bromberg et al., 2012; Calvi et al., 2003; Greenbaum et
al., 2012), its role in the regulation of specific leukemias is more evident. In AML,
the LSC compartment that expresses N-cadherin is relatively resistant to
chemotherapy treatments and highly enriched following chemotherapy (Zhi et al.,
2010). Subsequent studies suggest that N-cadherin expression facilitates LSCs
to initiate and induce AML development (Qiu et al., 2014). In combination, these
data indicate that N-cadherin participates in the protection of LSCs and the
relapse of AML; therefore, the regulation of N-cadherin function in AML is of
significant interest.
The dynamic regulation of cadherin-mediated adhesiveness is thought to
involve modulation of cadherin density arrangement on the cell surface (Hong et
al., 2013). Moreover, clustering of cell surface cadherins is known to modify
cadherin-mediated adhesion and signal transduction, but the mechanism of
cadherin clustering is poorly understood (Nelson, 2008). Combining superresolution imaging, CD82 mutational analysis, and in vivo functional studies, we
utilize a multiscale approach that identifies CD82 as a regulator of AML cell
adhesion and bone marrow homing. Our work establishes a mechanism where
the membrane organization of CD82, which is dependent upon specific posttranslational modifications, regulates N-cadherin clustering and membrane
density. We demonstrate that the spatial regulation of N-cadherin by CD82 leads
to functional in vivo consequences for AML cell behavior.

3.3 Results/Discussion
3.3.1 CD82 expression increases AML cell homing to the bone
marrow and modulates N-cadherin mediated adhesion.
To gain mechanistic insight into how CD82 affects bone marrow homing,
we used the previously described control, CD82 overexpression (CD82OE), and
CD82 knock down (CD82KD) human KG1a cells (Fig.3.1A) to monitor changes in
AML cell homing using NSG mice. Sixteen hours following injection, we detected
no difference in AML cell localization to the spleen or blood (Fig.3.1B). However,
when we analyzed the bone marrow, we identified a marked reduction in bone
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Figure 3.1: CD82 expression regulates homing to the bone marrow and
adhesion to niche components. (A) Flow cytometry analysis of CD82 surface
expression using previously described CD82OE, CD82KD and control KG1a cell
lines27 (ATCC, Manassas, VA, USA; CCL-246.1). Cells were characterized
using Alexa Fluor 647 anti-human CD82 (clone ASL-24, BioLegend, San Diego,
CA, USA). Data were acquired using an Accuri flow cytometer C6 (BD
Bioscience, San Jose, CA, USA) and analyzed with FlowJo X software (Tree
Star, Inc., Ashland, OR, USA). (B) Bone marrow homing of CD82OE, KD or Ctrl
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KG1a cells. Cells were labeled with carboxyfluorescein succinimidyl ester
(CFSE) according to the manufacturer's protocol. After labeling, 1 × 106 cells
were injected intravenous into female NOD. Cg-PrkdcscidIl2rgtm1wjl/SzJ (NSG)
mice 8–12 weeks of age. NSG mice were housed and bred at the Animal
Research Facility under specific pathogen-free conditions at the University of
New Mexico Health Sciences Center (Albuquerque, NM, USA). All procedures
were approved by the University of New Mexico Institutional Animal Care and
Use Committee and carried out in accordance with the NIH Guide for the Care
and Use of Laboratory Animals. Sixteen hours after injection, the blood, spleen
and bone marrow were harvested. A single cell suspension was generated and
red blood cells were lysed with ACKs buffer (15M NH4Cl, 10mM KHCO3, 0.1mM
EDTA). Cells were treated with Fc block, and then stained for human-CD45 and
analyzed by flow cytometry for CFSE and huCD45 (Clone HI30, BioLegend)
double positive cells. Percent input was calculated on the basis of the number of
double positive events multiplied by total tissue cell number divided by the
number of cells injected all multiplied by 100 (n=5 mice). (C and E) Flow
cytometry analysis of CD82 on the surface of primary AML cells. (D and F)
Tissue harvest from 8- to 10-week-old male and female NSG mice 16 h after
intravenous injection of CFSE-labeled primary AML cells (1 × 106 cells) using the
protocol described above (n=5 mice/patient sample). AML patient samples were
deidentified and obtained from the UNM Health Science center (HSC) cell bank.
Flow cytometry analysis of (G) N-cadherin (Clone 8C11, BioLegend) surface
expression on Ctrl, CD82KD or CD82OE KG1a cells. Fluorescence-based cell
adhesion assay using Ctrl, CD82KD and CD82OE cells. Cells were labeled with
2 µM calcein (Invitrogen, Carlsbad, CA, USA) and allowed to adhere to (H)
SaOS-2 osteoblastic cells (ATCC) or (I) purified N-cadherin (R&D Systems,
Minneapolis, MN, USA) for 1 h. Non-adherent cells were removed by washing
and remaining fluorescent cells were measured by using synergyH1 plate reader
(Biotek, Winooski, VT, USA) and analyzed with the Gen5 2.00.18 plate reader
software (n=3 replicates). (J) Flow cytometry analysis for CD82 following the
nucleofection of mCherry or the mCherry-CD82 vectors into the CD82KD cells.
(K) Osteoblastic cell adhesion analysis (as previously described) for CD82KD
cells upon CD82 reintroduction. For all graphs, mean is displayed with error bars
denoting s.d., all variances were determined to be similar; no randomization or
blinding methods were used; statistics were performed using two-sided unpaired
t-test. (*p<0.05, **p<0.01, ***p<0.001).
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marrow homing of the CD82KD cells along with a modest increase in the bone
marrow homing of CD82OE cells when compared to control cells. Therefore,
CD82 expression can modify the in vivo trafficking of AML cells. To further
evaluate this finding, we compared the homing capacity of primary human AML
cells with differential CD82 expression (Fig.3.1C,E). Consistent with the cell line
data, we find that AML cells with higher CD82 expression display improved bone
marrow homing when compared to AML cells with lower expression of CD82
(Fig.3.1D,F). The combined cell line and primary AML cell data suggest that
CD82

expression

modulates

AML

cell

homing

to

the

bone

marrow

microenvironment, which is an indicator of aggressive AML.
Bone marrow homing of AML cells requires a series of complex steps
involving a combination of cell migration and adhesion signaling. The chemokine
receptor, CXCR4, with its ligand, stromal derived factor-1 (SDF-1), is the major
receptor signaling pathway used for bone marrow homing by HSPCs (Aiuti et al.,
1997) and various types of leukemic cells (Zaitseva et al., 2014). While functional
interactions between tetraspanins and CXCR4 signaling were shown previously
(Yoshida et al., 2008), we did not detect any CXCR4 expression differences
between the control, CD82OE, and CD82KD cells (Suppl.Fig.S.3.1A,B).
Additional analysis of cell migration toward SDF-1 illustrates no difference in the
migratory behavior of these cells in a transwell assay (data not shown).
Therefore, these data suggest that the observed changes in bone marrow
homing are not likely due to CD82-mediated effects on the CXCR4 homing
signal.
Next, we turned to evaluate whether CD82 expression may affect AML cell
adhesion within the bone marrow by screening the cell lines for expression
changes in the cadherin family of cell-cell adhesion molecules (Kemler, 1993;
Takeichi, 1995). While we were unable to detect differences in the expression of
E-cadherin and P-cadherin (Suppl.Fig.S.3.1C,D), the surface expression of Ncadherin was significantly reduced in the CD82KD cells (Fig.3.1G). Recently, Ncadherin enrichment was identified on the surface of LSCs, which was proposed
to enable the cell adhesion of AML cells to the bone marrow (Qiu et al., 2014; Zhi
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et al., 2010). Therefore, we used a fluorescence-based adhesion assay to
measure changes in cell adhesion to osteoblasts and purified N-cadherin.
Consistent with the homing experiments, we find that CD82KD results in a
decrease in cell adhesion to osteoblastic cells as well as purified N-cadherin,
whereas CD82OE cells display an increase in cell adhesion (Fig.3.1H,I).
Furthermore, the reintroduction of CD82 back into the CD82KD cells recovered
the reduced adhesion phenotype (Fig.3.1J,K). Together, these data implicate a
specific role for N-cadherin in CD82-mediated AML cell adhesion.

3.3.2 CD82 membrane clustering is altered by glycosylation and
palmitoylation status.
A distinct feature of tetraspanins is their ability to associate with other
tetraspanins, cell adhesion molecules and signaling receptors, thereby serving as
molecular facilitators for membrane proteins (Bassani and Cingolani, 2012;
Hemler, 2008b). Therefore, the mechanism by which CD82 regulates AML cell
adhesion and homing is likely to be dependent upon its ability to form higher
order protein complexes in the cell membrane. Moreover, the regulation of TEM
formation and stability is of significant interest. Previously, our group and others
showed that the palmitoylation of the membrane proximal cysteines of CD82
promotes the oligomerization and dynamic reorganization of proteins into
microdomains (Berditchevski et al., 2002; Termini et al., 2014; Yang et al., 2004;
Zhou et al., 2004). Furthermore, cell surface glycosylation, which can alter
protein-protein interactions, also regulates the membrane organization of
proteins. The glycosylation of membrane bound proteins is perturbed in many
cancers and can be regulated by oncogenic factors (Dwivedi et al., 1988; Seales
et al., 2003; Swindall et al., 2013). Recently the membrane glycosylation of CD82
was shown to play a role in cell adhesion and motility in specific cancers (Wang
et al., 2012a; White et al., 1998). To evaluate how palmitoylation and
glycosylation of CD82 affect its membrane organization and the aggressive
potential of AML, two constructs were generated where:

1) the membrane

proximal cysteines were mutated to serine, preventing palmitoylation (PalmCD82) (Mazurov et al., 2007; Termini et al., 2014), and 2) the three N-linked
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glycosylation sites were mutated to glutamine, inhibiting glycosylation (NglyCD82) (Fig.3.2A). These constructs were stably transfected into KG1a cells and
Figure 3.2B indicates that the Ngly-CD82 and Palm-CD82 cells express similar
CD82 surface levels as the CD82OE cells. Interestingly, both mutants contain
intracellular CD82, which may further suggest changes in CD82 protein
trafficking that are regulated by these post-translational modifications.
Next, we assessed how these CD82 mutations affect the membrane
organization of the CD82 scaffold. To measure differences in microdomain
organization between control, CD82OE, Ngly-CD82 and Palm-CD82 cells, we
used

the

super-resolution

imaging

technique,

direct

stochastic

optical

reconstruction microscopy (dSTORM) (Heilemann et al., 2008). Super-resolution
imaging allows us to quantify changes in CD82 membrane organization at the
level of individual molecules on the nanometer scale (Fig.3.2C-F). Initially, the
reconstructed dSTORM images were analyzed using the Hopkins index, which
determines the extent to which CD82 is present in a random distribution on the
cell surface (Mattila et al., 2013; Zhang et al., 2006). Consistent with our visual
observations, we find that each of the CD82 expressing AML cells has a Hopkins
index that is significantly higher than what would be expected for a random
distribution of molecules (0.5), demonstrating that CD82 is not randomly
distributed, but organized into membrane clusters (Fig.3.2G).
The CD82 dSTORM images were also analyzed using the density-based
spatial clustering of applications with noise clustering algorithm (DBSCAN)
(Fig.3.2C-F,zoom) as previously described (Ester et al., 1996b). From these
measurements, we determined that CD82OE cells have an increased CD82
cluster diameter and area with respect to control cells, which is likely due to the
increased expression of CD82 (Fig.3.2H,I). Interestingly, the CD82 cluster size
quantified for both the Ngly-CD82 and Palm-CD82 cells indicates an even further
increase in CD82 cluster diameter and area when compared to CD82OE cells
(Fig.3.2H,I). Measurements of the Palm-CD82 cells detect the most significant
increase in CD82 cluster size and decrease in CD82 cluster organization, which
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Figure 3.2. Palmitoylation of CD82 is critical for CD82 membrane
organization. (A) Cartoon of CD82 highlighting N-linked glycosylation and
palmitoylation sites. Using the mCherry-CD82 plasmid (Termini et al., 2014),
three N-linked glycosylation sites on CD82, Asparagine 129, 157 and 198 were
mutated individually to glutamine using a QuickChange II site-directed
mutagenesis kit (Agilent) according to the manufacture’s instructions (NglyCD82). All mutations were confirmed by DNA sequence analysis (ACGT Inc.).
CD82 palmitoylation mutant was generated as previously described (Palm-CD82)
(Termini et al., 2014). (B) Flow cytometry analysis of CD82 surface expression
on CD82OE, Ngly-CD82, and Palm-CD82 cells. (C-F) Reconstructed dSTORM
images of CD82 distribution on each cell line (n ≥ 3 cells per cell line). The
previously described labeling, imaging, and fitting protocols were followed
(Huang et al., 2011; Termini et al., 2014). (G) Hopkins analysis of CD82 cellular
membrane organization using reconstructed dSTORM images was performed

126

using SuperCluster Matlab software from the UNM Spatiotemporal Modeling
Center. The reconstructed dSTORM images were also analyzed with the
DBSCAN algorithm to generate DBSCAN images (C-F zooms), which represent
clustered CD82 localizations in color and non-clustered CD82 localizations in
gray. A 6 x 6 µm box was examined for clustering using an epsilon value of 100
nm and an n value of 10 localizations. Quantification of (H) CD82 cluster
diameter and (I) CD82 cluster area based on DBSCAN analysis (n ≥ 3 cells per
cell line). (J-L) dSTORM imaging and DBSCAN analysis for CD82 cluster area
and diameter was performed on four primary AML samples. (** p < 0.01, *** p <
0.001; one-way ANOVA, post-hoc t-test with Welch’s correction for groups with
unequal standard deviations).
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is consistent with previous work demonstrating the importance of the
palmitoylation sites in the lateral packing of CD82 (Termini et al., 2014; Zhou et
al., 2004). Previous work from our lab identified smaller CD82 cluster sizes in the
Palm-CD82 cells using pair-auto correlation function analysis, which is an
averaged radial cluster measurement. In contrast, the DBSCAN algorithm
enables the quantification of larger scale clusters of varying shapes and sizes,
which is what we find for CD82. As for the N-glycosylation mutation, the effects
on CD82 cluster size are more modest, however we do detect an increase in
CD82 cluster diameter and area. We also imaged and analyzed the CD82 cluster
area and diameter in primary AML cells. Consistent with the cell line data,
Fig.3.2J-L further illustrate the differentiation clustering of CD82 in primary
patient samples. In combination, these data illustrate that while the CD82OE,
Ngly-CD82 and Palm-CD82 cells all have similar CD82 surface expression, the
Ngly- and Palm- mutations change the CD82 membrane distribution into larger
ordered CD82 clusters. Therefore, these specific post-translational modifications
regulate the membrane organization of CD82, which may in turn modulate
protein-protein interactions important for bone marrow homing and adhesion.

3.3.3 N-cadherin clustering is regulated by CD82 membrane
organization.
Next, we set out to determine whether the described changes in CD82
membrane organization affect the expression and distribution of N-cadherin.
First, we confirmed that N-cadherin surface expression is consistent between the
CD82OE, Ngly-CD82, and Palm-CD82 cell lines (Fig.3.3A). Next, we performed
confocal immunofluorescence imaging to analyze N-cadherin distribution in the
cells. Figure 3.3B illustrates that both CD82 and N-cadherin are localized to the
plasma membrane in each of the cells except for the CD82KD cells, which have
reduced expression levels of CD82 and a punctate distribution of N-cadherin. In
addition to the change in N-cadherin distribution upon CD82KD, a reduction in Ncadherin expression is observed, which is consistent with the flow cytometry data
(Fig.3.1F). Moreover, double staining of primary AML cells suggests a similar
surface expression profile for CD82 and N-cadherin (Fig.3.3C). To further assess
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Figure 3.3: CD82 interacts with N-cadherin on the plasma membrane. (A)
Flow cytometry analysis of N-cadherin surface expression on CD82OE, NglyCD82, and Palm-CD82 cells (Clone 8C11, BioLegend). (B) Confocal
immunofluorescence imaging of CD82 and N-cadherin. Cells were fixed in 4%
PFA then blocked and permeabilized with PBS + 1.0 % BSA + 0.1% tween 20.
Alexa Fluor 647-conjugated anti-human CD82 (Clone ASL-24, BioLegend) and
anti-human N-cadherin (clone 32/N-cadherin, BD Bioscience) antibodies were
diluted 1:500 in permeabilization buffer and added to the sample overnight at 4C.
Cells were washed and then Alexa Fluor 488-goat-anti-mouse secondary
antibodies were added to the cells for 1hr at room temperature. Following PBS
washes, cells were imaged by laser scanning confocal microscopy with a Zeiss
Axiovert 100M inverted microscope (LSM 510) system using excitation
wavelengths of 488 or 633 nm and a 63X 1.2 N.A. oil immersion objective. Image
analysis was performed using the Zeiss LSM 510 software and Image J (NIH,
Bethesda, MD). Double surface expression analysis by flow cytometry for (C)
CD82 and (D) N-cadherin on primary AML cells. (E) Co-immunoprecipitation of
CD82 and N-cadherin. Co-immunoprecipitations were performed using BRIJ O10
cell lysates incubated with CD82 antibody (Clone B-L2, Abcam) or control IgG
antibody (Santa Cruz Biotechnology) and then immunoprecipitated using protein
A/G Beads (Santa Cruz Biotechnology). Western blots were performed as
previously described (24) using the N-cadherin antibody (32/N-Cadherin, BD
Biosciences).
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potential protein-protein interactions between CD82 and N-cadherin, we
completed co-immunoprecipitation experiments using Brij lysates. The ability of
CD82 to pull down N-cadherin in this mild detergent (Fig.3.3D) suggests that
CD82 and N-cadherin are present in a protein complex.
Surface clustering of N-cadherin can trigger signaling events, which
promote cell adhesion (Hong et al., 2013). Furthermore, the regulatory
mechanism of cadherin clustering is a critical aspect of cadherin adhesion since
the adhesive capacity of individual cadherins is negligible (Nelson, 2008).
Therefore, the lateral association between cadherin receptors is a prerequisite for
the formation of adhesive dimers (Chitaev and Troyanovsky, 1998). To quantify
how changes in CD82 membrane organization affect the nanoscale organization
of N-cadherin, we again used dSTORM (Fig.3.4A-D). Analysis of the N-cadherin
dSTORM images with the DBSCAN algorithm (Fig.3.4E-H) suggests that Ncadherin cluster size and diameter is significantly decreased in Ngly-CD82 and
Palm-CD82 cells when compared to control and CD82OE cells (Fig.3.4I,J). More
importantly, Palm-CD82 cells display a marked decrease in the number of Ncadherin clusters when compared to CD82OE or control cells (Fig.3.4K).
Additional analysis of Palm-CD82 cells also identified that the majority of the Ncadherin molecules are distributed diffusely throughout the membrane and not
localized to organized clusters (Fig.3.4L). Thus, the palmitoylation of CD82 and
its lateral assembly significantly affects the formation of N-cadherin adhesive
protein complexes. Interestingly, we also find that the Ngly-CD82 cells
demonstrate a significant increase in the density or molecular confinement of Ncadherin molecules into a cluster (Fig.3.4M), which is predicted to modulate Ncadherin function. We find that N-glycosylation of CD82 maintains N-cadherin
clusters at approximately 80 nm. However, when the N-linked glycosylation sites
on CD82 are mutated, the average size of N-cadherin clusters shrinks to
approximately 65 nm, which leads to an increase in the molecular confinement of
N-cadherin in each cluster. Together, these data suggest that while
palmitoylation of CD82 regulates N-cadherin assembly into clusters, Nglycosylation of CD82 affects the nanoscale packing of N-cadherin. Therefore, in
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Figure 3.4. CD82 regulates N-cadherin cell membrane organization and
AML homing. (A-D) Reconstructed dSTORM images of N-cadherin distribution
on each cell line. (E-H) DBSCAN images of N-cadherin clustering generated from
DBSCAN analysis from the highlighted white boxes from the reconstructed
dSTORM images (n ≥ 6 cells per cell line). Clustered N-cadherin localizations are
displayed in color and non-clustered N-cadherin localizations are in gray. An
epsilon value of 50 nm and an n value of 30 localizations were used to examine
N-cadherin clustering. Quantification of (I) N-cadherin cluster diameter, (J) Ncadherin cluster area, (K) number of N-cadherin clusters, (L) percent N-cadherin
localizations clustered, and (M) density of N-cadherin in a cluster based on
DBSCAN analysis (n ≥ 6 cells per cell line). Bone marrow homing analysis of
CFSE labeled control, (N) Ngly-CD82 and (O) Palm-CD82 cells injected i.v. into
NSG mice and analyzed as described in figure 1. (P) Ngly-CD82 cells were
pretreated with 40 g of N-cadherin blocking antibody (GC-4: Sigma) or IgG
control (Santa Cruz Biotechnology) for 30 min at 37C prior to i.v. injection into
NSG mice. Sixteen hours following injection, homing analysis was completed as
previously described. (Q) Working model of how CD82 post-translational
modifications regulate N-cadherin protein organization and confinement, thereby
contributing to functional differences in adhesion and homing. (** p < 0.01, *** p <
0.001; one-way ANOVA, poc-hoc t-test with Welch’s correction for groups with
unequal standard deviations).
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addition to N-cadherin expression, the regulation of N-cadherin membrane
organization by CD82 may also be an important regulatory mechanism for
controlling N-cadherin function and subsequent behavior of AML.

3.3.4 Molecular scale organization of CD82 alters the bone
marrow homing capacity of AML cells.
The lateral assembly of cadherins in the membrane can stimulate signaling
events and promote cell adhesion (Hong et al., 2013). Therefore, we assessed
whether the CD82-mediated changes in N-cadherin clustering affect the homing
of AML cells into the bone marrow. We injected the Ngly-CD82, Palm-CD82 and
control cells into NSG mice to measure potential differences in bone marrow
homing. Interestingly, we detect a significant increase in the ability of the NglyCD82 cells to home to the bone marrow when compared to control cells, while
the Palm-CD82 cells display a substantial decrease in bone marrow homing
(Fig.3.4N,O). Analysis of the blood and spleen for Ngly-CD82 and Palm-CD82
cell localization identified no differences. To assess the role of N-cadherin in the
enhanced homing of the Ngly-CD82 cells, we pretreated the cells with the Ncadherin blocking antibody (GC-4) prior to injection. Fig.3.4P shows a disruption
in Ngly-CD82 cells homing when N-cadherin is inhibited. Together these data
demonstrate that CD82 and its post-translational modifications regulate Ncadherin cluster size, organization, and density, which modulate AML bone
marrow homing.
While protein expression plays a critical role in AML (Xu et al., 2014), our
study suggests that protein organization can be equally important. We define a
pathway by which CD82 regulates bone marrow homing of AML cells through the
membrane clustering of N-cadherin (Fig.3.4Q). Establishment of AML within the
bone marrow has extremely poor patient outcomes and we speculate that Ncadherin clustering may serve as a valuable marker to predict the aggressive
behavior of AML. In addition, these findings provide an alternative model for
targeting AML where modulation of protein organization within the membrane
may be an effective treatment to dislodge AML cells from the protective
environment of the bone marrow. Although N-cadherin is a focus of this study,
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we propose that N-cadherin will most likely model other adhesive proteins
expressed on the cell surface such as selectins and integrins. In fact, CD82
regulation of specific integrin organization has been previously described in a
variety of cellular systems (Malik et al., 2009; Miranti, 2009; Termini et al., 2014).
In

summary,

these

observations

strengthen

the

significance

of

tetraspanin-mediated membrane organization within a complex multi-step
process such as bone marrow homing. Moreover, we reason that CD82 serves
as to regulate cellular behavior by modulating the topological distribution of
protein networks on the cell membrane. It is plausible that this regulation
ultimately leads to more robust signaling and adhesive potential that can be
harnessed in disease states such as AML where cancer stem cells have a
greater fitness advantage over normal HSPCs. Together, these data suggest that
membrane clustering of proteins can regulate the aggressive potential of AML
cells and may serve as a novel therapeutic target for future disease treatments.
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4.1 Abstract
Patients with acute myeloid leukemia (AML) have increased myeloid cells
within their bone marrow that exhibit aberrant signaling. Therefore, therapeutic
targets that modulate disrupted signaling cascades are of significant interest. In
this study, we demonstrate that the tetraspanin membrane scaffold, CD82,
regulates protein kinase c alpha (PKCα)-mediated signaling critical for AML
progression. Utilizing a palmitoylation mutant form of CD82 with disrupted
membrane organization, we find that the CD82 scaffold controls PKCα
expression and activation. Combining single molecule and ensemble imaging
measurements, we determine that CD82 stabilizes PKCα activation at the
membrane and regulates the size of PKCα membrane clusters. Further
evaluation of downstream effector signaling identified robust and sustained
activation of ERK1/2 upon CD82 overexpression that results in enhanced AML
colony formation. Together, these data propose a mechanism where CD82
membrane organization regulates sustained PKCα signaling that results in an
aggressive leukemia phenotype. These observations suggest that the CD82
scaffold may be a potential therapeutic target for attenuating aberrant signal
transduction in AML.

4.2 Introduction
Acute myeloid leukemia (AML), the most common acute leukemia
affecting adults, is characterized by increased immature myeloid blasts within the
bone marrow, which interferes with normal hematopoiesis (Colmone et al., 2008).
While an increasing number of chemotherapy drugs are being made available,
AML remains a highly fatal disease due to its significant relapse rate following
standard treatment (Walter et al., 2010b). Modeling studies have demonstrated
that the expression and activation of signaling molecules can be used to predict
AML patient remission attainment, relapse, and survival (Kornblau et al., 2006).
For example, increased expression of the protein kinase C (PKC) isoform PKCα
correlates with poor survival in AML patients (Kurinna et al., 2006). Therefore,
therapeutic targeting of specific aberrant signaling in AML can be used to treat
this aggressive disease.
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The PKC family of enzymes are serine/threonine kinases that can be
further classified into conventional, novel, and atypical PKCs (Newton, 1995).
The conventional PKC isoforms include PKCα, β1, β2 and γ, all of which require
Ca2+ and diacylglycerol (DAG) to become activated. Upon activation, PKC is
initially phosphorylated within the cytoplasm and translocates to the plasma
membrane following full phosphorylation. This translocation process is controlled
by DAG production but may be bypassed with the use of the PKC activator,
phorbol 12-myristate 13-acetate (PMA) (Nakashima, 2002). PKC activation
initiates various signaling responses such as the activation of Rac1, RhoA, and
the mitogen-activated protein kinases (MAPK) signaling cascades (Chang et al.,
1998; Kolch et al., 1993; Nakashima, 2002; Schonwasser et al., 1998). As such,
PKC activation controls many basic cellular processes including adhesion,
migration, and proliferation, which all contribute to cancer progression.
In AML patients, PKCα gene expression is upregulated when compared to
CD34(+) normal donors (Ruvolo et al., 2011). Furthermore, treating AML cell
lines with the PKC inhibitor, enzastaurin, blocks the phosphorylation of PKCα and
its downstream target, ERK, and also prevents PKCα membrane recruitment
(Ruvolo et al., 2011). Additional work suggests that increased levels of phosphoPKC are correlated with increased AML cell viability (Zabkiewicz et al., 2014).
However, the molecules and mechanisms that control PKC activation and
downstream signaling remain poorly defined.
Tetraspanins serve as molecular scaffolds within the plasma membrane to
generate highly organized membrane domains, termed tetraspanin enriched
microdomains (TEMs) (Charrin et al., 2009b; Hemler, 2005). TEMs consist of
interactions between tetraspanins and with other membrane proteins including
integrins and signaling receptors such as the epidermal growth factor receptor
(EGFR) and c-kit (Anzai et al., 2002; Berditchevski et al., 2002; Odintsova et al.,
2000). The maintenance of TEMs promote cellular functions including cell
adhesion, migration, and proliferation (Lammerding et al., 2003; Shi et al., 2000;
Yanez-Mo et al., 1998). The palmitoylation of tetraspanins regulate TEM
organization through the control of protein-protein interactions (Berditchevski et
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al., 2002; Charrin et al., 2002; Yang et al., 2004), which can in turn mediate
cellular signaling. For example, expression of the palmitoylation deficient form of
CD151 weakens tetraspanin association with integrins, resulting in diminished
AKT phosphorylation in response to laminin-5 engagement (Berditchevski et al.,
2002). Moreover, inhibition of CD81 palmitoylation reduced signaling in B cells,
as assessed by PLCγ2 and VAV phosphorylation (Cherukuri et al., 2004).
Therefore, tetraspanin palmitoylation can control various aspects of cellular
signaling.
In addition to membrane proteins, tetraspanins interact with cytosolic
proteins such as the serine/threonine binding protein 14-3-3 (Clark et al., 2004)
and G protein subunits (Little et al., 2004). Moreover, previous work established
that CD151 assists in the recruitment of Rac1 to the plasma membrane, in
addition to associating with PKCα(Clark et al., 2004; Hong et al., 2012; Little et
al., 2004). Interestingly, tetraspanins CD9, CD81 and CD82 were shown to
associate with PKCα upon PMA activation (Zhang et al., 2001), while CD9 and
CD151 were also shown to coimmunoprecipitate with PKCα (Gustafson-Wagner
and Stipp, 2013). In the present study, we focus on identifying how this
tetraspanin association modulates PKC signaling, with a specific emphasis on
CD82.
CD82 is upregulated in several human leukemias, including AML
(Burchert et al., 1999) and recent work identified CD82 upregulation in
chemotherapy-resistant CD34(+)/CD38(-) AML cells (Nishioka et al., 2015b),
often responsible for disease relapse. The objective of this study is to determine
how the CD82 scaffold and its membrane organization regulate PKCα-mediated
signaling and influence AML progression. Using a combination of single molecule
and ensemble imaging techniques, we find that CD82 modulates the spatial and
temporal dynamics of PKCα signaling in AML cells. Our data demonstrate that
the molecular organization of CD82 regulates PKCα stabilization and clustering
at the plasma membrane, which controls downstream ERK signaling and AML
colony formation. Together, our findings suggest that CD82 organization may be
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a suitable target for controlling AML progression through its regulation of PKCα
signaling.

4.3 Results
4.3.1 The CD82 scaffold regulates PKCα expression and activation.
To identify how CD82 membrane scaffolding affects PKCα signaling, we
generated KG1a AML cell lines stably overexpressing wild type CD82 (CD82OE)
or a palmitoylation mutant (Palm-CD82OE) form of CD82 tagged to the mCherry
fluorescent protein. In the palmitoylation mutant, five membrane proximal
cysteine residues are mutated to serines, preventing CD82 palmitoylation
(Fig.4.1A)(Mazurov et al., 2007). We also generated CD82 knockdown KG1a
cells (CD82KD) cells, where stable expression of a CD82-specific shRNA
reduces total CD82 expression by 50% and surface levels by 95%. To quantify
differential CD82 total and surface expression, we used flow cytometry analysis
of permeabilized (Fig.4.1B) and non-permeabilized cells, respectively (Fig.4.1C).
We also measured the expression of other tetraspanins in these cell lines, finding
similar levels of CD9 in all cell lines (Suppl.Fig.S.4.1A), and decreased levels of
CD151 (Suppl.Fig.S.4.1B) in the CD82KD cells compared to controls.
Interestingly, we find decreased levels of surface (Suppl.Fig.S.4.1C) and total
(Suppl.Fig.S.4.1D) CD81 in CD82KD and CD82OE cells compared to control
cells. We also checked the tetraspanin profile of two additional myeloid leukemia
cell

lines

(K562

and

U937)

overexpressing

WT-CD82

or

Palm-CD82

(Suppl.Fig.S.4.2A-E,I-M). While K562 cells display increased CD9 expression in
the CD82OE cells, the CD81 and CD151 expression levels remain unchanged
(Suppl.Fig.S.4.2F-H). U937 cells display increased CD9 expression in CD82OE
and Palm-CD82OE cells, whereas Palm-CD82OE cells also exhibit a slight
increase in CD81 expression; CD151 remains unchanged (Suppl.FigS.4.2N-P).
Therefore, CD82 overexpression regulates the tetraspanin expression in
leukemic cells.
To analyze how CD82 scaffolding regulates the expression and activation
of PKCα, we first quantified the expression levels of total and activated PKCα

143

144

145

146

Figure 4.1 The CD82 scaffold regulates PKCα expression and activation. (A)
Cartoon depicting mutated palmitoylation sites within CD82 and mCherry fusion.
Flow cytometry analysis of (B) total and (C) surface CD82 expression using
CD82KD, control, CD82OE, and Palm-CD82OE KG1a cells (Biolegend, ASL-24).
(n≥3 experiments; error bars indicate SD; mean fluorescence intensity
normalized to control levels). (D) Western blot analysis for total and phosphoPKCα expression. Densitometric analysis of (E) total and (F) phosphorylated
PKCα expression from Western blot analyses (n≥4 experiments; error bars
indicate SD). (G) Real-time PCR analysis of KG1a cells. (H)
Immunofluorescence imaging of CD82 (Biolegend, ASL-24) and PKCα-488
(primary, abcam, Y124; secondary, Invitrogen, rabbit-488) under resting and 1 hr
of PMA treatment with corresponding line scan plots for both channels. All
channels were scaled equally across conditions. (I) Western blot analysis of total
and phosphorylated PKCα expression following PMA stimulation (n≥4
experiments; error bars indicate SD). (J) Cells were treated with DMSO, PMA or
PMA+MG132 for 4 hrs and total and phospho-PKCα were quantified using
Western blot analysis and densitometry. (n≥4 independent experiments; error
bars indicate SD; post-hoc unpaired t-test).

147

using Western blot analysis. (All data presented in this manuscript except
supplementary utilize KG1a cells with additional cell line analysis quantified in
supplemental data). Figures 4.1D-F demonstrate that the CD82OE cells have a
twofold increase in total PKCα expression and a 1.3-fold increase in
phosphorylated (active) PKCα expression compared to control cells. In contrast,
we find that the Palm-CD82OE cells express approximately 50% less total PKCα
and 60% less phospho-PKCα when compared to control cells. Similar changes in
PKCα expression and activation were identified using stable U937 and K562
cells overexpressing wild type CD82 or Palm-CD82 (Suppl.Fig.S.4.2Q-R). Upon
CD82KD in KG1a cells, we are unable to detect the expression of PKCα or its
active form by Western blot (Fig.4.1D-F). RT-PCR analysis of the cell lines
measures a transcriptional down regulation of PKCα in CD82KD cells and no
change in PKCα transcript between the control and CD82 overexpressing cells
(Fig.4.1G). Together, these data suggest a critical role for CD82 expression and
membrane organization in regulating PKCα expression and activation in AML.
Upon full activation, PKCα translocates to the plasma membrane from the
cytoplasm, which is essential for PKCα signaling. Using immunofluorescence
imaging, we find that under resting conditions PKCα is primarily localized within
the cytoplasm, whereas, upon PKCα activation with PMA for 1 hr, PKCα
translocates to the plasma membrane (Fig.4.1H). We also observe by line scan
analysis that the intensity plots for the CD82 and PKCα channels have a similar
shape under PMA stimulated conditions, suggesting that PKCα activation
stimulates PKCα to move to CD82 membrane regions. These data illustrate that
despite the CD82 palmitoylation mutation, PKCα effectively translocates to the
plasma membrane upon activation. Following activation, PKCα can be
dephosphorylated and degraded in order to down-regulate PKCα-mediated
signaling (Hansra et al., 1996; Lee et al., 1996; Melnikov and Sagi-Eisenberg,
2009; Wang et al., 2016). Therefore, we assessed whether CD82 scaffolding
preserves PKCα protein levels upon activation, thereby providing a sustained
signal. Upon PMA stimulation for 1 or 4 hrs, we find that total and phospho-PKCα
expression is maintained at a higher proportion in the CD82OE cells when
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compared to Palm-CD82OE cells (Fig.4.1I). Next, we investigated if the reduced
PKCα expression upon activation is due to proteasomal degradation. Combining
four hr of PMA with the proteasomal inhibitor, MG132, we find that PKCα
expression is rescued to basal levels in control and Palm-CD82OE cells
(Fig.4.1J). Collectively, these data suggest that CD82 scaffolding hyperstabilizes
PKCα levels upon activation.

4.3.2 The CD82 scaffold regulates short-term PKCα membrane
association.
One mechanism by which the CD82 scaffold could prolong PKCα
activation is by stabilizing PKCα membrane recruitment. To visualize the
molecular recruitment of PKCα to the plasma membrane upon activation, we
performed single particle tracking (SPT) analysis. Using transiently transfected
GFP-PKCα cells (Fig.4.2A-C) stimulated with PMA (Fig.4.2E-G), we analyzed the
membrane track length or “dwell time” of GFP-PKCα, which we define as the
time between the membrane appearance and disappearance of GFP-PKCα.
Figures 4.2I-K display representative GFP-PKCα trajectories, which were
generated by filtering and connecting localizations with the parameters described
in the Methods section. A cumulative distribution plot of the GFP-PKCα track
lengths indicates that the Palm-CD82OE cells have an increased proportion of
short-lived GFP-PKCα tracks compared to control or CD82OE cells, suggesting a
shortened PKCα dwell time (Fig.4.2M). We also quantified PKCα dwell time
based on the average track length per cell analyzed (n≥19 cells) (Fig.4.2N) or per
independently performed experiment (n=3 experiments) (Fig.4.2O), finding the
same trend observed in our cumulative distribution plot. Interestingly, when
analyzing GFP-PKCα dwell time in the CD82KD cells (Fig.4.2D,H,L), we are
unable to detect a change in track length (Fig.4.2R), suggesting a potential
compensatory scaffold function from other tetraspanins in the CD82KD cells,
which may be inhibited by the palmitoylation mutant form of CD82. In
combination, these data suggest that CD82 scaffolding has a modest effect on
the initial membrane recruitment of PKCα.

149

150

151

Figure 4.2 The CD82 scaffold regulates PKCα association with the
membrane. (A-D) Flow cytometry analysis indicates the percentage of GFPPKCα expression in transiently transfected cells. (E-H) Epifluorescence imaging
of transfected cells showing GFP-PKCα localization +/- PMA. (I-L) PKCα
trajectories from 600 frames of analyses are displayed. (M) Cumulative
distribution plot of PKCα track length (n≥31227 tracks from n≥19 cells of each
kind; the Kolmogorov-Smirnov test was used to compare cumulative
distributions). (N) Average GFP-PKCα track length per cell and (O) per
experiment (error bars indicate SD; n≥19 cells, n=3 experiments; post-hoc
unpaired t-test). (R) Average track length per cell was quantified in control and
CD82KD cells (error bars indicate SD; n=22 cells).
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4.3.3 PKCα is recruited to the CD82 scaffold upon stimulation.
An extensive series of immunoprecipitation studies demonstrated that
upon PMA stimulation, PKCα interacts with CD82 (Zhang et al., 2001), although
little is known about the dynamics of this interaction. Our SPT analyses suggest
that CD82 palmitoylation may regulate the membrane stabilization of PKCα on a
short time scale. However, we are particularly interested in whether CD82
scaffolding can stabilize long-lived PKCα membrane interactions, which could
potentiate prolonged signal transduction. Using Förster resonance energy
transfer (FRET), we measured the recruitment and retention of PKCα relative to
the CD82 scaffold over time. FRET was measured by quantifying fluorescence
intensity changes in the donor fluorophore (GFP-PKCα) after the acceptor
(mCherry-CD82) was photobleached. CD82OE and Palm-CD82OE cells
transiently transfected with GFP-PKCα were imaged under resting conditions and
upon PMA stimulation for 5 mins or 1 hr to assess both short and long-term
PKCα recruitment, respectively. Under resting conditions, we detect minimal
FRET between CD82 and PKCα in both the CD82OE and Palm-CD82OE cells,
although the CD82OE cells have higher basal FRET than the Palm-CD82OE
cells (Fig.4.3A,B,G). Upon PMA stimulation, FRET is significantly increased in
the CD82OE and Palm-CD82OE cells compared to resting cells (Fig.4.3C,D,G),
indicating that PKCα interacts with both the wild type and palmitoylation mutant
form of CD82 upon activation. After of 1 hr of stimulation, we find that the
increased FRET efficiency is maintained in the CD82OE cells, whereas the
FRET is significantly reduced in the Palm-CD82OE cells over the same
timeframe (Fig.4.3E-G). These data suggest that disruption of the CD82 scaffold,
in the case of the palmitoylation mutant, reduces the membrane association of
PKCα with CD82. Together, these findings demonstrate that CD82 and PKCα
have a prolonged membrane interaction that is hyperstabilized by overexpression
of the CD82 scaffold.
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Figure 4.3 PKCα is stabilized by the CD82 scaffold. CD82OE or PalmCD82OE KG1a cells were transfected with GFP-PKCα and imaged under (A-B)
resting or upon PMA stimulation for (C-D) 5 mins or (E-F) 1 hr. (G) Percent FRET
efficiencies were calculated in a region of interest per cell. (n=4 experiments,
n≥21 cells per treatment, error bars indicate SEM, post-hoc unpaired t-test).
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4.3.4 PKCα clustering at the membrane is controlled by the CD82
scaffold.
Tetraspanins can regulate the clustering of membrane proteins (Marjon et
al., 2015; Termini et al., 2014; van Spriel et al., 2012). Interestingly, PKC has
also been shown to oligomerize (Swanson et al., 2014) and aggregate upon
activation(Huang, 1989). Therefore, we next wanted to determine how altered
interactions between CD82 and PKCα described in our FRET studies could
modulate PKCα clustering. Using the super-resolution imaging (SRI) technique,
direct stochastic optical reconstruction microscopy (dSTORM), we resolved the
molecular landscape of PKCα in control, CD82OE and Palm-CD82OE cells
stimulated with PMA for 5 mins or 1 hr.
The organization of signaling proteins into clusters may stabilize signaling
by providing steric protection from negative regulators(Cebecauer et al., 2010).
Therefore, we used the SRI data and quantified PKCα clustering with the densitybased spatial clustering of applications with noise (DBSCAN) algorithm (Ester et
al., 1996c) (Fig.4.4A). Under resting conditions, we detect a similar number of
PKCα clusters between control and CD82OE cells, whereas the Palm-CD82OE
cells display a significantly reduced number of PKCα clusters compared to
control and CD82OE cells (Fig.4.4B). Next, upon PMA stimulation for 5 min or 1
hr, we again measure no significant change in the number of PKCα clusters in
either the control or CD82OE cells. However, in the Palm-CD82OE cells, PMA
stimulation results in a significant increase in PKCα cluster number (Fig.4.4B). In
fact, upon PMA stimulation for 1 hr, the control, CD82OE and Palm-CD82OE
cells all exhibit similar numbers of PKCα clusters (Fig.4.4B). These data suggest
that while Palm-CD82OE cells have reduced PKCα clusters under basal
conditions, PMA treatment stimulates a similar number of PKCα clusters in all
cells.
It has been previously suggested that the size of signaling molecule
clusters is predicted to have a significant impact on signal transduction
(Cebecauer et al., 2010). Therefore, we next addressed how CD82 scaffolding
affects PKCα cluster size. Further analysis of the DBSCAN data indicates that
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Figure 4.4 PKCα clustering at the membrane is controlled by the CD82
scaffold. Control, CD82OE and Palm-CD82OE KG1a cells were treated with
DMSO, or PMA for 5 mins or 1 hr and imaged for PKCα (abcam, Y124;
Invitrogen, rabbit-647) using dSTORM. (A) The DBSCAN algorithm was used to
examine cluster organization within a subregion of the cells. Clustered
localizations are indicated by color, whereas gray localizations did not meet the
clustering parameters (ε=50nm, n=30 localizations). The DBSCAN algorithm was
used to determine the (B) number of PKCα clusters, (C) PKCα cluster diameter,
and (D) PKCα molecular density (n≥4 cells of each condition, error bars indicate
SD, post-hoc unpaired t-test). CD82KD cells were transfected with GFP-PKCα
and imaged using dSTORM. (E) PKCα clustering was quantified using the
DBSCAN clustering algorithm in cells treated with DMSO or PMA (ε=50nm, n=10
localizations). (F) The number of clusters (n=7 cells, error bars indicate SD) and
(G) the cluster diameter were quantified (n≥561 clusters, error bars indicate
SEM, unpaired t-test).
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under resting conditions, PKCα cluster diameter is similar between control and
CD82OE cells, but is reduced in the Palm-CD82OE cells (Fig.4.4C). Upon PMA
stimulation for 5 min, only the CD82OE cells exhibit an increase in PKCα cluster
area. However, upon PMA stimulation for 1 hr, all the cells increase their PKCα
cluster size with the CD82OE promoting even larger “superclusters” (Baddeley et
al., 2009).
We also assessed how CD82 scaffolding modulates PKCα molecular
density, or the number of PKCα localizations found per cluster area, because this
is another mechanism by which PKCα may be recruited into clusters upon
activation. Our data demonstrate that upon PMA stimulation for 5 mins, control
cells display increased PKCα molecular density compared to resting conditions
(Fig.4.4D). Meanwhile, the other cell lines exhibit similar PKCα molecular density
upon resting or stimulated conditions. These data illustrate that CD82
concentration affects the means by which PKCα is initially recruited to the
membrane. More specifically, in the case of the control cells, a lower
concentration of CD82 results in PKCα becoming organized into densely packed
clusters upon initial activation, whereas in the CD82OE cells, PKCα organizes
into larger clusters (Fig.4.4C), while in the mutant Palm-CD82OE cells, PKCα is
recruited into more clusters of the same size (Fig.4.4B,C). These data
demonstrate that CD82 concentration and mutation regulate unique aspects of
PKCα membrane clustering.
We also assessed PKCα clustering in the CD82KD cells by transiently
transfecting in GFP-PKCα and performing SRI analyses (Fig.4.4E). Upon PMA
stimulation for 1 hr, we measure an increase in the number of PKCα clusters,
consistent with PKCα membrane translocation (Fig.4.4F). However, in contrast to
the other cell lines, PKCα cluster area remains unchanged in the CD82KD cells
following PMA activation (Fig.4.4G), suggesting that the CD82 scaffold is
necessary to promote or stabilize the larger PKCα clusters measured following
PMA stimulation. Combined, these data demonstrate that CD82 scaffolding
significantly impacts PKCα cluster size.
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4.3.5 CD82 modulates ERK1/2 activity downstream of PKCα
stimulation.
The ability of PKCα to propagate a signal is dependent upon activation
and sufficient membrane recruitment, which allows PKCα to phosphorylate a
substrate and elicit a downstream response. Our findings suggest that CD82
stabilizes PKCα at the plasma membrane and promotes larger-scale clustering.
We next examined how this stabilization and clustering affects PKCα–mediated
signal propagation. One pathway that has been studied extensively with respect
to PKCα is the MAPK pathway. Incidentally, it has been shown that MAPK can
be constitutively active in leukemias and targeting this activation can help to
promote AML blast susceptibility to apoptosis (Milella et al., 2001). To determine
how CD82 scaffolding affects PKCα-mediated signaling through MAPK, we
stimulated cells with PMA and monitored p38 and ERK1/2 activation. Western
blot analysis indicates that p38 expression and activation remain unchanged
following PMA stimulation in all cell lines (Fig.4.5A). Moreover, we find no change
in total ERK1/2 expression between the cells (Fig.4.5B,C) and detect only
minimal phospho-ERK1/2 expression in unstimulated cells (Fig.4.5D,E).
However,

upon

PMA

stimulation,

phospho-ERK1/2

expression

varies

substantially between the cells. We find that there is increased phospho-ERK1/2
expression in the CD82OE cells compared to control and Palm-CD82OE cells
upon 15 mins of PMA stimulation (Fig.4.5D-F). Interestingly, the CD82OE cells
maintain significantly higher phospho-ERK expression upon 1 hr of PMA
stimulation compared to Palm-CD82OE cells (Fig.4.5F). Similar results were
observed using an alternative leukemia cell line (Suppl.Fig.S.4.2Q). These data
demonstrate that CD82 scaffolding is critical for regulating the signaling kinetics
of ERK1/2 downstream of PKCα activation.

4.3.6 CD82 regulates AML colony formation in a PKCα-dependent
manner.
Finally, we wanted to determine how PKCα activation and ERK signaling
affect the leukemia colony forming potential of AML cells. We treated cells with
DMSO, PMA alone, or PMA in combination with the ERK1/2 inhibitor, FR180204.
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Figure 4.5 CD82 modulates ERK1/2 activity downstream of PKCα
stimulation. (A) Control, CD82OE and Palm-CD82OE cells were treated with
DMSO or PMA for 1 hr and analyzed by Western blot analysis for total (D13E1)
and phospho-p38 (Thr180/Tyr182). Representative Western blot showing control
and (B) CD82OE cells or (C) Palm-CD82OE cells treated with PMA for 0, 5, 15,
or 60 mins and analyzed for total ERK1/2 (137F5) expression. Representative
Western blot depicting (D) control and CD82OE or (E) Palm-CD82OE cells
treated with PMA for 0, 5, 15, or 60 mins and analyzed for phospho-ERK1/2
(Thr202/Thr204) expression. (F) Graphical depiction of phospho-ERK expression
over time quantified by Western blot analysis. (n≥4 experiments, error bars depict
SEM; post-hoc unpaired t-test).
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Cells were then plated in MethoCult H4334 media for 14 days, after which, the
leukemia

colony-forming

units

(CFU-L)

were

counted

via

microscopy.

Interestingly, following PMA treatment, we find that the CD82OE cells display
more than four times as many CFU-L compared to control and Palm-CD82OE
cells (Fig.4.6A,B). Interestingly, in all cells treated with PMA and the ERK1/2
inhibitor, colony growth was completely inhibited. These data suggest that the
CD82 scaffold enhances PKCα signaling for controlling leukemia colony
formation, which occurs through ERK1/2 signaling. From these collective data,
we suggest the current model (Fig.4.6C) where the CD82 scaffold recruits and
stabilizes PKCα in clusters, which sustains ERK1/2 signaling for the development
of an aggressive leukemia phenotype.

4.4 Discussion
In this study, we provide new insights into how tetraspanins can serve as
membrane scaffolds that control signal transduction in AML. As PKCα is a critical
signaling hub for controlling AML cell proliferation and survival (Kornblau et al.,
2006), we focused on identifying the properties of tetraspanins that contribute to
aberrant PKCα signaling in AML. Numerous studies defined an interaction
between PKCα and tetraspanins, but the mechanisms regulating this association
and the downstream signaling consequences remain unclear. Our study
describes a role for CD82 membrane organization in regulating PKCα
expression, membrane stabilization and signaling.
Increased phospho-PKCα expression has been correlated with poor
survival rates in AML patients (Kurinna et al., 2006), while elevated phosphoPKCα levels are correlated with increased AML cell viability(Zabkiewicz et al.,
2014). Data from our study demonstrate that the overexpression of CD82
increases total and phospho-PKCα expression (Fig.4.1D). These findings are
consistent with previous results where increased CD82 expression elevated
PKCα phosphorylation (Wang et al., 2007b). Upon mutation of the palmitoylation
sites within CD82, we detect decreased total and phospho-PKCα expression
(Fig.4.1D) when compared to control or CD82OE cells, offering the interesting
possibility that CD82 scaffolding modulates PKCα expression. A similar decrease
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Figure 4.6. CD82 regulates AML colony formation in a PKCα-dependent
manner. (A) and (B) Control, CD82OE and Palm-CD82OE cells grown in
clonogenic assays in the presence of PMA alone (10ng/ml), or PMA+FR180204
(100µM), or equal volumes of DMSO and assessed after 14 days by microscopy
for the number of leukemia colony-forming units per 96mm2 (n≥4 experiments,
error bars indicate SD). (C) Proposed model whereby the scaffolding function of
CD82 regulates the membrane clustering and stabilization of PKCα, which
controls ERK1/2 signaling and AML colony forming potential.
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in PKCα expression was observed in previous studies when CD82 expression
was knocked down by siRNA (Wang et al., 2007b), further supporting the
importance of the CD82 scaffold for maintaining PKCα expression. In this study,
we find that PKCα transcript levels are similar between the control, CD82OE and
Palm-CD82OE cells (Fig.4.1G), suggesting that changes in protein production
are less likely to be responsible for the change in PKCα protein expression
observed. However, the PKCα transcript levels of PKCα in the CD82KD cells are
significantly decreased, suggesting that CD82 may have transcriptional control of
PKCα in these cells, though the mechanism remains undiscovered. Our data
make the case that CD82 scaffolding can dramatically increase PKCα
expression, through the stabilization of PKCα at the plasma membrane.
A number of previous studies have proposed that tetraspanins serve as
protein recruitment platforms. For example, the presence of CD82 was shown to
enhance the PKCα phosphorylation of c-Cbl following HB-EGF activation, which
led the authors to suggest that CD82 could in fact serve to recruit PKCα
(Odintsova et al., 2013). Additionally, a described role for CD151 was to recruit
PKCα into proximity with the α6β4 integrin, which significantly impacted tumor
initiation and progression (Li et al., 2013a). Our SPT data suggests a decrease in
PKCα membrane dwell time in the Palm-CD82OE cells (Fig.4.2M-O), indicating
that disruption of the CD82 scaffold organization may shorten PKCα membrane
interactions. Our PKCα tracking experiments used GFP, which has a relatively
short fluorescent lifetime; as such, we detect sub-second PKCα track lengths.
This may account for the modest change seen in PKCα track length in the PalmCD82OE cells. Interestingly, the CD82OE cells also exhibit deceased levels of
CD81 (Suppl.Fig.S.4.1B), which can also interact with PKC (Zhang et al., 2001).
We hypothesize that this occurs in the CD82OE cells but not the Palm-CD82OE
cells because the role of CD81 and CD82 has redundancy in the CD82OE cells,
leading to a downregulation of CD81 in CD82OE cells. However, in the PalmCD82OE cells, we hypothesize that the palmitoylation deficient form of CD82
may not be fully functional. Therefore, CD81 may serve a compensatory role for
regulating PKCα dynamics and therefore, it’s expression is needed in the Palm-
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CD82OE cells. Moreover, the differential CD81 expression may mask a larger
change in PKCα membrane stabilization as detected with SPT. Despite the
experimental limitations, these data suggest that CD82 organization retains
PKCα at the membrane.
Biochemical characterization of tetraspanins suggests that PKCα and
PI4K may have distinct tetraspanin recruitment sites, indicating the potential for
differential recruitment of signaling enzymes to specific tetraspanins (Zhang et
al., 2001). One possible explanation for how decreased PKCα dwell time could
occur is through diminished interactions with the CD82 signaling platform. Our
FRET analyses (Fig.4.3) indicate that PKCα interacts with both wild type and
Palm-CD82, demonstrating that CD82 palmitoylation is not essential for the
interaction to occur. However, following 1 hr of PMA stimulation, the FRET
efficiency between PKCα and CD82 is sustained, while it is significantly
diminished in the Palm-CD82OE cells. These data suggest that CD82 scaffolding
contributes to the long-lived protein interactions between PKCα and CD82 at the
membrane. Interestingly, PKCα can also be palmitoylated, which was shown to
facilitate its membrane recruitment (Ford et al., 1998). Therefore, future studies
will explore how PKCα palmitoylation contributes to the robust membrane
interaction between CD82 and PKCα.
While tetraspanins have been described to regulate membrane protein
clustering (Marjon et al., 2015; Termini et al., 2014; van Spriel et al., 2012), our
study explores how tetraspanins modulate cytosolic protein clustering. Previous
work has demonstrated that the number and size of Ras clusters contributes to
the downstream response(Harding and Hancock, 2008; Tian et al., 2007).
Moreover, increased expression of galectin-1, a Ras membrane scaffold, can
enhance Ras-mediated signaling (Elad-Sfadia et al., 2002). The current study
has uncovered a role for CD82 in regulating PKCα oligomerization, a concept
that was hypothesized to have physiological signaling consequences (Swanson
et al., 2014). In order to bypass the loss of PKCα expression that occurs in the
cells after prolonged PMA stimulation (Fig.4.1I), we stimulated cells for just 5
mins and visualized PKCα. Our data demonstrate that the PKCα clusters in
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CD82OE cells are significantly larger than both control and Palm-CD82OE cells
upon 5 mins of stimulation (Fig.4.4C). It is important to take into account the ratio
of surface CD82 to PKCα in our cell lines for interpretation of these data. By
setting the control cells at a 1/1 ratio of CD82: PKCα, the CD82OE cells have a
ratio of 2/2, while the Palm-CD82OE cells have a ratio of 2/0.5. Although the
Palm-CD82OE cells have fourfold as much CD82 as PKCα, they are unable to
generate larger PKCα clusters upon 5 mins of stimulation but exhibit an increase
in the number of clusters (Fig.4.4B-C). We suggest that the excess of CD82 in
the Palm-CD82OE cells serves as a platform to enhance the recruitment of
PKCα to the membrane in new clusters. As the scaffolding capacity of CD82 is
disrupted in the Palm-CD82OE cells, we hypothesize that PKCα is unable to
assemble into larger clusters, but it is indeed recruited, consistent with our FRET
data in Fig.4.3. Meanwhile, the control cells have half as much CD82 and PKC
compared to the CD82OE cells and also do not display an increase in cluster
size. Rather, the control cells have the same number of clusters, though the
clusters become more densely packed (Fig.4.4D). Therefore, it appears that the
amount of CD82 helps establish the ability for PKCα to organize into more
clusters, while palmitoylation mutation of CD82 assists with the ability for PKCα
to grow into larger clusters upon stimulation. Furthermore, these data support the
concept that the CD82 scaffold can modulate the stoichiometry of signaling
molecules recruited to a set number of signaling platforms, although at this time,
the mechanism responsible for establishing the number of PKCα clusters
remains unclear.
Aberrant activation of the ERK pathway is implicated in AML progression
(Blume-Jensen and Hunter, 2001). Previous studies have shown that inhibiting
MAPK signaling in AML can lead to increased apoptosis and reduced
proliferation(James et al., 2003; Kerr et al., 2003; Lunghi et al., 2003; Milella et
al., 2007). Additional studies have shown that the treatment of lymphoid cells
with CD81 and CD9 antibodies modulated proliferation through alterations in the
ERK1/2/MAPK pathway (Carloni et al., 2004; Hemler, 2005; Murayama et al.,
2004). Our data indicate that increased expression of CD82 results in a robust
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and sustained activation of ERK1/2 upon PMA stimulation that is maintained out
to 1 hr (Fig.4.5F). However, in the Palm-CD82OE cells, the ERK1/2 activation is
abrogated to approximately 50% of the CD82OE response at 1 hr following PMA
stimulation. We postulate that the sustained levels of activated PKCα in the
CD82OE cells (Fig.4.1I) serves to stimulate and maintain the activation of
ERK1/2. Conversely, we suggest that the reduced levels of PKCα seen in the
Palm-CD82OE cells upon activation (Fig.4.1I) leads to a quick turnover of in
ERK1/2 signaling. It has been hypothesized that membrane clustering of
signaling molecules can regulate signal transduction, with smaller, short-lived
“nanoclusters” responsible for rapid signaling and larger “microclusters”
promoting sustained signal transduction (Cebecauer et al., 2010). Our findings
are consistent with this notion, demonstrating that increased PKCα “microcluster”
formation seen in the CD82OE cells (Fig.4.4C) correlates with sustained ERK1/2
signaling. Our findings demonstrate that CD82 scaffolding primarily affects the
long-lived phase of ERK signaling, which further implicates that the CD82mediated effects on the spatial and temporal dynamics of PKCα can significantly
impact the prolonged downstream ERK1/2 effector signaling.
ERK activity has been linked to cell proliferation and leukemia
chemoresistance (Steelman et al., 2004; Willard and Crouch, 2001). Additionally,
CD82 expression was shown to be increased in the chemotherapy-resistant
CD34(+)/CD38(-) cells in AML (Nishioka et al., 2015b). Our leukemia colonyforming unit assays indicate that CD82OE cells form significantly more AML
colonies when compared to control or Palm-CD82OE cells, suggesting that
CD82OE cells have a colony forming advantage independent of PKCα
stimulation. Interestingly, following PMA treatment, CD82OE cells generate an
even greater increase in leukemia CFU formation, indicating that PKCα activation
and downstream signaling regulate the aggressiveness of AML. Moreover, our
data demonstrate that modifications in the CD82 scaffold can regulate ERK
activation downstream of PKCα, which when inhibited with FR180204,
significantly impacts leukemia CFU formation. Together, these data suggest that
targeting CD82 scaffold may provide an alternative route towards regulating

172

PKCα and its downstream signaling response in AML. Tetraspanins are already
being used in clinical trials for the treatment of chronic lymphocytic leukemia
(Beckwith et al., 2015). Therefore, the ability to specifically disrupt the CD82
membrane organization, where aberrant signaling can be initiated and sustained,
may represent a novel approach to the treatment of AML.

4.5 Methods
4.5.1 Cell culture
The KG1a, K562 and U937 cell lines (American Type Culture Collection)
were cultured in RPMI 1640 medium supplemented with 10%FBS, 2mM lglutamine, 100u/ml penicillin, and 100µm/ml streptomycin. Cells were incubated
at 37°C, 95% humidity, and 5%CO2. For stimulation experiments, cells were
treated with 10ng/ml of PMA alone (Sigma), or combined with FR180204 (Sigma)
at 100µM or equivalent volumes of DMSO.

4.5.2 Plasmids/cell line generation
The mCherry-CD82 and mCherry-Palm-CD82 plasmids were constructed
as previously described(Termini et al., 2014). Cells were nucleofected with the
aforementioned plasmids or the mCherry-C1 plasmid (Invitrogen) and then
sorted for mCherry expressing cells using fluorescence activated cell sorting at
the Flow Cytometry Facility, UNMHSC and kept under selection using 500ug/ml
of G418. Stable CD82 knockdown was established using KG1a cells transfected
with the CD82 shRNA plasmid (Santa Cruz Biotechnology , sc-35734-SH); cells
were put under puromycin selection for 4 weeks and sorted for negative CD82
surface expression. The GFP-PKCα plasmid, cloned in the pEGFP-N3 vector,
was generously provided by Dr. Yousuf Hannun from Stony Brook University,
Stony Brook, NY. Cells were transiently nucleofected with GFP-PKCα according
to the manufacturer’s protocol (Amaxa, Lonza Group).

4.5.3 Western blotting
Western blots were performed as previously described (Termini et al.,
2014). Antibodies used for Western blotting were purchased from Cell Signaling
Technology as follows: calnexin (C5C9), PKCα (#2056, polyclonal), phosphoPKCα (Thr638), p42/44 (137F5), phospho-p42/44 (Thr202/Thr204), p38 (D13E1),
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phospho-p38 (Thr180/Tyr182), or β-Actin (Sigma, AC-74); all antibodies were
used at a 1:1000 dilution. Horseradish peroxidase conjugate enzymes were
stimulated with SuperSignal West Pico Chemiluminescent Substrate or Femto
Maximum Sensitivity Substrate (Life Technologies). Blots were imaged using the
ChemiDoc XRS Imager (Bio-Rad) and analyzed using ImageJ (National Institutes
of Health) densitometry software.

4.5.4 Flow cytometry
For surface expression, cells were labeled with antibody or the
corresponding isotype control in 1%BSA/PBS for 30 mins on ice. For total
expression, cells were fixed with 4% paraformaldehyde and blocked with
1%BSA/PBS/0.2%Tween for 1 hr before labeling. Cells were washed 3 times and
analyzed using an Acuri C6 flow cytometer; histograms were generated using
FlowJo software. Mean fluorescence values were normalized to the “control” cell
line level. Antibodies used were CD82-647 (Biolegend, ASL-24), CD81-FITC
(Biolegend, 5A6), CD151-PE (BD Biosciences, 14A2.H1), and CD9-647 (Bio-Rad,
MM2/57).

4.5.5 Real-time PCR
The TRIzol Reagent protocol was used to isolate total RNA; cDNA was
synthesized using qScript cDNA SuperMix protocol. Fast SYBR Green Master
Mix was used for PCR reaction. The following primers were used for
amplification: PKCα forward: 5’ ATC CGC AGTGGA ATG AGT CCT TTA CAT 3’,
PKCα reverse: 5’ TTG GAA GGT TGT TTC CTG TCT TCA GAG 3’, GAPDH
forward:

5’-GTCGGTGTCAACGGATTT-3’,

human

GAPDH

reverse:

5’-

ACTCCACGACGTACTGAGC-3’. The PCR plate was read using the 7500 Fast
Real-Time PCR System (Applied Biosystems). The Ct value from the sample
was normalized to the expression of GAPDH. Expression values were averaged
from three independent experiments and expression level changes were
calculated using the 2-ΔΔCT method.

4.5.6 Immunofluorescence
Cells

were

fixed

with

4%

paraformaldehyde

and

then

blocked/permeabilized with 1%BSA/PBS/0.2%Tween. Cells were then incubated
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with primary antibodies (CD82-Alexa647, 1:125, Biolegend ASL-24; PKCα,
1:200, abcam, Y124). Cells were then labeled with a rabbit-Alexa488 secondary
antibody (1:200, Invitrogen). Cells were imaged by laser scanning confocal
microscopy with a Zeiss Axiovert 100M inverted microscope (LSM 510) system
(Carl Zeiss, Jena, Germany) using an excitation wavelength of 488 or 633nm and
a 63X/1.2 numerical aperture oil immersion objective. Image analysis was
performed using the Zeiss LSM 510 software.

4.5.7 Super-resolution microscopy
Cells were plated on chamber slide wells that were treated with fibronectin
(25µg/ml,

Millipore).

Cells

were

fixed

with

4%

paraformaldehyde

and

blocked/permeabilized (1%BSA/PBS/0.2%Tween). Cells were labeled with an
anti-PKCα antibody (1:200, abcam, Y124), washed, and incubated with a goat
anti-rabbit

AlexaFluor647

secondary

antibody

(1:200;

Invitrogen).

Cells

transfected with GFP-PKCα were labeled with an anti-GFP Alexa647 antibody
(Biolegend,

FM264G).

Cells

were

washed

post-label

fixed

with

4%

paraformaldehyde. Cells were washed and imaged in dSTORM imaging buffer
consisting of 50mM Tris, 10mM NaCl, 10% w/v glucose, 168.8 u/ml glucose
oxidase (Sigma #G2133), 1404.0 U/ml catalase (Sigma #C9332), and 50mM
MEA, pH8.5. Red reference beads were used to stabilize the sample during
imaging; drift corrections were performed using MCL NanoDrive stage controller
(Mad City Labs, Nano-CLP100). The sample was imaged for 10,000 frames
using a custom TIRF microscope system as described previously(Valley et al.,
2015) that uses an inverted microscope (IX71, Olympus America Inc.). A 637nm
laser (HL63133DG, Thorlabs) is coupled along with a 405nm laser (Crystal laser),
into two mode fibers and focused onto the objective lens with a 1.45 NA (UAPON
150XTIRF, Olympus America, Inc.) for data acquisition. For imaging, emission
light was filtered using bandpass filter (FF01-692/40-25, Semrock) and data was
collected on an electron-multiplying charge-coupled device (EMCCD) Camera
(iXon 897; Andor Technologies, South Windsor, CT). Pixel size was 106.7 nm.
Images were acquired at ~20ms (50 frames/second) for a 256x256 pixel region.
All of the instrumentation is controlled by custom-written software in Matlab
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(MathWorks Inc.). For one color imaging, the 637nm and 405nm lasers were
used concurrently. The 561nm laser was used for bead stabilization.
Data collected was then analyzed using a method previously described,
where the pixel values are converted to photon counts and a 2D localization
algorithm is used to determine the x and y positions of emitters, total photon
counts, and the background photon counts (Huang et al., 2011). The localized
emitters were then put through a series of thresholds of various fitting parameters.
The fitting parameters used are maximum background photons=80 and minimum
photons per frame per emitter=500.
The SuperCluster Matlab software (http://stmc.health.unm.edu/tools-anddata/index.html) was used for SRI cluster analysis using the DBSCAN module.
Clusters in Fig.4.4A-D were determined as having at least 30 localizations within
a 50nm search radius, while clusters in Fig.4.4E-G only required 10 localizations.
DBSCAN provides the number of clusters detected and their area. The
equivalent cluster diameter represents the diameter of a circle with the same
cluster area detected by DBSCAN. Molecular density is calculated as the number
of localizations in a cluster divided by the cluster area.

4.5.8 Förster resonance energy transfer (FRET)
Stable KG1a cells were transfected with GFP-PKCα and plated on 25µg/µl
of fibronectin overnight. Cells were imaged using the Leica SP8 System using a
63X water objective equipped with an objective heater which maintained samples
as 34°C throughout imaging. The excitation light source was a white-light laser
system set at 488nm (GFP) and 561nm (mCherry). Fluorescence from the
488nm channel was collected using a HyD1 detector and fluorescence from the
561nm channel was collected using the HyD SMD2 in standard mode.
Photobleaching was performed at 100% 561nm laser power for 2 frames. GFP
and mCherry levels in cells outside of the field of bleaching demonstrate that
inherent photobleaching did not play a significant role in reducing GFP or
mCherry fluorescence over the course of imaging. FRET efficiencies were
calculated

using

the

formula:

bleach)/Donorpost-bleach where

Efficiency

=

(Donorpost-bleach

–

Donorpre-

D is the fluorescence intensity in a plasma membrane
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region of interest of fixed shape and size (3x7 ellipse). Analysis was performed
using the Leica Application Suite AF Lite software.

4.5.9 Single particle tracking (SPT)
SPT was performed using the TIRF microscope optical setup as described
in the “Super-resolution Microscopy” section. A 488nm laser (Cyan Scientific;
Spectra-Physics) was used for GFP excitation. The sample emission light was
detected using an EMCCD camera (iXon 897; Andor Technologies). 500 frames
per cell were acquired at 20 frames/sec.

An objective heater maintained

samples as 34°C throughout imaging.
SPT data processing was performed as described previously(Schwartz et
al., 2015). The algorithm first finds box centers from raw data, and then fits these
centers to determine the location of single particles. The localizations are then
filtered and trajectories are built by connecting localizations. The minimum
number of photons to threshold a box was 1.5 photons. Once boxes were
determined, the box region size to use to determine the localization of single
molecules was 7 pixels. In order to filter localizations, the minimum number of
photons to consider a localization was 20 photons, while the minimum distance
between localized fits was 3 pixels. The maximum number of pixels to search for
connections was 8 pixels in x or y. The maximum number of frame gaps to
search for connections was 5 frames. The minimum track length to consider valid
before gap closing assignments was 2 frames.

4.5.10 Leukemia colony-forming unit assay
100,000

KG1a

cells

were

treated

with

PMA

(10ng/ml)

alone,

PMA+FR180204 (100µM) or equivalent volumes of DMSO. Cells were plated in
MethoCult H4434 Classic Medium and allowed to grow for 14 days and then
leukemia colony forming units (>30 cells) were counted.

4.5.11 Statistics
Statistical analyses were performed using GraphPad Prism 6 software.
For multiple comparisons, one or two-way ANOVA was performed, followed by a
Bonferroni multiple comparison analysis Post-hoc unpaired t-tests were
performed as referenced, using Welch’s correction if variances were unequal.
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Alpha=.05 in all analyses. The Kolmogorov-Smirnov test was used to compare
cumulative distributions. (*<.05, **<.01, ***<.001, ****<.0001).
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Chapter 5: Conclusions, significance and future directions
5.1 Conclusions
The studies described in this dissertation provide novel information
regarding how tetraspanins propagate their control of cellular adhesion, homing
and signaling. We have identified tetraspanin CD82 as a critical regulator of
hematopoietic stem/progenitor cell adhesion as well as acute myeloid leukemia
homing and signaling. Furthermore, our studies have used super-resolution
imaging techniques to reveal the molecular landscape of membrane proteins,
including CD82, the α4 integrin subunit, and N-cadherin.
In chapter 1, our data demonstrate that the palmitoylation of CD82
contributes to HSPC adhesion to ECM components. We determined that the
overexpression of CD82 increases the surface expression of the α4 integrin
subunit by reducing α4 internalization and increasing α4 recycling. We found that
overexpressing a palmitoylation deficient version of CD82 does not increase
HSPC adhesion, which led us to examine how CD82 palmitoylation regulates
integrin organization. Our data demonstrate that the palmitoylation of CD82
contributes to the molecular packing, or density, of the α4 integrin subunit. We
also determined that this increase occurs in a ligand-dependent manner. These
data indicate that integrin organization should be considered as a means by
which HSPC adhesion can be increased, with the ultimate goal of improving HSC
transplantation.
In chapter 2, we took a closer examination of how CD82 contributes to
AML interactions with the bone marrow microenvironment. With the use of
primary AML patient samples, our data show that AML blasts with increased
CD82 expression exhibit increased bone marrow homing. With the use of AML
cell lines that overexpress either palmitoylation or glycosylation deficient versions
of CD82, we identify a role for these post-translation modifications in mediating
AML homing. Furthermore, our data show that palmitoylation mutation diminishes
CD82 scaffolding, while glycosylation mutation enhances CD82 organization. We
also examined how CD82 scaffolding modulates the clustering of N-cadherin.
Our data demonstrate that palmitoylation mutation reduces the percentage of N-

179

cadherin localizations organized into clusters. These clusters are also reduced in
size. Therefore, we propose that CD82 scaffolding regulates the organization of
N-cadherin for the control of AML homing.
In chapter 3, we took a visual and quantitative examination into how PKCα
interacts with CD82. Our data show that the expression and palmitoylation of
CD82 are critical for maintaining PKCα expression. Meanwhile, increased CD82
expression can protect PKCα from degradation upon activation. Using single
particle tracking, we determined that CD82 palmitoylation mutation diminishes
individual PKCα membrane interactions. Furthermore, using FRET analyses, we
find that wild-type and palmitoylation mutant forms of CD82 can interact with
PKCα. However, this interaction is transient in our palmitoylation mutant cells. A
closer examination into how CD82 regulates the oligomerization of PKCα upon
activation shows that CD82 overexpression promotes PKCα organization into
large clusters. Meanwhile, removal of the palmitoylation sites of CD82
significantly reduces PKCα cluster area. Using Western blot analyses, we
determine that CD82 overexpression can enhance ERK1/2 signaling downstream
of PKCα activation when compared to our palmitoylation mutant cells. We also
examined how alterations in PKCα activation manifest in AML colony formation.
Our data show that the overexpression of CD82 significantly enhances leukemia
colony formation, whereas palmitoylation mutant cells form few leukemia
colonies. Furthermore, colony formation downstream of PKCα activation can be
attenuated with the treatment with an ERK1/2 inhibitor. These data demonstrate
the critical role of ERK1/2 signaling downstream of PKCα in mediating the
formation of an aggressive AML phenotype.
Collectively, these projects point to the need for further investigation
regarding the suitability of CD82 and in particular the scaffolding of CD82, as
molecular

targets

to

enhance

hematopoietic

stem

cell

transplantation.

Additionally, our findings demonstrate that the palmitoylation of CD82 may serve
as a potential therapeutic target to dislodge AML cells from the bone marrow
niche, while attenuating aberrant signaling.
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Figure 5.1: Conclusion and hypothesized models. (A) CD82 regulates
hematopoietic stem/progenitor cell adhesion by promoting the tightly packed
organization of the α4 integrin subunit in a ligand-dependent manner. The
palmitoylation of CD82 is critical for promoting the molecular density of α4. (B)
CD82 promotes AML bone marrow homing in a N-cadherin dependent manner.
Mutation of the glycosylation sites within CD82 promotes the tight packing of Ncadherin, which enhances AML bone marrow homing. (C) CD82 serves as a
signaling scaffold for the recruitment of PKCα, which promotes sustained
signaling to enhance leukemia colony growth. The palmitoylation of CD82 is
critical for this process, as mutation of the palmitoylation sites within CD82
disrupts PKCα-mediated signaling and colony growth.
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5.2 Significance
Within the field of tetraspanin research, it is commonly accepted that
tetraspanins can regulate integrin-mediated adhesion (Barreiro et al., 2005;
Barreiro et al., 2008; Bassani and Cingolani, 2012; Feigelson et al., 2003;
Gustafson-Wagner and Stipp, 2013; He et al., 2005; Lammerding et al., 2003).
More specifically, tetraspanins can regulate integrin expression (He et al., 2005),
avidity (Feigelson et al., 2003) as well as integrin-mediated signaling through
FAK (Iwasaki et al., 2013; Jung et al., 2012; Yamada et al., 2008) for the control
of cellular adhesion. However, few reports have examined how tetraspanins
regulate integrin organization (van Spriel et al., 2012), which could also
contribute to cellular adhesion. As such, in Chapter 2, we used single-molecule
imaging techniques to determine how CD82 regulates integrin organization for
the control of cellular adhesion. Previous studies have shown that integrinmediated adhesion is optimal when integrin subunits are separated by just 58
nm, as compared with integrins separated by 73nm (Arnold et al., 2004). In line
with such findings, we find that cells exhibit increased adhesion when α4 integrin
subunits are more densely packed compared α4 integrin clusters that are more
diffusely organized.
A recent report used super-resolution imaging to resolve the organization
of tetraspanin enriched microdomains (Zuidscherwoude et al., 2015). Consistent
with our data (Fig 2.4), the authors find that tetraspanins organize into clusters
that are approximately 100nm in diameter. Biochemical studies have also shown
that tetraspanin scaffolding regulates interactions between tetraspanins and
integrins (Berditchevski et al., 2002; Yang et al., 2002), which may alter the
webbing of TEMs. Consistent with these findings, we find that the overexpression
of the palmitoylation-deficient form of CD82 significantly diminishes CD82
clustering (Fig. 2.4, Fig. 3.2). Although we did not examine the role of CD82
scaffolding in regulating the organization of other tetraspanins, we hypothesize
that disruption in the CD82 scaffold impacts the organization of other
tetraspanins and receptors within the plasma membrane.
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As the plasma membrane is crowded with numerous membrane proteins,
it is highly likely that altering the tetraspanin expression levels will affect the
plasma membrane composition. For example, in our CD82OE cells, we found a
decrease in CD81 expression (Fig.S4.1). This is likely to accommodate for the
increase in CD82 and subsequent tetraspanin scaffolding within the membrane.
Additionally, in our Palm-CD82OE cells, we find an increase in CD81 expression,
which is likely an attempt to compensate for the disruption in TEM integrity that is
caused by overexpression of the palmitoylation deficient form of CD82.
Furthermore, we find that CD82 expression regardless of palmitoylation mutation
increases α4 integrin surface expression (Fig. 2.2). As we found that CD82 and
the α4 integrin subunit do not associate with one another on the plasma
membrane (Fig.S2.4), we hypothesize that other tetraspanins, such as CD81,
CD9 and CD151 may regulate the stabilization of the α4 integrin on the surface
through protein-protein interactions.
We found that the CD82-mediated increase in α4 integrin expression
occurs not through alterations in transcription, but rather through deceased α4
integrin internalization and increased protein recycling (Fig. 2.3). As tetraspanins
have been shown to regulate the trafficking of several other proteins such as
EGFR (Odintsova et al., 2000) and GPCRs (Xu et al., 2004), these data are
consistent with the conventions within the field. Moreover, in our CD82OE and
Palm-CD82OE cells we find an increased expression of the pro- and mature
forms of the α4 integrin subunit (Fig. 2.2). It is not clear within the literature if the
immature form of α4 can exist on the plasma membrane. As such, it is difficult to
determine if the increase in the immature form of the α4 integrin subunit is due to
alterations during protein production or the altered tetraspanin landscape seen
on the plasma membrane. Therefore, these data question whether CD82mediated alterations in α4 integrin expression are strictly due to changes in
membrane stabilization or also result from alterations in α4 integrin production.
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Although extensive biochemical analyses have shown that tetraspanins
can interact with transmembrane proteins, our understanding of how tetraspanins
regulate the organization of such receptors remains limited. Our work provides
visual and quantitative evidence of how CD82 expression and scaffolding
regulate the molecular organization of the α4 integrin subunit. Our report is the
first of its kind to identify a role for tetraspanins in promoting tightly packed
integrins for the control of cellular adhesion.
With regards to AML, previous reports have demonstrated that CD82
expression is increased in CD34(+)/CD38(-) chemotherapy resistant AML cells
(Nishioka et al., 2013). Furthermore, the bone marrow has been demonstrated to
offer this population of cells a protective microenvironment, thereby allowing cells
to evade chemotherapeutic treatments (Meads et al., 2008). Therefore,
understanding the interplay between CD82 and bone marrow interactions will
clarify how CD82 offers AML cells selective resistance to therapies.
We find that AML blasts with increased CD82 expression have improved
homing to the bone marrow. These findings are consistent with previous work
that identifies a role for CD82 in regulating the bone marrow homing of HSCs
(Larochelle et al., 2012). Previous work has shown that N-cadherin can regulate
interactions between healthy hematopoietic stem cells and the bone marrow
microenvironment (Calvi et al., 2003). As such, we aimed to determine if CD82
alters N-cadherin for the control of bone marrow homing. There is limited work
focused on the role of tetraspanins in regulating N-cadherin. As such, our study
is significant because it identifies a role for CD82 in regulating the organization of
N-cadherin, which had not been previously demonstrated. Our data provide
visual and quantitative evidence that CD82 can control the clustering of Ncadherin for the control of AML bone marrow homing. Furthermore, N-cadherin
oligomerization has been shown to contribute to adhesion strengthening
(Niessen and Gumbiner, 2002). Therefore, our data suggest that CD82 promotes
the oligomerization of N-cadherin for the control of AML homing. As such,
targeting CD82 may offer a means by which N-cadherin can be neutralized to
dislodge AML cells from the bone marrow. Furthermore, we find that the
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palmitoylation and N-linked glycosylation of CD82 are critical regulators of Ncadherin-mediated AML homing to the bone marrow. Therefore, manipulating the
scaffolding capacity of CD82 may ultimately downregulate N-cadherin mediated
AML adhesion within the niche thereby sensitizing AML cells to therapeutics.
Beyond the organization of N-cadherin, using immunoprecipitation
analyses, we find that the N-linked glycosylation of CD82 controls the ability for
CD82 to interact with N-cadherin. Moreover, mutation of the N-linked
glycosylation sites within CD82 improves the association between CD82 and Ncadherin (Fig.3.3). We hypothesize that removing a bulky sugar moiety from the
extracellular domain of CD82 may expose new sites available for N-cadherin to
interact with CD82, thereby enhancing their association. Further analysis
examining the precise sites of association will improve our understanding of how
N-linked glycosylation regulates protein-protein interactions.
In Chapter 4, we examined the role of CD82 in regulating PKCα signaling
in AML. Although previous work using immunoprecipitation assays identified an
interaction between PKCα and CD9, CD81 and CD82, very little was known
about what regulates this interaction and how this feeds into signaling dynamics
(Zhang et al., 2001). Our work took advantage of single molecule and ensemble
fluorescence imaging techniques to further elucidate the role of CD82 in
mediating PKCα signaling. We determined that the scaffolding of CD82 is a
critical regulator of the generation of stable PKCα-CD82 interactions.
Additionally, we are the first to have resolved the molecular organization of PKCα
using single-molecule imaging. A recent report from the Lipp lab demonstrated
that PKCα-PKCα interactions are critical for PKCα to form higher order oligomers
(Bonny et al., 2016). By using CD82KD cells, we demonstrate that activation of
PKCα stimulates the recruitment of more PKCα localizations to the plasma
membrane, but they are unable to organize into higher ordered structures. As
such, our data suggest that the presence of CD82 is essential for PKCα
molecules to effectively oligomerize.
As tetraspanins have also been demonstrated to regulate MAPK signaling
for the control of tumor growth and cellular migration (Danglot et al., 2010;
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Franco et al., 2010; Li et al., 2013b). However, the contribution of tetraspanin
scaffolding to the regulation of MAPK signaling has yet to be examined. As such,
we assessed the consequences of defective CD82 scaffolding with regards to
ERK signaling. We find that CD82 scaffolding is a critical regulator of ERK1/2
activation downstream of PKCα signaling. Meanwhile, CD82 scaffolding is also a
critical regulator of the formation of leukemia colonies downstream of PKCα and
ERK1/2. Therefore, the scaffolding of CD82 generates a more aggressive
disease phenotype.
5.2.1 Clinical Significance
The success of hematopoietic stem cell transplantation remains limited by
the ability for HSPCs to reach the bone marrow microenvironment and make
stable contact with niche components. As such, our work is significant for
potential therapeutic options to enhance HSPC niche adhesion. For example, the
enforced expression of CD82 in the HSPC population may serve as a means to
alter integrin clustering for the control of HSPC homing/adhesion. Additionally,
because we now know that the organization of integrins into tightly packed
clusters is critical for HSPC adhesion, therapeutics that promote integrin
clustering prior to transplantation may offer a means by which HSPC success
can be improved.
Our work also suggests that CD82 may be a suitable target to ultimately
downregulate N-cadherin mediated AML adhesion within the niche. As the niche
offers a protective microenvironment allowing cells to evade treatment, disruption
of AML adhesion may provide an opportunity to sensitize AML cells to
therapeutics by mobilizing them out of the protective bone marrow niche into the
blood for more effective targeting. Furthermore, we suggest that the disruption of
the CD82 scaffold could serve as a means by which to attenuate PKC-mediated
signaling. In particular, there is evidence that patient samples with high levels of
activated PKCα have reduced susceptibility to chemotherapeutics (Milella et al.,
2001; Ruvolo et al., 2011). Therefore, initial screening for PKCα expression and
activation levels in a clinical setting could potentially identify patients who may be
responsive to targeting the CD82 scaffold.
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5.3 Future directions
There are still several unanswered questions about the means by which
CD82 contributes to HSC homing. As homing is a complicated process, involving
migration, extravasation, and adhesion, it remains to be seen whether CD82
regulates all or some of these processes through its control of integrin
organization. For example, the α4 integrin subunit was shown to mediate
transendothelial/stromal migration of CD34(+) cells in NSG mice (Peled et al.,
2000). Therefore, it is quite possible that CD82 mediated alterations in α4 integrin
organization could assist with HSC entry from the vasculature into the
microenvironment in addition to isolated bone marrow adhesion. Future studies
focused on the isolated role of CD82 in mediating HSC migration and
extravasation through the vasculature will provide valuable mechanistic insight.
Our projects have focused primarily on the role of CD82 in mediating bone
marrow interactions. However, it is highly likely that CD82 also contributes to
adhesive and migratory interactions with other supporting niches, such as the
vascular niche. As VCAM-1 is highly enriched in the vasculature and we have
identified VCAM-1 mediated alterations in the α4 integrin subunit organization,
we hypothesize that CD82 also contributes to HSC interactions with the
vasculature. Furthermore, the role of integrin clustering in mediating HSPC
migration has yet to be examined. It is quite possible that integrin clustering
assists with the ability for integrins to be sequestered, relocated, and recycled
quickly, which contributes to migration. Future studies focus on how CD82
regulates integrin clustering for the control of cellular migration and how
alterations in integrin trafficking contribute to this process may provide insight into
how integrins mediate HSPC-niche interactions.
The bone marrow niche is a complicated microenvironment with numerous
cellular and extracellular components. We have yet to examine the role of CD82
in regulating HSC interactions with mesenchymal stem cells, CXCL12-abundant
reticular cells, or adipose cells, all of which are found within the HSC niche.
HSCs make unique interactions with these cells, which may occur in a CD82
dependent manner. As different cellular components deposit unique extracellular
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matrices, we hypothesize that CD82 may regulate the organization of different
integrin subunits based on ligand specificity. As such, a careful examination of
the role of CD82 in regulating the organization of ligand specific in a ligand
dependent manner will provide significant mechanistic insight into the role of
tetraspanins in mediating molecular organization.
We have established that CD82 expression and post-translational
modifications control AML interactions with the bone marrow through alterations
in N-cadherin molecular organization. N-cadherin serves as a scaffold for the
recruitment of β-catenin and p120. However, we do not yet know how alterations
in N-cadherin organization regulate downstream signaling. Furthermore, Ncadherin serves to recruit intermediates that help establish stable attachments to
the actin cytoskeleton. This could significantly impact the ability for cells to
adhere or migration. As such, the role that N-cadherin organization plays in
mediating cytoskeletal dynamics remains to be examined.
Although our data identify CD82 expression and post-translational
modifications as regulators of AML homing, we have yet to examine the role this
plays in longer-term disease states. For example, mutation of the CD82
glycosylation sites offers cells an improved ability to home to the bone marrow
after 16 hours. We do not yet know how these cells will behave when long-term
xenografts are performed. As β-catenin can mediate cellular proliferation and
survival, there is a potential role for N-cadherin organization in regulating
downstream signaling, which may further enhance AML-niche interactions.
We have also assessed the role for CD82 in regulating the spatial and
temporal dynamics of PKCα. Our data show that disruption of the CD82 scaffold
offers a unique means to attenuate PKCα signaling, and thereby diminish AML
growth in vitro. Future studies should focus how other tetraspanins regulate
PKCα signaling, as several have been shown to interaction with PKC isoforms.
Furthermore, the role of CD82 in mediating PKCβI and PKCβII membrane
interactions has yet to be examined. PKCβ can be deregulated in several
disease pathologies beyond AML. Therefore, CD82 targeting may be suitable in
clinical settings beyond leukemia.
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Connections between integrins signaling and PKCα have been described,
but the shared role that tetraspanins may have in regulating both of these
classes of molecules has yet to be discovered. As such, we hypothesize that the
link between integrins and PKCα signaling may be mediated in part by
tetraspanins. Our studies have provided mechanistic insight regarding how CD82
palmitoylation is critical for sustained PKCα signaling. Work has shown that the
β1 integrin subunit can be phosphorylated by PKCα, which may regulate integrin
activation. Therefore, we hope that future studies will take a closer examination
towards how CD82-mediated changes in PKCα signaling can regulate integrin
activation and organization. These studies may provide even more evidence that
CD82 and in particular the palmitoylation of CD82 should be targeted in AML.
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Appendices
Appendix A: Abbreviations used
ADP – adenosine diphosphate
AML – acute myeloid leukemia
AMIDAS – adjacent to MIDAS
APP – amyloid precursor protein
BMP – bone morphogenic protein
CBF – core binding factor
CAR cells – CXCL12-abundant reticular cells
CCG – Cys-Cys-Gly amino acid motif within large tetraspanin loop
CD82KD-- KG1a knockdown cells created with CD82 shRNA
CD82OE – KG1a overexpressing cells that overexpress CD82 tagged with the
mCherry fluorescent protein
CFSE – carboxyfluorescein succinimidyl ester
CFU – colony forming unit
CHO – Chinese hamster ovarian cell line
CLL – chronic lymphocytic leukemia
CMP – common myeloid progenitor
cPKCs – classical protein kinase Cs
CXCL12 – C-X-C motif ligand 12, also known as SDF-1
CXCR4- C-X-C chemokine receptor 4
DAG – diacylglycerol
dSTORM – direct stochastic optical reconstruction microscopy
DBSCAN – density-based spatial clustering of applications with noise
EC domain – Extracellular cadherin domain
EC1 – small extracellular loop of tetraspanins
EC2 – large extracellular loop of tetraspanins
ECM – extracellular matrix
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EGF – epidermal growth factor
EGFR – epidermal growth factor receptor
ER – endoplasmic reticulum
ERK – extracellular signal-regulated kinases
E-selectin – Endothelial selectin
ETO – eight-twenty-one
FAK – focal adhesion kinase
FLT-3 – FMS-like tyrosine kinase 3
FRET - Förster resonance energy transfer
G-CSF – granulocyte-colony stimulating factor
GM-CSF – granulocyte-macrophage colony-stimulating factor
GPCR – G-protein-coupled receptor
GRAIL– gene related to anergy in lymphocytes
GSC – germline stem cell
GTP – guanosine triphosphate
GVHD – graft-versus-host disease
HA – hyaluronic acid
HGF – hepatocyte growth factor
HLA – human leukocyte antigen
HSPC – hematopoietic stem/progenitor cell
HSC – hematopoietic stem cell
ICAM-1 – intracellular adhesion molecule-1
ILK – integrin linked kinase
ITD – internal tandem duplication
LDV – leucine-aspartic acid-valine sequence
LFA-1 – leukocyte function-associated antigen
Lin (-) – lineage negative
LSC – leukemia stem cell
LT-HSPC – long-term hematopoietic stem/progenitor cell
MAPK – mitogen-activated protein kinase
MARCKS – myristoylated alanine-rich c-kinase receptor substrate
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MLL – mixed-lineage leukemia
MIDAS – metal-ion dependent adhesion site
MPL – myeloproliferative leukemia
MPP – multipotent progenitor cell
MSC – mesenchymal stem cell
MSD – mean squared displacement
NCID – Notch intracellular domain
NSG – NOD scid gamma
Palm-CD82OE – KG1a overexpressing cells that overexpress palmitoylation
deficient form of CD82 tagged with the mCherry fluorescent protein
PI – phosphatidylinositol
PI3K – phosphoinositide-3-kinase
PI4K – phosphatidylinositol 4-kinase
PI4P – phosphatidylinositol 4-phosphate
PLC-γ – Phospholipase C-γ
PKC – protein kinase C
PML – promyelocytic leukemia
PMA – phorbol 12-myristate 13-acetate
PSI – plexin-semaphorin-integrin
PTB – phosphotyrosine-binding
RACK – receptors for the activated C kinase
RARα – retinoic acid receptor alpha
RDS – retinal degeneration slow
RGD – arginine-glutamine-aspartic acid sequence
RTK – receptor tyrosine kinase
rtPCR – real time polymerase chain reaction
SAPK/JNK – stress-activated protein kinase/Jun amino-terminal kinase
SCF – stem cell factor
SDF-1 – stromal cell-derived factor-1, also known as CXCL12
SNO – N-cadherin+CD45SPT – single particle tracking
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SRI – super-resolution imaging
STAT5 – signal transducer and activator of transcription 5
Tcf/Lef – T-cell factor/lymphoid enhancer factor
TEM – tetraspanin enriched microdomain
TGF – transforming growth factor
THPO – thrombopoietin
TIRF – total internal reflection fluorescence
TKI – tyrosine kinase inhibitor
TPA – Tetradecanoylphorbol-13-acetate
VAMP – vesicular associated membrane protein
VCAM-1 – vascular cell adhesion molecule-1
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Appendix B: Supplemental methods
Real time PCR
Total RNA was isolated using TRIzol Reagent protocol for suspension cells (Life
Technologies). cDNA was synthesized using manufacturer protocol for qScript
cDNA SuperMix (Quanta Biosciences). Fast SYBR Green Master Mix (Applied
Biosystems) was used to prepare the PCR reaction mix. The following primers
were

used

for

amplification:

Human

CCTCCTTGGTCCTCATGTCAT-3’,
CATGCGCAACATTCTGATCCT-3’,
GTCGGTGTCAACGGATTT-3’,

integrin

human
human
human

α4

forward

integrin
GAPDH
GAPDH

α4

primer:

reverse:
forward:
reverse:

5’5’5’5’-

ACTCCACGACGTACTGAGC-3’. The PCR plate was read using the 7500 Fast
Real-Time PCR System (Applied Biosystems). The Ct value from the sample
was normalized to the expression of GAPDH. Expression values were averaged
from three independent experiments. Fold differences in expression levels were
calculated using the 2-ΔΔCT method.

Affinity binding assays
Cells were treated with either 0.1% DMSO or blocked with LDV (1 µM) and
incubated for 30 min at 37°C. LDV-FITC (Tocris) at increasing concentrations
(0nM, 0.25nM, 0.75nM, 2.5nM, 7.5nM, 25nM, 75nM, and 250nM) was then
added in duplicate to eppendorf tubes containing 400 µL blocked or non-blocked
cells, and the cells were incubated for an additional 30 min at 37°C with gentle
shaking. Following centrifugation and resuspension in 200 µL media, blocked
and non-blocked cells were assessed by flow cytometry to assess levels of
specific ligand-integrin binding, as measured by mean fluorescence minus
baseline (blocked). LDV-FITC concentration was plotted against mean channel
fluorescence. The binding affinity was determined from the generated binding
curve using the built-in one site specific binding (hyperbola) model in Prism.

Affinity dissociation “off-rate” assays
Cells were treated with either DMSO or blocked with LDV in media. A saturating
LDV-FITC concentration of 75 nM was then added to 200 µL blocked or nonblocked cells in triplicate. Samples were continuously stirred with a 5x2 mm
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magnetic stir bar, and real-time flow cytometry was used to assess the
dissociation kinetics or “off-rate” of LDV-FITC upon addition of a saturating,
competitive concentration of unlabeled LDV (1 µM), which was added 1 min after
starting the measurements. The mean fluorescence readings were collected over
a 6-min time period and were baseline-corrected and normalized to 1. The
dissociation rate constant, koff, was determined from the nonlinear fit using the
dissociation – one phase exponential decay model in Prism.
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Appendix C: Chapter 2 supplemental figures

Supplemental figure S.2.1: CD82 re-expression rescues cellular adhesion
to fibronectin. KG1a CD82KD cells were transiently transfected with (A)
mCherry or (B) mCherry-CD82 constructs. (C) CD82 expression of transiently
transfected cells was assessed using flow cytometry. (D) These cells were
assessed for cellular adhesion to FBS and fibronectin using a fluorescencebased adhesion assay.

196

Supplemental figure S.2.2: The effect of CD82 overexpression on integrin
surface expression. CD82 KD, control, CD82OE, and Palm-CD82OE cells were
examined for surface expression of the (A) α3, (B) α5, (C) β3 and (D) β7 integrin
subunits as assessed by flow cytometry analysis.

197

Supplemental figure S.2.3: CD82 Regulates cellular adhesion to VCAM-1.
Cellular adhesion of CD82KD, WT, CD82OE and Palm-CD82OE KG1a cells was
measured using fluorescence-based adhesion assay. Cells were plated on 10
µg/ml of recombinant VCAM-1.
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Supplemental figure S.2.4: CD82 regulation of the α4 integrin. (A) CD82
immunoprecipitation was performed with control, CD82OE, and Palm-CD82OE
KG1a cells lysed in BRIJ O10. The immunoprecipitant and unbound
supernatants were analyzed by Western blot using α4 and CD82 specific
antibodies. (B) Real-time PCR was performed for the α4 subunit mRNA levels in
control and CD82KD KG1a cells. The formula 2-ΔΔCt indicates the relative gene
expression level when compared to control cells as normalized to GAPDH. The
data displayed represents the mean ± SD from three independent experiments.
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Supplemental figure S.2.5: The effect of CD82 expression on VLA4 affinity.
(A) Affinity binding assay in which control and CD82OE cells were treated with
either 0.1% DMSO or blocked with the α4β1-specific ligand, LDV (1µM) and then
incubated with increasing concentrations of LDV-FITC (0nM – 250 nM). Blocked
and nonblocked cells were analyzed by flow cytometry to assess levels of
specific ligand-integrin binding, as measured by mean fluorescence minus
baseline (blocked). The dissociation constant, Kd, was determined from the
nonlinear fit. (B) The cells were treated with either DMSO or blocked with LDV
and then incubated with an LDV-FITC concentration of 75nM. Real-time flow
cytometry was used to analyze the dissociation kinetics or “off-rate” of LDV-FITC
over the six-minute time-course upon addition of a saturating, competitive
concentration of unlabeled LDV (1µM) at the 1-minute mark. The mean
fluorescence readings were baseline-corrected and normalized to 1. The
dissociation rate constant, Koff, was determined from the nonlinear fit.
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Supplemental figure S.2.6: The DBSCAN algorithm detects small and large
scale organization of α4 on the cell surface. The DBSCAN clustering
algorithm was used to detect α4 clusters of various sizes on the cell surface of
(A) control, (B) CD82OE, and (C) Palm-CD82OE cells plated on fibronectin. The
DBSCAN parameters used were ε = 1 px, n = 30 localizations. Colored
localizations denote localizations organized into a cluster and grey localizations
indicate molecules not organized as they did not meet the DBSCAN parameters.
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Supplemental figure S.2.7: Alteration of DBSCAN parameters does not
change the distribution of clusters found using the DBSCAN algorithm. A
56 x 56 px region of the same four cells was analyzed using modified DBSCAN
parameters of (A) ε = 0.5 px, n = 20 localizations and (B) ε = 0.5 px, n = 30
localizations. The clusters obtained were analyzed for their cumulative
distribution curve and examined statistically using the Kolmogorov-Smirnov test.
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Supplemental figure S.2.8: The DBSCAN algorithm detects clusters of α4 in
cells plated on N-cadherin and VCAM-1. The DBSCAN clustering algorithm
was used to detect α4 clusters of various sizes on the cell surface of control,
CD82OE, and Palm-CD82OE cells plated on VCAM-1 (A-C) and N-cadherin (DF). The DBSCAN parameters used were ε = 1 px, n = 30 localizations. Colored
localizations denote localizations organized into a cluster and grey localizations
indicate molecules not organized as they did not meet the DBSCAN parameters.
Cumulative distribution plot of the clusters compiled from n = 3 cells of each cell
line plated on VCAM-1 (G) and N-cadherin (H), n > 250 clusters. Statistics were
determined using the Kolmogorov-Smirnov test.
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Appendix D: Chapter 3 supplemental figure

Supplemental Figure S.3.1. Flow cytometry analysis of (A) CXCR4 (Clone
12G5, BD Bioscience), (C) E-cadherin (clone 36/E-cadherin, BD Bioscience) and
(D) P-cadherin (clone 56/P-cadherin) surface expression on Ctrl, CD82KD or
CD82OE KG1a cells. (B) Western blot analysis of total CXCR4 protein
expression (clone Ab-2 (1-14), Calbiochem) on Ctrl, CD82KD or CD82OE KG1a
cells with actin (clone AC-74, Sigma) used as the loading control.
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Appendix E: Chapter 4 supplemental figures
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Supplemental figure S.4.1. CD82 regulates tetraspanin expression levels.
Surface expression of tetraspanins assessed in stable KG1a cells using flow
cytometry with antibodies specific to (A) CD9 (AbdSerotec, MM2/57), (B) CD151
(BD Biosciences, 14A2.H1), and (C) CD81 (Biolegend, 5A6). (D) Permeabilized
cells were used to assess total CD81 expression. Quantification of normalized
mean fluorescence intensity is depicted below histograms (n≥3 independent
experiments, error bars denote SD).
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Supplemental figure S.4.2. CD82 regulates PKCα expression and activation
in other AML cell lines. (A-C) The mCherry, mCherry-CD82 or mCherry-PalmCD82 constructs were stably expressed in K562 cells. K562 cells were analyzed
for surface expression of (D-E) CD82 (ASL-24), (F) CD81 (5A6), (G) CD9
(MM2/57) and (H) CD151 (14A2.H1) (n≥3 experiments, error bars denote SD).
(I-K) The mCherry, mCherry-CD82 or mCherry-Palm-CD82 constructs were
stably expressed in U937 cells. U937 cells were analyzed for surface expression
of (L-M) CD82 (ASL-24), (N) CD81 (5A6), (O) CD9 (MM2/57) and (P) CD151
(14A2.H1) (n≥3 experiments, error bars denote SD). (Q) Western blot analysis of
stable K562 cells and densitometry was performed to quantify total and phosphoPKCα expression levels (n≥3 experiments, error bars denote SD). (R) Western
blot analysis of stable U937 cells and densitometry was performed to quantify
total and phospho-PKCα expression levels (n≥3 experiments, error bars denote
SD). (S) U937 cells were treated with PMA for 0, 5, or 15 mins and analyzed for
total and phospho-ERK expression.
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